<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id>
<journal-title>Frontiers in Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Microbiol.</abbrev-journal-title>
<issn pub-type="epub">1664-302X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmicb.2020.586433</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Microbiology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Bacteriocins to Thwart Bacterial Resistance in Gram Negative Bacteria</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Telhig</surname> <given-names>Soufiane</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x2020;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1081688/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Ben Said</surname> <given-names>Laila</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x2020;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1095801/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Zirah</surname> <given-names>S&#x00E9;verine</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/376368/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Fliss</surname> <given-names>Ismail</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/23098/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Rebuffat</surname> <given-names>Sylvie</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/577874/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Institute of Nutrition and Functional Foods, Universit&#x00E9; Laval</institution>, <addr-line>Qu&#x00E9;bec, QC</addr-line>, <country>Canada</country></aff>
<aff id="aff2"><sup>2</sup><institution>Laboratory Molecules of Communication and Adaptation of Microorganisms, Mus&#x00E9;um National d&#x2019;Histoire Naturelle, Centre National de la Recherche Scientifique</institution>, <addr-line>Paris</addr-line>, <country>France</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Mathew Upton, University of Plymouth, United Kingdom</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Daniel Walker, University of Glasgow, United Kingdom; David &#x0160;majs, Masaryk University, Czechia</p></fn>
<corresp id="c001">&#x002A;Correspondence: Sylvie Rebuffat, <email>sylvie.rebuffat@mnhn.fr</email></corresp>
<fn fn-type="other" id="fn002"><p><sup>&#x2020;</sup>These authors have contributed equally to this work</p></fn>
<fn fn-type="other" id="fn004"><p>This article was submitted to Antimicrobials, Resistance and Chemotherapy, a section of the journal Frontiers in Microbiology</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>09</day>
<month>11</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>11</volume>
<elocation-id>586433</elocation-id>
<history>
<date date-type="received">
<day>23</day>
<month>07</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>16</day>
<month>10</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2020 Telhig, Ben Said, Zirah, Fliss and Rebuffat.</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Telhig, Ben Said, Zirah, Fliss and Rebuffat</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<p>An overuse of antibiotics both in human and animal health and as growth promoters in farming practices has increased the prevalence of antibiotic resistance in bacteria. Antibiotic resistant and multi-resistant bacteria are now considered a major and increasing threat by national health agencies, making the need for novel strategies to fight bugs and super bugs a first priority. In particular, Gram-negative bacteria are responsible for a high proportion of nosocomial infections attributable for a large part to <italic>Enterobacteriaceae</italic>, such as pathogenic <italic>Escherichia coli</italic>, <italic>Klebsiella pneumoniae</italic>, and <italic>Pseudomonas aeruginosa</italic>. To cope with their highly competitive environments, bacteria have evolved various adaptive strategies, among which the production of narrow spectrum antimicrobial peptides called bacteriocins and specifically microcins in Gram-negative bacteria. They are produced as precursor peptides that further undergo proteolytic cleavage and in many cases more or less complex posttranslational modifications, which contribute to improve their stability and efficiency. Many have a high stability in the gastrointestinal tract where they can target a single pathogen whilst only slightly perturbing the gut microbiota. Several microcins and antibiotics can bind to similar bacterial receptors and use similar pathways to cross the double-membrane of Gram-negative bacteria and reach their intracellular targets, which they also can share. Consequently, bacteria may use common mechanisms of resistance against microcins and antibiotics. This review describes both unmodified and modified microcins [lasso peptides, siderophore peptides, nucleotide peptides, linear azole(in)e-containing peptides], highlighting their potential as weapons to thwart bacterial resistance in Gram-negative pathogens and discusses the possibility of cross-resistance and co-resistance occurrence between antibiotics and microcins in Gram-negative bacteria.</p>
</abstract>
<kwd-group>
<kwd>bacteriocins</kwd>
<kwd>microcins</kwd>
<kwd>antibiotics</kwd>
<kwd>resistance</kwd>
<kwd>Gram-negative bacteria</kwd>
<kwd>enterobacteria</kwd>
</kwd-group>
<counts>
<fig-count count="3"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="226"/>
<page-count count="25"/>
<word-count count="0"/>
</counts>
</article-meta>
</front>
<body>
<sec id="S1">
<title>Introduction</title>
<p>Since their discovery antibiotics have been routinely used in human medicine and in livestock production as therapeutic agents or growth promoters. Use of antibiotics for livestock greatly exceeds that of uses for humans, with approximately 70&#x2013;80 percent of total consumption (<xref ref-type="bibr" rid="B195">Van Boeckel et al., 2017</xref>). Furthermore, the global use of antibiotics would rise by 67% by 2030 in high-income countries and nearly double in Brazil, the Russian Federation, India, China and South Africa (<xref ref-type="bibr" rid="B194">Van Boeckel et al., 2015</xref>). According to the World Health Organization (<xref ref-type="bibr" rid="B210">World Health Organization [WHO], 2017</xref>) the overuse and misuse of antibiotics in human and animal, as well as the intrinsic capacity of antibiotics to induce broad spectrum killing (<xref ref-type="bibr" rid="B206">Wester et al., 2002</xref>) has led to the emergence of multidrug-resistant bacteria (MDR) that are rapidly increasing worldwide and have now become a serious public health problem. In 2016, the United Nations General Assembly recognized the use of antibiotics in the livestock sector as one of the primary causes of antimicrobial resistance (AMR) (<xref ref-type="bibr" rid="B195">Van Boeckel et al., 2017</xref>). Moreover, it has been shown that farm animal and human microbiota are reservoirs for AMR (<xref ref-type="bibr" rid="B78">Gibson et al., 2016</xref>; <xref ref-type="bibr" rid="B151">P&#x00E4;rn&#x00E4;nen et al., 2018</xref>; <xref ref-type="bibr" rid="B23">Brown et al., 2019</xref>; <xref ref-type="bibr" rid="B185">Sun et al., 2020</xref>). Currently, AMR is already killing 700,000 people a year, and it is predicted to cause 10 million deaths per year by 2050 with a cumulative cost of US&#x0024; 100 trillion (<xref ref-type="bibr" rid="B46">de Kraker et al., 2016</xref>). According to the Centers for Disease Control and Prevention (CDC) AMR challenge, <italic>Enterobacteriaceae</italic>, including <italic>Escherichia coli, Shigella</italic>, <italic>Salmonella</italic>, and <italic>Klebsiella</italic> spp. amongst others, present a serious and/or urgent threat to world health. Indeed, as Gram-negative bacteria, <italic>Enterobacteriaceae</italic> are notorious for their capacity to resist antimicrobial therapy (<xref ref-type="bibr" rid="B86">Hawkey, 2015</xref>; <xref ref-type="bibr" rid="B117">Li et al., 2015</xref>; <xref ref-type="bibr" rid="B225">Zowawi et al., 2015</xref>). Furthermore, even though <italic>Enterobacteriaceae</italic> represent only a small percentage of the host microbiota and are not all pathogens, they are still responsible for important morbidity (<xref ref-type="bibr" rid="B58">Doi et al., 2017</xref>; <xref ref-type="bibr" rid="B122">MacVane, 2017</xref>), making them an important target for new drug development.</p>
<p>The AMR crisis is exacerbated by the fact that resistances are emerging and disseminating faster than the development of new drugs. Indeed, over the past three decades the number of developed and approved antibiotics has more than halved (<xref ref-type="bibr" rid="B198">Ventola, 2015</xref>), leading to an increasing demand for new antimicrobial agents or strategies. Genetically modified phages, antibacterial modified oligonucleotides, inhibitors of bacterial virulence and CRISPR-Cas9 strategy are also discussed for extrapolating them to the field of antimicrobial therapeutics (<xref ref-type="bibr" rid="B55">Dickey et al., 2017</xref>; <xref ref-type="bibr" rid="B77">Ghosh et al., 2019</xref>). Meanwhile, other promising strategies, such as probiotics, lysins and antimicrobial peptides are in various stages of development (<xref ref-type="bibr" rid="B77">Ghosh et al., 2019</xref>). Globally, although several alternatives exist in nature, the challenge still remains to demonstrate their efficacy and their use in human and animal.</p>
<p>Bacteriocins form a large family of antimicrobial peptides (AMP) produced by bacteria (<xref ref-type="bibr" rid="B103">Klaenhammer, 1988</xref>). Their biological characteristics and activities have been deeply described in a new web-accessible database named BACTIBASE, which is freely available at the <ext-link ext-link-type="uri" xlink:href="http://bactibase.pfba-lab.org">http://bactibase.pfba-lab.org</ext-link> web-based platform. Bacteriocins can be either unmodified or posttranslationally modified peptides, the latter thus belonging to the large family of ribosomally synthesized and posttranslationally modified peptides (RiPPs) (<xref ref-type="bibr" rid="B7">Arnison et al., 2013</xref>; <xref ref-type="bibr" rid="B138">Montalb&#x00E1;n-L&#x00F3;pez et al., 2020</xref>). Known as inhibitors of pathogens <italic>in vitro</italic>, many bacteriocins have a high specific activity against clinical strains including antibiotic-resistant ones (<xref ref-type="bibr" rid="B43">Cotter et al., 2013</xref>). Their effectiveness as inhibitors of pathogenic and spoilage microorganisms has been largely explored (<xref ref-type="bibr" rid="B45">Davies et al., 1997</xref>; <xref ref-type="bibr" rid="B48">Deegan et al., 2006</xref>). It is thus widely believed that some could be usable for therapeutic purposes and as an alternative to conventional antibiotics (<xref ref-type="bibr" rid="B183">Snyder and Worobo, 2014</xref>; <xref ref-type="bibr" rid="B65">Egan et al., 2017</xref>).</p>
<p>Bacteriocins produced by enterobacteria are called microcins (<xref ref-type="bibr" rid="B13">Baquero and Moreno, 1984</xref>). They form a restricted and underexplored group of bacteriocins compared to the hundreds members of those from lactic acid bacteria, with only some twenty members identified so far, among which only around fifteen have been more deeply characterized (<xref ref-type="table" rid="T1">Table 1</xref> and <xref ref-type="supplementary-material" rid="FS1">Supplementary Figure S1</xref>). Microcins are less than 10 kDa modified or unmodified peptides (<xref ref-type="bibr" rid="B160">Rebuffat, 2012</xref>) having key ecological functions, and particularly a role in microbial competitions (<xref ref-type="bibr" rid="B12">Baquero et al., 2019</xref>; <xref ref-type="bibr" rid="B118">Li and Rebuffat, 2020</xref>). They have potent activity with minimum inhibitory concentrations (MIC) ranging in the nanomolar to micromolar range and narrow spectra of antimicrobial activity directed essentially against Gram-negative bacterial congeners (<xref ref-type="bibr" rid="B160">Rebuffat, 2012</xref>; <xref ref-type="bibr" rid="B12">Baquero et al., 2019</xref>). To exert their crucial roles in competition, microcins share a common strategy to penetrate into their bacterial targets. They piratize nutrient uptake pathways of phylogenetically close bacteria vying for the same resources. The iron import pathways is the most frequently attacked (<xref ref-type="bibr" rid="B160">Rebuffat, 2012</xref>). When inside bacteria, microcins interfere and perturb a variety of bacterial mechanisms, such as transcription (<xref ref-type="bibr" rid="B1">Adelman et al., 2004</xref>), translation (<xref ref-type="bibr" rid="B135">Metlitskaya et al., 2006</xref>), DNA structure (<xref ref-type="bibr" rid="B200">Viz&#x00E1;n et al., 1991</xref>), mannose transport (<xref ref-type="bibr" rid="B19">Bieler et al., 2006</xref>), energy production (<xref ref-type="bibr" rid="B193">Trujillo et al., 2001</xref>; <xref ref-type="bibr" rid="B224">Zhao et al., 2015</xref>), or the cell envelope function (<xref ref-type="bibr" rid="B54">Destoumieux-Garz&#x00F3;n et al., 2003</xref>; <xref ref-type="bibr" rid="B73">Gerard et al., 2005</xref>; <xref ref-type="bibr" rid="B224">Zhao et al., 2015</xref>). Due to their specific characteristics and complex mechanisms of action, microcins are viewed as a possible alternative to conventional antibiotics, helping with the immediate AMR problem (<xref ref-type="bibr" rid="B43">Cotter et al., 2013</xref>; <xref ref-type="bibr" rid="B136">Mills et al., 2017</xref>; <xref ref-type="bibr" rid="B121">Lu et al., 2019</xref>; <xref ref-type="bibr" rid="B149">Palmer et al., 2020</xref>). Because of their narrow spectrum of inhibition, they would potentially have less side effects than antibiotics, allowing preservation of the microbiota diversity and minimizing the risk of resistance dissemination.</p>
<table-wrap position="float" id="T1">
<label>TABLE 1</label>
<caption><p>Structural characterization of microcins assembled into posttranslationally modified microcins (classes I and IIb) and unmodified microcins (class IIa) that contain or not disulfide bridges.</p></caption>
<table cellspacing="5" cellpadding="5" frame="hsides" rules="groups">
<thead>
<tr>
<td valign="top" align="left">Class</td>
<td valign="top" align="left">Microcin</td>
<td valign="top" align="left">MM<sup>(a)</sup> (Da)</td>
<td valign="top" align="left">PTMs/disulfide bonds</td>
<td valign="top" align="left">Structure</td>
<td valign="top" align="left">Producing organism</td>
<td valign="top" align="left">References</td>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Class I (modified)</td>
<td valign="top" align="left">McC</td>
<td valign="top" align="left">1177</td>
<td valign="top" align="left">Peptidyladenylate with the C-terminal Asp<sup>7</sup> linked to AMP via a phosphoramidate linkage and bearing an aminopropyl on the phosphate</td>
<td valign="top" align="left">Nucleotide peptide</td>
<td valign="top" align="left"><italic>E. coli</italic></td>
<td valign="top" align="left"><xref ref-type="bibr" rid="B83">Guijarro et al., 1995</xref></td>
</tr>
<tr>
<td/>
<td valign="top" align="left">MccJ25</td>
<td valign="top" align="left">2107</td>
<td valign="top" align="left">Macrolactam ring between Gly<sup>1</sup> and Glu<sup>8</sup> threaded by the Tyr<sup>9</sup>- Gly<sup>21</sup> tail locked inside by Phe<sup>19</sup> and Tyr<sup>20</sup> side chains (lasso topology)</td>
<td valign="top" align="left">Lasso peptide</td>
<td valign="top" align="left"><italic>E. coli</italic></td>
<td valign="top" align="left"><xref ref-type="bibr" rid="B164">Rosengren et al., 2003</xref></td>
</tr>
<tr>
<td/>
<td valign="top" align="left">MccB17</td>
<td valign="top" align="left">3093</td>
<td valign="top" align="left">Gly<sup>39</sup>Ser<sup>40</sup>Cys<sup>41</sup> and Gly<sup>54</sup>Cys<sup>55</sup>Ser<sup>56</sup> motifs modified to oxazole-thiazole and thiazole-oxazole heterocycles</td>
<td valign="top" align="left">Linear azol(in)e-containing peptide (LAP)<sup>(b)</sup></td>
<td valign="top" align="left"><italic>E. coli</italic></td>
<td valign="top" align="left"><xref ref-type="bibr" rid="B119">Li et al., 1996</xref></td>
</tr>
<tr>
<td valign="top" align="left">Class IIa (unmodified)</td>
<td valign="top" align="left">MccV</td>
<td valign="top" align="left">8734</td>
<td valign="top" align="left">1 disulfide bond (Cys<sup>76</sup> &#x2013; Cys<sup>87</sup>)</td>
<td valign="top" align="left">Unmodified peptide</td>
<td valign="top" align="left"><italic>E. coli</italic></td>
<td valign="top" align="left"><xref ref-type="bibr" rid="B69">Fath et al., 1994</xref></td>
</tr>
<tr>
<td/>
<td valign="top" align="left">MccL</td>
<td valign="top" align="left">8884</td>
<td valign="top" align="left">2 disulfide bonds (Cys<sup>29</sup> &#x2013; Cys<sup>33</sup>; Cys<sup>78</sup> &#x2013; Cys<sup>89</sup>)</td>
<td valign="top" align="left">Unmodified peptide</td>
<td valign="top" align="left"><italic>E. coli</italic> LR05</td>
<td valign="top" align="left"><xref ref-type="bibr" rid="B156">Pons et al., 2004</xref></td>
</tr>
<tr>
<td/>
<td valign="top" align="left">MccS<sup>(c)</sup></td>
<td valign="top" align="left">9746</td>
<td valign="top" align="left">2 putative disulfide bonds (Cys<sup>57</sup>, Cys<sup>90</sup>, Cys<sup>109</sup>, Cys<sup>118</sup>)</td>
<td valign="top" align="left">Unmodified peptide</td>
<td valign="top" align="left"><italic>E. coli</italic> G3/10</td>
<td valign="top" align="left"><xref ref-type="bibr" rid="B226">Zsch&#x00FC;ttig et al., 2012</xref></td>
</tr>
<tr>
<td/>
<td valign="top" align="left">MccPDI<sup>(c)</sup><break/><break/><break/>MccN/24</td>
<td valign="top" align="left">9953<break/><break/><break/>7222</td>
<td valign="top" align="left">2 putative disulfide bonds (Cys<sup>57</sup>, Cys<sup>90</sup>, Cys<sup>109</sup>, Cys<sup>118</sup>) with Cys<sup>57</sup>-Cys <sup>90</sup> bond required for activity No disulfide bond (no Cys residue)</td>
<td valign="top" align="left">Unmodified peptide<break/><break/><break/>Unmodified peptide</td>
<td valign="top" align="left"><italic>E. coli</italic> 25<break/><break/><break/>Uropathogenic <italic>E. coli</italic></td>
<td valign="top" align="left"><xref ref-type="bibr" rid="B64">Eberhart et al., 2012</xref> <xref ref-type="bibr" rid="B98">Kaur et al., 2016</xref></td>
</tr>
<tr>
<td valign="top" align="left">Class IIb</td>
<td valign="top" align="left">MccE492</td>
<td valign="top" align="left">7887<sup>(d)</sup> 8718<sup>(e)</sup></td>
<td valign="top" align="left">Linear trimer of N-2,3-(dihydroxybenzoyl)-<sc>L</sc>-serine (DHBS) anchored at the C-terminal Ser<sup>84</sup></td>
<td valign="top" align="left">Siderophore peptide</td>
<td valign="top" align="left"><italic>K. pneumoniae</italic></td>
<td valign="top" align="left"><xref ref-type="bibr" rid="B187">Thomas et al., 2004</xref></td>
</tr>
<tr>
<td/>
<td valign="top" align="left">MccM</td>
<td valign="top" align="left">7284<sup>(d)</sup> 8115<sup>(e)</sup></td>
<td valign="top" align="left">Linear trimer of N-2,3-(dihydroxybenzoyl)-<sc>L</sc>-serine (DHBS) anchored at the C-terminal Ser<sup>77</sup></td>
<td valign="top" align="left">Siderophore peptide</td>
<td valign="top" align="left"><italic>E. coli</italic> Nissle 1917</td>
<td valign="top" align="left"><xref ref-type="bibr" rid="B196">Vassiliadis et al., 2010</xref></td>
</tr>
<tr>
<td/>
<td valign="top" align="left">MccH47</td>
<td valign="top" align="left">4865<sup>(d)</sup> 5696<sup>(e)</sup></td>
<td valign="top" align="left">Linear trimer of <italic>N</italic>-2,3-(dihydroxybenzoyl)-<sc>L</sc>-serine (DHBS) anchored at the C-terminal Ser<sup>60</sup></td>
<td valign="top" align="left">Siderophore peptide</td>
<td valign="top" align="left"><italic>E. coli</italic> Nissle 1917</td>
<td valign="top" align="left"><xref ref-type="bibr" rid="B196">Vassiliadis et al., 2010</xref></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<attrib><italic><sup>(a)</sup>Average masses with the cysteines involved in disulfide bonds when relevant.<sup>(b)</sup>Also termed thiazole-oxazole modified microcin (TOMM).<sup>(c)</sup>Putative structure.<sup>(d)</sup>Molecular mass without PTM.<sup>(e)</sup>Molecular mass including the DHBS trimer PTM.</italic></attrib>
</table-wrap-foot>
</table-wrap>
<p>However, since there is a finite number of entry points and potential targets within a bacterium, microcins and antibiotics can share similar bacterial receptors and pathways to reach their intracellular targets. Moreover, as for antibiotics, the application of specific microcins might be curtailed by the development of resistance (<xref ref-type="bibr" rid="B43">Cotter et al., 2013</xref>). Thus, bacteria might evolve common mechanisms of resistance against microcins and antibiotics. This review will highlight the potential of microcins as an alternative to antibiotics to fight against bacterial resistance in Gram-negative pathogens and discuss the possibilities of cross-resistance and co-resistance occurrence in Gram-negative bacteria.</p>
</sec>
<sec id="S2">
<title>Characteristics of Microcins</title>
<p>Bacteriocins that are produced by both Gram-positive and Gram-negative bacteria have been defined by <xref ref-type="bibr" rid="B93">James et al. (2013)</xref> as ribosomally synthesized peptides capable of mediating inhibitory effects against bacteria. In <italic>Enterobacteriaceae</italic> and more specifically in <italic>E. coli</italic>, microcins (for extensive reviews see <xref ref-type="bibr" rid="B13">Baquero and Moreno, 1984</xref>; <xref ref-type="bibr" rid="B62">Duquesne et al., 2007a</xref>; <xref ref-type="bibr" rid="B12">Baquero et al., 2019</xref>) have been shown to be produced along with colicins, which are large antibacterial proteins (<xref ref-type="bibr" rid="B32">Cascales et al., 2007</xref>). To distinguish them from colicins, the name &#x201C;microcin&#x201D; was coined since their first discovery (<xref ref-type="bibr" rid="B9">Asensio and Perez-Diaz, 1976</xref>), based on their smaller size of less than 10 kDa. Such as most bacteriocins, microcins are active against phylogenetically related bacteria including enteropathogenic <italic>Klebsiella</italic>, <italic>Shigella</italic>, <italic>Salmonella</italic> and <italic>E. coli</italic>, notorious for their capacity to develop antibiotic resistances, and considered serious and urgent threats by the CDC. These Gram-negative bacteriocins are ubiquitously distributed in Nature and their production is consistently observed in multiple genera. Those include <italic>Escherichia</italic>, <italic>Salmonella</italic>, <italic>Shigella</italic>, <italic>Klebsiella</italic>, <italic>Enterobacter</italic>, and <italic>Citrobacter</italic> (<xref ref-type="bibr" rid="B80">Gordon and O&#x2019;Brien, 2006</xref>; <xref ref-type="bibr" rid="B81">Gordon et al., 2007</xref>; <xref ref-type="bibr" rid="B24">Budic et al., 2011</xref>; <xref ref-type="bibr" rid="B61">Drissi et al., 2015</xref>; <xref ref-type="bibr" rid="B202">Wang et al., 2016</xref>; <xref ref-type="bibr" rid="B36">Cheung-Lee et al., 2019</xref>). The development of DNA sequencing methods and the availability of an increasing number of genomes revealed that clusters of genes orthologous to microcin biosynthesis and self-immunity genes are widespread in bacteria. Indeed, analogs of historically described microcins produced by <italic>Enterobacteriaceae</italic>, essentially in the RiPP family, have been predicted and most often deeply characterized in other Gram-negative bacteria including human pathogens, <italic>Helicobacter</italic> (<xref ref-type="bibr" rid="B11">Bantysh et al., 2014</xref>), <italic>Burkholderia</italic> (<xref ref-type="bibr" rid="B104">Knappe et al., 2008</xref>), <italic>Pseudomonas</italic> (<xref ref-type="bibr" rid="B134">Metelev et al., 2013</xref>), <italic>Klebsiella</italic> (<xref ref-type="bibr" rid="B132">Metelev et al., 2017a</xref>, <xref ref-type="bibr" rid="B133">b</xref>; <xref ref-type="bibr" rid="B190">Travin et al., 2020</xref>), <italic>Acinetobacter</italic> (<xref ref-type="bibr" rid="B132">Metelev et al., 2017a</xref>), <italic>Citrobacter</italic> (<xref ref-type="bibr" rid="B36">Cheung-Lee et al., 2019</xref>), or in the symbiotic nitrogen-fixing bacterium <italic>Rhizobium</italic> (<xref ref-type="bibr" rid="B191">Travin et al., 2019</xref>) (<xref ref-type="supplementary-material" rid="FS1">Supplementary Figure S1A</xref>). They were even predicted in Gram-positive bacteria and cyanobacteria (<xref ref-type="bibr" rid="B11">Bantysh et al., 2014</xref>). This points that a sharp distinction between bacteriocins from Gram-positive and Gram-negative bacteria is artificial and that the chemical diversity of microcin-like peptides is intended to expand rapidly.</p>
<sec id="S2.SS1">
<title>The Two Classes of Microcins</title>
<p>Compared to the huge number of Gram-positive bacteriocins, microcins are distinguished by a high structural heterogeneity inside a restricted number of identified and well-characterized representatives. A widely accepted classification was proposed by <xref ref-type="bibr" rid="B62">Duquesne et al. (2007a)</xref> based on both the peptide size and degree of posttranslational modification (PTM). The known microcins are grouped in two classes, class I with molecular masses below 5 kDa and the presence of extensive PTM and class II with molecular masses between 5 and 10 kDa that can be modified or not (<xref ref-type="table" rid="T1">Table 1</xref>). A brief description of the microcins from the two classes is provided below to help following the next sections. For more detailed overview of the microcins, see two recent reviews (<xref ref-type="bibr" rid="B12">Baquero et al., 2019</xref>; <xref ref-type="bibr" rid="B118">Li and Rebuffat, 2020</xref>).</p>
<p>Class I assembles three plasmid-encoded microcins that have been well structurally characterized as RiPPs (<xref ref-type="supplementary-material" rid="FS1">Supplementary Figure S1A</xref>): microcin C (McC) a nucleotide peptide, microcin B17 (MccB17) a linear azol(in)e-containing peptide, and microcin J25 (MccJ25), a lasso peptide. McC is presently the only nucleotide member of the family. However, similar biosynthetic gene clusters are distributed within bacterial genomes (<xref ref-type="bibr" rid="B11">Bantysh et al., 2014</xref>), which suggests an unexplored diversity for such peptides. McC is produced by <italic>E. coli</italic> cells harboring the <italic>mccABCDEF</italic> gene cluster (<xref ref-type="fig" rid="F1">Figure 1</xref>) under a <italic>mccA</italic>-encoded formylated heptapeptide precursor, which is further modified (<xref ref-type="bibr" rid="B83">Guijarro et al., 1995</xref>; <xref ref-type="bibr" rid="B177">Severinov and Nair, 2012</xref>) and processed into a structural mimic of aspartyl adenylate which is the toxic entity (<xref ref-type="bibr" rid="B100">Kazakov et al., 2008</xref>) (<xref ref-type="supplementary-material" rid="FS1">Supplementary Figure S1A</xref>). MccB17 is produced as a 69 amino acid precursor by <italic>E. coli</italic> strains bearing the <italic>mcbABCDEFG</italic> gene cluster (<xref ref-type="fig" rid="F1">Figure 1</xref>). Mature MccB17 contains 43 amino acids that are structured into thiazole and oxazole heterocycles (4 thiazoles and 4 oxazoles rings either isolated or fused into oxazole/thiazole- and thiazole/oxazole-bis-heterocycles) by the PTM enzymes (<xref ref-type="bibr" rid="B119">Li et al., 1996</xref>; <xref ref-type="bibr" rid="B76">Ghilarov et al., 2019</xref>) (<xref ref-type="supplementary-material" rid="FS1">Supplementary Figure S1A</xref>). Such heterocycles are also found in hybrid non-ribosomal peptide-polyketide natural products such as the anti-tumor drug bleomycin, as well as in RiPPs such as cyanobactin (<xref ref-type="bibr" rid="B130">McIntosh and Schmidt, 2010</xref>) or streptolysin (<xref ref-type="bibr" rid="B137">Mitchell et al., 2009</xref>), forming the LAP [also termed thiazole/oxazole-modified microcin (TOMM)] peptide family (<xref ref-type="bibr" rid="B131">Melby et al., 2011</xref>). Microcin B-like bacteriocins produced by <italic>Pseudomonas, Klebsiella</italic> and <italic>Rhizobium</italic> have been reported (<xref ref-type="bibr" rid="B134">Metelev et al., 2013</xref>, <xref ref-type="bibr" rid="B133">2017b</xref>; <xref ref-type="bibr" rid="B191">Travin et al., 2019</xref>). MccJ25 was isolated first from the <italic>E. coli</italic> strain AY25 isolated from an infant feces bearing the <italic>mcjABCD</italic> gene cluster (<xref ref-type="bibr" rid="B170">Salom&#x00F3;n and Farias, 1992</xref>) (<xref ref-type="fig" rid="F1">Figure 1</xref>). Its maturation from a 58 amino acid precursor into a 21 amino acid lasso peptide is ensured by two enzymes, McjB and McjC, encoded in the microcin gene cluster (<xref ref-type="bibr" rid="B63">Duquesne et al., 2007b</xref>; <xref ref-type="bibr" rid="B212">Yan et al., 2012</xref>). This unique lasso topology, which is characterized by threading of the C-terminal tail through a seven to nine lactam ring closed by an isopeptide bond, is locked in place with the two bulky side chains of Phe and Tyr aromatic amino acids for MccJ25 (<xref ref-type="bibr" rid="B164">Rosengren et al., 2003</xref>) (<xref ref-type="supplementary-material" rid="FS1">Supplementary Figure S1A</xref>). It is responsible for the sturdiness of MccJ25 and is required for its antibacterial activity (<xref ref-type="bibr" rid="B161">Rebuffat et al., 2004</xref>; <xref ref-type="bibr" rid="B204">Wang and Zhang, 2018</xref>). Genome mining approaches have revealed a wide distribution of lasso peptides in Gram-positive and Gram-negative bacteria (<xref ref-type="bibr" rid="B123">Maksimov et al., 2012</xref>; <xref ref-type="bibr" rid="B88">Hegemann et al., 2013</xref>; <xref ref-type="bibr" rid="B188">Tietz et al., 2017</xref>; <xref ref-type="bibr" rid="B35">Cheung-Lee and Link, 2019</xref>). Many lasso peptides produced by proteobacteria do not show antibacterial activity (<xref ref-type="bibr" rid="B88">Hegemann et al., 2013</xref>). This questions their ecological role or can be due to difficulty to decipher the reasons for their narrow activity spectrum.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption><p>A schematic representation of archetypical organization of microcin and microcin-like gene clusters. Arrows indicate individual microcin genes; arrows are not drown to scale and their direction does not necessarily indicate the direction of transcription that can change between homologous specific gene clusters. The A genes code for the precursors. Genes coding for microcin PTM enzymes and for export systems (efflux pumps, ABC exporters) that expel the microcins out of the producers are in blue and in violet, respectively. Genes whose products contribute to self-immunity of the producing strains (either immunity proteins or exporters/efflux pumps) are colored yellow. When genes code for proteins ensuring simultaneously two functions, they harbor the two corresponding colors. The gene coding for RRE, which ensures leader peptide recognition in MccJ25 and MccJ25-like peptides is shown as hatched motif. The functions of the different PTM enzymes are indicated as follows, taking McC, MccB17, MccJ25 and MccE492 as models. McC and analogs: <italic>mccB</italic> product ensures MccA adenylation, <italic>mccD-</italic> and <italic>mccE-</italic>encoded enzymes (MccD and MccE N-terminal domain) are required for phosphate modification with propylamine; MccB17 and analogs: <italic>mcbBCD-</italic>encoded three-component synthetase catalyzes dehydration and cyclization to form azolines, which are subsequently oxidized to azoles; MccJ25 and analogs: <italic>mcjC</italic> product acts as a lasso cyclase that closes the macrolactam ring through an isopeptide bond and <italic>mcjB</italic> product is a leader peptidase; MccE492 and siderophore peptides: <italic>mceCDIJ</italic> are required for PTM with <italic>mceC</italic> encoding a glycosyltransferase that ensures glycosylation of enterobactin and <italic>mceD</italic> an enterobactin esterase that cleaves the glycosylated enterobactin macrolactone ring into its linear derivatives. <italic>mceIJ</italic> are involved in attachment of the PTM to MccE492 C-terminus. The function of <italic>mceE</italic> gene (gray) is undefined.</p></caption>
<graphic xlink:href="fmicb-11-586433-g001.tif"/>
</fig>
<p>Class II microcins form a more homogeneous group than their class I cousins (<xref ref-type="table" rid="T1">Table 1</xref> and <xref ref-type="supplementary-material" rid="FS1">Supplementary Figures S1B,C</xref>), although they are subdivided into class IIa, encompassing MccL (<xref ref-type="bibr" rid="B156">Pons et al., 2004</xref>), MccN/24 (<xref ref-type="bibr" rid="B98">Kaur et al., 2016</xref>), MccPDI (<xref ref-type="bibr" rid="B64">Eberhart et al., 2012</xref>), MccS (<xref ref-type="bibr" rid="B226">Zsch&#x00FC;ttig et al., 2012</xref>) and MccV (<xref ref-type="bibr" rid="B82">Gratia, 1925</xref>), and class IIb (MccE492, MccH47, MccM, <xref ref-type="bibr" rid="B196">Vassiliadis et al., 2010</xref>). MccN was formely termed Mcc24 (<xref ref-type="bibr" rid="B146">O&#x2019;Brien and Mahanty, 1994</xref>) and is termed MccN/24 in this review. What distinguishes class IIa from class IIb is the presence or not of a siderophore moiety derived from enterobactin anchored at the peptide C-terminal serine carboxylate (<xref ref-type="supplementary-material" rid="FS1">Supplementary Figures S1B,C</xref>). This catechol-type siderophore PTM sparked coining the name &#x201C;siderophore microcins&#x201D; to class IIb microcins (<xref ref-type="bibr" rid="B160">Rebuffat, 2012</xref>). Class II microcins result from a proteolytic processing of a precursor with a leader peptide extension, which occurs at a conserved double-glycine (or Gly-Ala) cleavage site, concomitantly with secretion. They have molecular masses between 5 and 10 kDa and exhibit high amino acid sequence similarities, even between class IIa and IIb (<xref ref-type="supplementary-material" rid="FS1">Supplementary Figures S1B,C</xref>). For examples, the class IIa unmodified MccV and MccN/24 possess high sequence similarities with the class IIb MccH47 and MccE492, respectively, although they do not carry a C-terminal PTM (<xref ref-type="bibr" rid="B145">O&#x2019;Brien, 1996</xref>; <xref ref-type="bibr" rid="B42">Corsini et al., 2010</xref>). It was suggested that the conserved C-terminal sequence of these microcins can direct the presence or not of the siderophore PTM and that the C-terminal regions of MccV and MccH47 can be interchanged (<xref ref-type="bibr" rid="B10">Azpiroz and Lavi&#x00F1;a, 2007</xref>). It was further proposed that both class IIa and IIb microcins possess a modular structure (<xref ref-type="bibr" rid="B10">Azpiroz and Lavi&#x00F1;a, 2007</xref>; <xref ref-type="bibr" rid="B139">Morin et al., 2011</xref>).</p>
<p>Class IIa microcins have been characterized from <italic>E. coli</italic> strains from various origins. The MccN/24 producer is an uropathogenic <italic>E. coli</italic> (<xref ref-type="bibr" rid="B98">Kaur et al., 2016</xref>) and the MccL producer comes from poultry intestine (<xref ref-type="bibr" rid="B166">Sabl&#x00E9; et al., 2003</xref>), while MccS is produced by a probiotic strain, <italic>E. coli</italic> G3/10 (Symbioflor2<sup>&#x00AE;</sup>; DSM17252) (<xref ref-type="bibr" rid="B226">Zsch&#x00FC;ttig et al., 2012</xref>). The producing strains are in some cases multi-microcin producers, such as <italic>E. coli</italic> LR05 that secretes MccB17, MccJ25 and the uncharacterized MccD93 in addition to MccL (<xref ref-type="bibr" rid="B166">Sabl&#x00E9; et al., 2003</xref>). Their gene cluster organization includes the four basic genes only, one structural gene encoding the precursor peptide, two export genes and one immunity gene (<xref ref-type="bibr" rid="B226">Zsch&#x00FC;ttig et al., 2012</xref>) (<xref ref-type="fig" rid="F1">Figure 1</xref>). If the five class IIa microcins are all devoid of PTMs, they are also all except MccN/24, stabilized by one (MccV) or two (MccL, MccPDI, MccS) disulfide bonds (<xref ref-type="bibr" rid="B213">Yang and Konisky, 1984</xref>; <xref ref-type="bibr" rid="B166">Sabl&#x00E9; et al., 2003</xref>; <xref ref-type="bibr" rid="B73">Gerard et al., 2005</xref>; <xref ref-type="bibr" rid="B139">Morin et al., 2011</xref>; <xref ref-type="bibr" rid="B226">Zsch&#x00FC;ttig et al., 2012</xref>) (<xref ref-type="table" rid="T1">Table 1</xref> and <xref ref-type="supplementary-material" rid="FS1">Supplementary Figure S1B</xref>).</p>
<p>Contrasting with class IIa and class I, class IIb microcins (<xref ref-type="supplementary-material" rid="FS1">Supplementary Figure S1C</xref>) are chromosome-encoded (<xref ref-type="bibr" rid="B154">Poey et al., 2006</xref>). MccE492 is secreted by <italic>Klebsiella pneumoniae</italic> human fecal strain RYC492 (<xref ref-type="bibr" rid="B47">de Lorenzo, 1984</xref>) bearing the <italic>mceABCDEFGHIJ</italic> gene cluster (<xref ref-type="bibr" rid="B53">Destoumieux-Garz&#x00F3;n et al., 2006</xref>; <xref ref-type="bibr" rid="B197">Vassiliadis et al., 2007</xref>; <xref ref-type="bibr" rid="B142">Nolan and Walsh, 2008</xref>) (<xref ref-type="fig" rid="F1">Figure 1</xref>). It is the first siderophore microcin to be characterized (<xref ref-type="bibr" rid="B187">Thomas et al., 2004</xref>), although it was primarily described as an unmodified peptide (<xref ref-type="bibr" rid="B207">Wilkens et al., 1997</xref>). Actually, it was shown further to be secreted under both modified and less active unmodified forms, due to its PTM process (<xref ref-type="bibr" rid="B197">Vassiliadis et al., 2007</xref>). The MccE492 PTM was identified as a glucosylated linear trimer of <italic>N</italic>-(2,3 dihydroxybenzoyl)-<sc>L</sc>-serine (DHBS) linked to the C-terminal serine carboxylate (<xref ref-type="supplementary-material" rid="FS1">Supplementary Figure S1C</xref>). The functions of the enzymes involved in establishment of the MccE492 PTM, MceC, MceD, MceI/MceJ, were identified (<xref ref-type="bibr" rid="B197">Vassiliadis et al., 2007</xref>; <xref ref-type="bibr" rid="B142">Nolan and Walsh, 2008</xref>). MccH47, initially isolated from the human fecal <italic>E. coli</italic> strain H47 (<xref ref-type="bibr" rid="B112">Lavi&#x00F1;a et al., 1990</xref>) and MccM were both characterized as siderophore microcins produced by several <italic>E. coli</italic> strains, including the probiotic strain Nissle, 1917 (Mutaflor<sup>&#x00AE;</sup>) (<xref ref-type="bibr" rid="B196">Vassiliadis et al., 2010</xref>). MccH47 and MccM carry the same PTM as MccE492 (<xref ref-type="bibr" rid="B196">Vassiliadis et al., 2010</xref>). Siderophore microcins possess a modular structure, where the N-terminal region is responsible for their cytotoxicity and the C-terminal region, which carries the siderophore moiety, is involved in recognition and uptake. For an overview on siderophore microcins, see <xref ref-type="bibr" rid="B126">Massip and Oswald (2020)</xref>.</p>
</sec>
<sec id="S2.SS2">
<title>Biosynthesis of Microcins</title>
<p>Microcin production takes place in the stationary phase (<xref ref-type="bibr" rid="B13">Baquero and Moreno, 1984</xref>) of bacterial growth, with the exceptions of MccE492 (<xref ref-type="bibr" rid="B47">de Lorenzo, 1984</xref>) and MccPDI (<xref ref-type="bibr" rid="B64">Eberhart et al., 2012</xref>). They are encoded by gene clusters, which exhibit a conserved organization, but contain a variable number of genes ranging from four to ten, according to the presence or not of PTMs on the mature microcin (<xref ref-type="fig" rid="F1">Figure 1</xref>). These gene clusters are generally plasmid-borne, except the chromosomally encoded class IIb microcins. The general biosynthetic pathway of microcins (which also applies to other bacteriocins) starts with the ribosomal synthesis of a precursor peptide that is typically composed of two regions, an N-terminal leader part and a core region. The core peptide of modified microcins, which belong to the wide RiPP family, is the region where the PTMs take place (<xref ref-type="bibr" rid="B138">Montalb&#x00E1;n-L&#x00F3;pez et al., 2020</xref>). In some cases, such as the siderophore microcins, the modifications may result from the non-ribosomal pathway, making these microcins a rare bridge spanning ribosomal and non-ribosomal biosynthesis pathways (<xref ref-type="bibr" rid="B129">McIntosh et al., 2009</xref>). The leader is involved in binding to or activation of many of the PTM enzymes, but also maintains the maturing peptide inactive during the process (<xref ref-type="bibr" rid="B7">Arnison et al., 2013</xref>), thus contributing to the protection of producing cells as regard their own toxic microcin. For many modified microcins (MccJ25, McC), this binding involves a peptide binding domain (RiPP precursor peptide recognition element, RRE), also present in a wide proportion of RiPP PTM enzymes and similar to a small protein involved in the biosynthesis of the RiPP pyrroloquinoline quinone (PQQ) (<xref ref-type="bibr" rid="B25">Burkhart et al., 2015</xref>; <xref ref-type="bibr" rid="B180">Sikandar and Koehnke, 2019</xref>). Recently, the crystal structure of the McbBCD synthetase ensuring the extensive modifications in MccB17 was solved, deciphering the organization and functioning of such a multimeric heterocyclase-dehydrogenase catalytic complex at the molecular level and affording the spatial relationships between the two distinct enzymatic activities and the leader peptide binding site (<xref ref-type="bibr" rid="B76">Ghilarov et al., 2019</xref>).</p>
<p>In all but a few cases, and irrespective of if the microcin is modified or not, maturation requires removal of the leader region to give the active bacteriocin (<xref ref-type="bibr" rid="B60">Drider and Rebuffat, 2011</xref>). This proteolytic cleavage is performed either before and independently of (class I), or concomitantly with (class II) export of the mature microcin (<xref ref-type="bibr" rid="B14">Beis and Rebuffat, 2019</xref>). It can be ensured either (i)- concomitantly with the PTM establishment by one of the dedicated enzymes (MccJ25 leader is cleaved off by the McjB leader peptidase encoded in the microcin gene cluster (<xref ref-type="bibr" rid="B212">Yan et al., 2012</xref>), or (ii)- by a protease from the producer, which is not encoded in the microcin gene cluster (MccB17 leader is cleaved off before export by the conserved proteins TldD/TldE which assemble as a heterodimeric metalloprotease to ensure this function) (<xref ref-type="bibr" rid="B75">Ghilarov et al., 2017</xref>), or (iii)- by a bifunctional ATP binding cassette (ABC) transporter of the peptidase-containing ATP-binding transporters (PCAT) family, which is encoded in the microcin gene cluster (cleavage of the class II microcin leader peptides is performed simultaneously with export of the maturated microcins by an ABC exporter endowed with an N-terminal protease extension) (<xref ref-type="bibr" rid="B85">H&#x00E5;varstein et al., 1995</xref>; <xref ref-type="bibr" rid="B126">Massip and Oswald, 2020</xref>).</p>
</sec>
<sec id="S2.SS3">
<title>Self-Immunity of Microcin Producers</title>
<p>Microcin gene clusters vary in the number of genes contained and the presence of genes encoding PTM enzymes, and they all carry genes ensuring self-immunity (<xref ref-type="fig" rid="F1">Figure 1</xref>). Each microcinogenic strain is protected against its arsenal of microcins and the self-immunity mechanisms differ from one microcin to another. For instance the self-immunity mechanism to McC is complex and relies on the products of three genes <italic>mccC</italic>, <italic>mccE</italic>, and <italic>mccF</italic> that ensure export of unprocessed microcin outside the cells (MccC pump) and modification of processed McC (MccE and MccF enzymes) (see section mechanisms of resistance) (<xref ref-type="bibr" rid="B143">Novikova et al., 2010</xref>; <xref ref-type="bibr" rid="B2">Agarwal et al., 2011</xref>, <xref ref-type="bibr" rid="B3">2012</xref>). By contrast, the immunity mechanism to MccL depends on a single gene <italic>mclI</italic> that encodes an immunity protein (<xref ref-type="bibr" rid="B166">Sabl&#x00E9; et al., 2003</xref>). Overall, self-immunity of the producers relies either on specific immunity proteins encoded in the gene clusters that bind to the toxic entities making them inefficient, or on efflux systems, mainly ABC transporters, which ensure export of the microcins to the external medium and simultaneously self-immunity of the producing bacteria. As examples, self-immunity to MccJ25 is provided exclusively by McjD, a highly specific ABC exporter which ensures simultaneously export of the microcin (<xref ref-type="bibr" rid="B14">Beis and Rebuffat, 2019</xref>), while full self-immunity to MccB17 requires both an immunity protein McbG and an ABC exporter McbEF (<xref ref-type="bibr" rid="B41">Collin and Maxwell, 2019</xref>).</p>
</sec>
</sec>
<sec id="S3">
<title>Mechanisms of Action</title>
<p>Comparison of the mechanisms used by antibiotics and microcins to kill sensitive bacteria shows that they may share different bacterial receptors, translocators and final targets (<xref ref-type="table" rid="T2">Table 2</xref> and <xref ref-type="fig" rid="F2">Figure 2</xref>). Thus, it is obvious that these two groups of antimicrobials may cross in several mechanisms of action. However, it is also expected that several mechanisms of action of microcins are very specific and are not involved in the inhibition activity of antibiotics. This characteristic is particularly relevant to address in terms of the risk of cross-resistance between microcins and antibiotics. These similarities and differences are highlighted below.</p>
<table-wrap position="float" id="T2">
<label>TABLE 2</label>
<caption><p>Comparison of the mechanisms involved in the antibacterial activity and the bacterial resistance for well characterized microcins and for conventional antibiotics sharing common targets with microcins.</p></caption>
<table cellspacing="5" cellpadding="5" frame="hsides" rules="groups">
<thead>
<tr>
<td valign="top" align="left">Antibiotic/Microcin</td>
<td valign="top" align="center" colspan="2">Mechanisms of action<hr/></td>
<td valign="top" align="center" colspan="2">Mechanisms of resistance<hr/></td>
</tr>
<tr>
<td/>
<td valign="top" align="left">Function impaired/<italic>Target</italic></td>
<td valign="top" align="left">Uptake system (OM/IM)</td>
<td valign="top" align="left">Process/<italic>Target</italic></td>
<td valign="top" align="left">Mechanism</td>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Penicillins Cephalosporins Beta-lactams</td>
<td valign="top" align="left">&#x2013; Bacterial cell wall disruption/<italic>Peptidoglycan breaking</italic></td>
<td valign="top" align="left">&#x2013; Porins; self-promoted pathway</td>
<td valign="top" align="left">&#x2013; Inactivation/&#x03B2;<italic>-lactam ring</italic><break/>&#x2013; Mutations/<italic>TonB Porins</italic><break/>&#x2013; Efflux pumps overexpression</td>
<td valign="top" align="left">&#x2013; &#x03B2;-lactam ring cleavage by &#x03B2;-lactamases<break/>&#x2013; Decrease of uptake of the antibiotic due to modifications of TonB sequence<break/>&#x2013; Decrease of uptake of the antibiotic<break/>&#x2013; Pumping out of the antibiotic</td>
</tr>
<tr>
<td valign="top" align="left">Fosfomycin</td>
<td valign="top" align="left">&#x2013; Bacterial cell wall/<italic>Peptidoglycan biosynthesis: UDP-N-acetylglucosamine enolpyruvyl transferase, MurA</italic><break/>&#x2013; Sugar transport into the cytoplasm</td>
<td valign="top" align="left">&#x2013; GlpT, UhpT sugar transporters</td>
<td valign="top" align="left">&#x2013; Mutations/<italic>Mur A</italic></td>
<td valign="top" align="left">&#x2013; Cys-Arg mutation in MurA active site<break/>&#x2013; Mutations in GlpT, UhpT transporters</td>
</tr>
<tr>
<td valign="top" align="left">Polymixins Colistin/polymixin E</td>
<td valign="top" align="left">&#x2013; Membrane permeabilization/<italic>LPS binding leading to detergent effect</italic><break/>&#x2013; Endotoxin neutralization</td>
<td valign="top" align="left">&#x2013; Porins</td>
<td valign="top" align="left">&#x2013; Enzymatic modification/<italic>LPS</italic><break/>&#x2013; Efflux pumps overexpression</td>
<td valign="top" align="left">&#x2013; Modification of LPS by the MCR1 phosphoethanolamine transferase<break/>&#x2013; Pumping out of the antibiotic</td>
</tr>
<tr>
<td valign="top" align="left">Rifamycins Rifampicin</td>
<td valign="top" align="left">&#x2013; Protein synthesis- Transcription step/<italic>&#x03B2; subunit of RNAP</italic></td>
<td valign="top" align="left">&#x2013; Siderophore receptor FhuA<break/>&#x2013; TonB system</td>
<td valign="top" align="left">Mutations./<italic>RNAP &#x03B2; subunit</italic></td>
<td valign="top" align="left">&#x2013; Mutations in <italic>rpoB</italic> gene</td>
</tr>
<tr>
<td valign="top" align="left">Streptolydigin</td>
<td valign="top" align="left">&#x2013; Protein synthesis-Transcription step/<italic>Inhibition of RNAP catalytic function by binding &#x03B2; and &#x03B2;&#x2032; subunits</italic></td>
<td valign="top" align="left">&#x2013; Porins</td>
<td valign="top" align="left">&#x2013; Mutations/<italic>RNAP &#x03B2; and &#x03B2;&#x2032; subunits</italic></td>
<td valign="top" align="left">&#x2013; Mutations in <italic>rpoB</italic> and <italic>rpoC</italic></td>
</tr>
<tr>
<td valign="top" align="left">Albomycin</td>
<td valign="top" align="left">&#x2013; Protein synthesis<break/>&#x2013; Translation step/<italic>Aminoacyl t-RNA synthetase</italic></td>
<td valign="top" align="left">&#x2013; Siderophore receptor FhuA<break/>&#x2013; TonB system</td>
<td valign="top" align="left">&#x2013; Enzymatic modification/<italic>Processed albomycin</italic></td>
<td valign="top" align="left">&#x2013; Acetylation of processed albomycin by transacetylase RimL</td>
</tr>
<tr>
<td valign="top" align="left">Quinolones (nalidixic acid, ciprofloxacin, norfloxacin,&#x2026;)</td>
<td valign="top" align="left">DNA replication/<italic>Type II topoisomerases (DNA gyrase, topoisomerase IV</italic>)</td>
<td/>
<td valign="top" align="left">&#x2013; Mutations<break/>&#x2013; Protein interactions/<italic>DNA gyrase, topoisomerase IV</italic><break/>&#x2013; Enzymatic modification/<italic>Piperazine ring</italic><break/>&#x2013; Mutations/<italic>Porins</italic><break/>&#x2013; Efflux pumps overexpression</td>
<td valign="top" align="left">&#x2013; Mutations in <italic>gyrA, gyrB</italic> or <italic>parC, parE</italic> (Ser<sup>83</sup> in GyrA)<break/>&#x2013; Protection of DNA gyrase and topoisomerase IV by the gyrase interacting protein qnr<break/>&#x2013; Piperazine ring acetylation (AAC(6&#x2018;)-Ib-c)<break/>&#x2013; Decrease of uptake of the antibiotic<break/>&#x2013; Pumping out of the antibiotic</td>
</tr>
<tr>
<td valign="top" align="left">Chloramphenicol</td>
<td valign="top" align="left">&#x2013; Protein synthesis/<italic>Binding to 50S ribosome subunit inhibiting the formation of peptide bonds</italic></td>
<td valign="top" align="left">&#x2013; Membrane transporter</td>
<td valign="top" align="left">&#x2013; Enzymatic modification/<italic>Chloramphenicol</italic></td>
<td valign="top" align="left">&#x2013; Acetylation by chloramphenicol acetyltransferases CATs</td>
</tr>
<tr>
<td valign="top" align="left">Aminoglycosides</td>
<td valign="top" align="left">&#x2013; Protein synthesis<break/>&#x2013; Translation step/<italic>Binding to 30S ribosome subunit</italic></td>
<td/>
<td valign="top" align="left">&#x2013; Enzymatic modification/<italic>Aminoglycosides</italic></td>
<td valign="top" align="left">&#x2013; Acetylation by acetyltransferases (AACs)<break/>&#x2013; Phosphorylation by phosphotransferases (APHs)<break/>&#x2013; Adenylation by nucleotidyltranferases (ANTs)</td>
</tr>
<tr>
<td valign="top" align="left">Tetracyclines</td>
<td valign="top" align="left">Protein synthesis -Translation step/<italic>Binding to 30S ribosome subunit that blocks aminoacyl-tRNA binding to RNA-ribosome complex</italic></td>
<td valign="top" align="left">&#x2013; Porins OmpF, OmpC</td>
<td valign="top" align="left">&#x2013; Resistance genes acquisition<break/>&#x2013; Enzymatic modification/<italic>Tetracyclines</italic><break/>&#x2013; Efflux pumps expression</td>
<td valign="top" align="left">&#x2013; Acquisition of <italic>tet</italic>, or <italic>otr</italic> resistance genes leading to production of ribosomal production proteins Tet<break/>&#x2013; Methylation by rRNA methylase<break/>&#x2013; Pumping out of the antibiotic</td>
</tr>
<tr>
<td valign="top" align="left">MccJ25</td>
<td valign="top" align="left">&#x2013; Protein synthesis-Transcription step/<italic>Binding to &#x03B2;&#x2032; subunit of RNAP (secondary channel)</italic></td>
<td valign="top" align="left">&#x2013; Siderophore receptor FhuA<break/>&#x2013; TonB system<break/>&#x2013; SbmA</td>
<td valign="top" align="left">&#x2013; Mutations/<italic>RNAP &#x03B2;&#x2032; subunit</italic><break/>&#x2013; Efflux pumps expression</td>
<td valign="top" align="left">&#x2013; Mutation in <italic>rpoC</italic> that encodes RNAP <italic>&#x03B2;&#x2032;</italic> subunit (T<sup>931</sup>I) and additional mutations (Q<sup>921</sup>P, T<sup>934</sup>M, H<sup>936</sup>Y)<break/>&#x2013; Pumping out of the microcin by ABC exporters (McjB, YojI)/TolC</td>
</tr>
<tr>
<td valign="top" align="left">MccB17</td>
<td valign="top" align="left">&#x2013; DNA replication and topology maintenance/<italic>Binding to DNA gyrase</italic></td>
<td valign="top" align="left">&#x2013; Porin OmpF/<break/>&#x2013; SbmA</td>
<td valign="top" align="left">&#x2013; Mutations/<italic>GyrB, GyrA OmpF, OmpR SbmA</italic><break/>&#x2013; Efflux pumps expression</td>
<td valign="top" align="left">&#x2013; Mutations in GyrB and GyrA: GyrB (W<sup>751</sup>R): full resistance; GyrB (K<sup>447</sup>E), GyrA (S<sup>83</sup>W): partial resistance<break/>&#x2013; Mutations in <italic>omp</italic>F and <italic>omp</italic>R<break/>&#x2013; Pumping out of the antibiotic by ABC exporter (McbEF)</td>
</tr>
<tr>
<td valign="top" align="left">McC</td>
<td valign="top" align="left">&#x2013; Protein synthesis<break/>&#x2013; Translation step/<italic>Aspartyl-tRNA synthetase (Asp-RS)</italic></td>
<td valign="top" align="left">&#x2013; Porin OmpF/YejABEF</td>
<td valign="top" align="left">&#x2013; Inactivation of the antibiotic <italic>Processed McC</italic><break/>&#x2013; Efflux pumps expression</td>
<td valign="top" align="left">&#x2013; Acetylation of processed McC by transacetylases [either encoded in McC gene cluster (MccE) or chromosome-encoded (RimL)]<break/>&#x2013; Cleavage of the heptapeptide-nucleotide amide bond by carboxypeptidases [serine carboxypeptidase encoded in McC gene cluster (MccF)]<break/>&#x2013; Cleavage of the phosphoramide bond in aspartamide adenosine by histidine triad hydrolases<break/>&#x2013; Pumping out of the antibiotic by ABC exporter MccC</td>
</tr>
<tr>
<td valign="top" align="left">MccE492</td>
<td valign="top" align="left">&#x2013; Inner membrane bilayer permeability/<italic>Formation of channels</italic><break/>&#x2013; Sugar transport/<italic>Binding to inner membrane components of mannose phosphotransferase system permease (ManPTS)</italic></td>
<td valign="top" align="left">&#x2013; Siderophore receptors FepA-, Cir-, Fiu-TonB system</td>
<td valign="top" align="left">&#x2013; Mutations in uptake system at the inner membrane/<italic>Catechol siderophore receptors</italic><break/>&#x2013; Mutations in mannose uptake system/<italic>ManXYZ</italic></td>
<td valign="top" align="left">&#x2013; Mutations/deletions in FepA, Cir, Fiu, TonB<break/>&#x2013; Deletion of inner membrane complex ManYZ</td>
</tr>
<tr>
<td valign="top" align="left">MccH47</td>
<td valign="top" align="left">&#x2013; Energy production (ATP synthesis)/<italic>Binding to F<sub>0</sub> subunits of ATP synthase</italic></td>
<td valign="top" align="left">&#x2013; Siderophore receptors FepA Cir Fiu - TonB system</td>
<td valign="top" align="left">&#x2013; Mutations in uptake system/<italic>Catechol siderophore receptors</italic></td>
<td valign="top" align="left">&#x2013; Mutations/deletions in FepA, Cir, Fiu</td>
</tr>
<tr>
<td valign="top" align="left">MccL</td>
<td valign="top" align="left">Membrane potential</td>
<td valign="top" align="left">&#x2013; Siderophore receptor Cir -TonB system/SdaC</td>
<td valign="top" align="left">&#x2013; Mutations in uptake systems/<italic>Catechol siderophore receptor</italic></td>
<td valign="top" align="left">&#x2013; Mutations in Cir, TonB</td>
</tr>
<tr>
<td valign="top" align="left">MccV</td>
<td valign="top" align="left">Inner membrane</td>
<td valign="top" align="left">&#x2013; Siderophore receptor Cir -TonB system/<break/>&#x2013; SdaC</td>
<td valign="top" align="left">&#x2013; Mutations in uptake systems/<italic>Catechol siderophore receptor</italic>, <italic>SdaC</italic></td>
<td valign="top" align="left">&#x2013; Mutations in Cir, TonB, SdaC</td>
</tr>
<tr>
<td valign="top" align="left">MccPDI</td>
<td valign="top" align="left">&#x2013; Energy production/<italic>ATP synthase</italic><break/>&#x2013; Inner membrane permeability</td>
<td valign="top" align="left">&#x2013; Porin OmpF</td>
<td valign="top" align="left">&#x2013; Mutations/<italic>Thiol-redox enzymes</italic>, <italic>OmpF</italic></td>
<td valign="top" align="left">&#x2013; Mutations in <italic>dsbA</italic>, <italic>dsbB</italic> encoding thiol-redox enzymes making S-S bonds</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption><p>Mechanisms of action of antibiotics <bold>(A)</bold> and microcins <bold>(B)</bold> against Gram-negative bacteria showing the membrane proteins involved in uptake into sensitive bacteria and the final targets. &#x03B2;-LAC, &#x03B2;-lactams; QNL, quinolones; TET, tetracycline; AMG, aminoglycosides; FOS, fosfomycin; CHL, chloramphenicol; CS, colistin; RIF, rifampicin; ALB, albomycin; P, pore; LPS, lipopolysaccharide. A letter and a number are assigned to each antibiotic and each microcin respectively, which are used in the scheme to identify the path they follow for their killing activity.</p></caption>
<graphic xlink:href="fmicb-11-586433-g002.tif"/>
</fig>
<sec id="S3.SS1">
<title>The Uptake Systems</title>
<p>The first obstacle to be overcome by an antimicrobial compound to reach its final target is the bacterial cell envelope (<xref ref-type="bibr" rid="B40">Collet et al., 2020</xref>). The extent of this barrier varies according to the target to be reached, the chemical structure of the antimicrobial compound and the bacterial species. For Gram-negative bacteria, antimicrobials have to pass first the outer membrane. Then, they can access the cytoplasmic membrane bilayer (inner membrane) and either insert inside or cross it for those antimicrobials having intracellular targets. Many antibiotics are hydrophilic compounds of low molecular mass and uptake across the outer membrane is ensured by passive diffusion using pores formed by specific &#x03B2;-barrel membrane proteins called porins. Porins are the most abundant proteins of the outer membrane in Gram-negative bacteria. They are classified as non-specific (general porins) and specific (selective porins), according to their threshold size and amino acids lining the aqueous channel (<xref ref-type="bibr" rid="B38">Choi and Lee, 2019</xref>). The transport varies according to the size, charge and hydrophilicity of the molecule. Recently, the dual function of the porin OmpF both as receptor and translocator for the pore-forming colicin N, has been elegantly demonstrated (<xref ref-type="bibr" rid="B94">Jansen et al., 2020</xref>). However, more hydrophobic or higher molecular mass compounds above the porin threshold require other strategies, among which hijacking receptors or transporters required for vital functions is a major one. Indeed, Gram-negative bacteriocins, colicins and microcins, widely parasitize such receptors to enter the periplasmic space, and particularly those involved in iron import. This receptor hijacking qualifies many microcins as &#x201C;Trojan horse&#x201D; compounds, as they mimic vital compounds that require being imported in cells, to penetrate sensitive bacteria (<xref ref-type="bibr" rid="B62">Duquesne et al., 2007a</xref>; <xref ref-type="bibr" rid="B142">Nolan and Walsh, 2008</xref>; <xref ref-type="bibr" rid="B177">Severinov and Nair, 2012</xref>).</p>
<p>Iron acquisition is an essential factor for microbial life. However, under aerobic conditions, free iron availability is limited by the very low solubility of ferric iron, and especially within a host, where iron is competed for by both the microbial community and the host (<xref ref-type="bibr" rid="B208">Wilson et al., 2016</xref>). To secure iron, bacteria have evolved to develop efficient Fe(III)-chelating agents (K<sub><italic>a</italic></sub> ranging from 10<sup>23</sup> to 10<sup>52</sup>), termed siderophores, to scavenge iron from their surrounding environment and import it. A study by <xref ref-type="bibr" rid="B115">Lewis et al. (2010)</xref> showed that siderophores are sufficient for allowing the culture of bacteria previously unculturable in laboratory conditions. Siderophores are non-ribosomally synthesized (<xref ref-type="bibr" rid="B44">Crosa and Walsh, 2002</xref>) and are important for enteropathogen survival (<xref ref-type="bibr" rid="B84">Hantke, 2003</xref>). Concomitantly, iron availability has been observed to regulate MccE492 gene expression (<xref ref-type="bibr" rid="B124">Marcoleta et al., 2013</xref>). The resulting Fe(III)-siderophore complex is then internalized by the producing strains via high affinity siderophore receptors anchored at the outer membrane, which are specifically involved in this function, but also ensure other strategic roles in microbial communities (<xref ref-type="bibr" rid="B105">Kramer et al., 2019</xref>). Siderophore receptors consist of a 22-stranded antiparallel &#x03B2;-barrel with external loops serving as ligand binding sites and an N-terminal globular domain forming a plug that occludes the barrel (<xref ref-type="bibr" rid="B107">Krewulak and Vogel, 2008</xref>). They are specific to the different siderophore chemical types, such as FhuA for ferrichrome or Cir, Fiu, and FepA for catechol siderophores in enterobacteria. These receptors are coupled to the TonB-ExbB-ExbD three-component machinery anchored at the inner membrane (TonB system), which transfers the energy source from the proton motive force of the cytoplasmic membrane to the outer membrane (<xref ref-type="bibr" rid="B107">Krewulak and Vogel, 2008</xref>), thus permitting active transport.</p>
<p>All microcins, whatever they are of class I or II, use either the siderophore receptor or the porin path to reach their final target (<xref ref-type="fig" rid="F2">Figure 2B</xref>). Siderophore microcins uptake requires the FepA-, Cir-, Fiu-TonB systems, with FepA having the most important role (<xref ref-type="bibr" rid="B53">Destoumieux-Garz&#x00F3;n et al., 2006</xref>; <xref ref-type="bibr" rid="B10">Azpiroz and Lavi&#x00F1;a, 2007</xref>; <xref ref-type="bibr" rid="B196">Vassiliadis et al., 2010</xref>). Unmodified microcins use the Cir-TonB system (MccV, MccL) (<xref ref-type="bibr" rid="B34">Chehade and Braun, 1988</xref>; <xref ref-type="bibr" rid="B139">Morin et al., 2011</xref>), or the porin OmpF which screens incoming products in a non-specific manner (<xref ref-type="bibr" rid="B173">Sato et al., 2000</xref>; <xref ref-type="bibr" rid="B96">Kaeriyama et al., 2006</xref>) (MccPDI) (<xref ref-type="bibr" rid="B224">Zhao et al., 2015</xref>), while class I microcins either use FhuA (MccJ25) (<xref ref-type="bibr" rid="B157">Pugsley et al., 1986</xref>; <xref ref-type="bibr" rid="B171">Salom&#x00F3;n and Far&#x00ED;as, 1993</xref>; <xref ref-type="bibr" rid="B127">Mathavan et al., 2014</xref>), or OmpF (MccB17, McC) (<xref ref-type="bibr" rid="B113">Lavi&#x00F1;a et al., 1986</xref>; <xref ref-type="bibr" rid="B144">Novikova et al., 2007</xref>) to reach the periplasmic space (<xref ref-type="fig" rid="F2">Figure 2B</xref>). In the case of loss of function of the TonB system, MccE492, MccH47, and MccM retain antimicrobial activity, suggesting the involvement of another translocator, such as the TolA-TolQ-TolC system known to mediate the import of certain colicins (<xref ref-type="bibr" rid="B114">Lazdunski et al., 1998</xref>). Similar observations were made for MccL and MccV (<xref ref-type="bibr" rid="B73">Gerard et al., 2005</xref>; <xref ref-type="bibr" rid="B139">Morin et al., 2011</xref>), suggesting that the function of the ExbB protein could be replaced by its homolog TolQ in TonB-dependent microcin activity. However, although the presence of the siderophore PTM enhances its efficiency, the non-modified form of MccE492 (without the C-terminal siderophore) is also able to kill sensitive bacteria, but at a significantly lower level. On their side, antibiotics, which are essentially low molecular mass hydrophobic compounds, are most often transported inside target bacteria via porin or iron siderophore receptor pathways (<xref ref-type="table" rid="T2">Table 2</xref>).</p>
</sec>
<sec id="S3.SS2">
<title>Mechanisms of Action Common to Antibiotics and Microcins</title>
<sec id="S3.SS2.SSS1">
<title>Disruption of the Cytoplasmic Membrane</title>
<p>Permeabilization and/or disruption of the bacterial cytoplasmic membrane of Gram-negative bacteria is the main mechanism of action of the non-ribosomal peptide antibiotics polymyxins B and E (<xref ref-type="table" rid="T2">Table 2</xref> and <xref ref-type="fig" rid="F2">Figure 2A</xref>), which share a high degree of structural similarity (<xref ref-type="bibr" rid="B175">Schindler and Teuber, 1975</xref>). Polymixin E (also called colistin) binds to the lipopolysaccharide (LPS) both in the bacterial outer membrane and in the cytoplasmic membrane and this interaction is essential for cytoplasmic membrane permeabilization, cell lysis and the bactericidal activity of this antibiotic (<xref ref-type="bibr" rid="B168">Sabnis et al., 2019</xref>). It should be noted that all polymyxins are inactive against Gram-positive bacteria, except few species such as <italic>Streptococcus pyogenes</italic> (<xref ref-type="bibr" rid="B192">Trimble et al., 2016</xref>).</p>
<p>Several class II microcins target the inner membrane, by perturbing either its integrity using different mechanisms of peptide membrane interaction, or the proteins which are embedded. This constitutes at least the primary part of their mechanism of action (<xref ref-type="table" rid="T2">Table 2</xref> and <xref ref-type="fig" rid="F2">Figure 2B</xref>). Indeed, the final killing trajectory of MccE492 appears to stop at the inner membrane. MccE492 induces a rapid depolarization and permeabilization of <italic>E. coli</italic> cytoplasmic membrane, without provoking cell lysis (<xref ref-type="bibr" rid="B111">Lagos et al., 1993</xref>; <xref ref-type="bibr" rid="B53">Destoumieux-Garz&#x00F3;n et al., 2006</xref>). It forms well-defined ion channels in planar phospholipid bilayers that are constituted of supramolecular peptide assemblies (<xref ref-type="bibr" rid="B111">Lagos et al., 1993</xref>; <xref ref-type="bibr" rid="B53">Destoumieux-Garz&#x00F3;n et al., 2006</xref>). It also interacts with the mannose phosphotransferase system permease ManXYZ (<xref ref-type="bibr" rid="B18">Bieler et al., 2010</xref>), associating specifically with its inner membrane components ManYZ. Therefore, MccE492 both perturbs the inner membrane permeability and interferes with the transport of mannose to kill sensitive congeners. Besides, MccE492 is known to form amyloid fibrils (<xref ref-type="bibr" rid="B17">Bieler et al., 2005</xref>; <xref ref-type="bibr" rid="B8">Arranz et al., 2012</xref>; <xref ref-type="bibr" rid="B4">Aguilera et al., 2016</xref>) that play a role in modulating its antimicrobial activity. These aggregates have been observed more significantly with the unmodified form of MccE492, suggesting their formation is not only an additional mechanism of protection of the producer strain, but also may act as a toxin reservoir. MccV destabilizes the membrane potential (<xref ref-type="bibr" rid="B213">Yang and Konisky, 1984</xref>) and further interacts with an inner membrane transporter, the serine permease SdaC (<xref ref-type="bibr" rid="B73">Gerard et al., 2005</xref>), which is involved in serine transport and acts as a specific receptor for MccV. It can be suggested that a perturbation of serine transport in sensitive bacteria could result, or that SdaC could drive MccV to form channels in the inner membrane. MccE492 and MccV thus illustrate the combined use of two different mechanisms involving the inner membrane or its components to kill sensitive bacteria. MccL primary target is also the cytoplasmic membrane. It provokes disruption of membrane potential of <italic>E. coli</italic> cells, but without inducing permeabilization of the inner membrane (<xref ref-type="bibr" rid="B139">Morin et al., 2011</xref>). A potential inner membrane target for MccL has not been identified. Finally, it has to be mentioned that at higher concentrations than the MIC, MccJ25 induces perturbations of the cytoplasmic membrane permeability and disruption of the cytoplasmic membrane gradient in <italic>Salmonella enterica</italic> (<xref ref-type="bibr" rid="B162">Rintoul et al., 2001</xref>; <xref ref-type="bibr" rid="B16">Ben Said et al., 2020</xref>), and perturbation of the respiratory chain enzymes in <italic>E. coli</italic>, accompanied with stimulation of the production of reactive oxygen species (<xref ref-type="bibr" rid="B15">Bellomio et al., 2007</xref>).</p>
</sec>
<sec id="S3.SS2.SSS2">
<title>Inhibition of Protein Biosynthesis</title>
<p>The bacterial 70S ribosome is composed of two ribonucleoprotein subunits forming the 30S and 50S subunits (<xref ref-type="bibr" rid="B215">Yoneyama and Katsumata, 2006</xref>). Aminoglycosides (AGs), such as streptomycin or gentamicin, and tetracyclines bind to the 16S ribosomal RNA of the 30S subunit (<xref ref-type="bibr" rid="B39">Chopra and Roberts, 2001</xref>; <xref ref-type="bibr" rid="B106">Krause et al., 2016</xref>). AGs bind to the A-site of the ribosome, causing inhibition of translation of mRNA by codon misreading on delivery of the aminoacyl-tRNA (<xref ref-type="table" rid="T2">Table 2</xref> and <xref ref-type="fig" rid="F2">Figure 2A</xref>). For their part, tetracyclines prevent incoming aminoacyl-tRNA from binding to the A site of the mRNA translation complex. As well, chloramphenicol inhibits protein synthesis by preventing the binding of t-RNAs to the A site of the ribosome (<xref ref-type="bibr" rid="B97">Kapoor et al., 2017</xref>). The bacterial ribosome is also the target for other antibiotic classes, such as the macrolides and ketolides or the streptogramins.</p>
<p>Contrasting with MccB17 and its <italic>Pseudomonas</italic> congeners which exert their antimicrobial activity by perturbing DNA topology setting up (see section below Inhibition of Nucleic Acid Biosynthesis), other MccB17-like bacteriocins perturb protein synthesis. Klebsazolicin from <italic>K. pneumoniae</italic>, which exhibits moderate antimicrobial activity against certain <italic>E. coli</italic>, <italic>Klebsiella</italic> and <italic>Yersinia</italic> strains (<xref ref-type="bibr" rid="B134">Metelev et al., 2013</xref>) targets the 70S ribosome and interferes with translation elongation. Moreover, it binds to the peptide exit tunnel, overlapping with the binding sites of macrolides or streptogramin-B. Similar to klebsazolicin, the MccB17-like phazolicin produced by <italic>Rhizobium</italic> sp., which exhibits narrow-spectrum antibacterial activity against some symbiotic bacteria of leguminous plants (<xref ref-type="bibr" rid="B191">Travin et al., 2019</xref>), also targets the 70S ribosome by obstructing the peptide exit tunnel, but through different binding mechanisms.</p>
<p>Albomycin, which consists of an antibiotic part linked to a siderophore moiety, inhibits aminoacyl t-RNA synthetases (aaRSs) that are essential for protein synthesis (<xref ref-type="bibr" rid="B177">Severinov and Nair, 2012</xref>) (<xref ref-type="table" rid="T2">Table 2</xref> and <xref ref-type="fig" rid="F2">Figure 2A</xref>). Similar, McC targets the aspartyl-tRNA synthetase (<xref ref-type="bibr" rid="B135">Metlitskaya et al., 2006</xref>), making it a translation inhibitor (<xref ref-type="table" rid="T2">Table 2</xref> and <xref ref-type="fig" rid="F2">Figure 2B</xref>). After having crossed the outer membrane thanks to the porin OmpF, McC requires the inner membrane ABC transporter YejABEF (<xref ref-type="bibr" rid="B144">Novikova et al., 2007</xref>) for its translocation within the cytoplasm. A comprehensive analysis by <xref ref-type="bibr" rid="B201">Vondenhoff et al. (2011)</xref> has shown that to mediate binding and translocation of substrates, the YejABEF transporter requires an N-terminal formyl-methionine and an arginine. These requirements are achieved with the formylated f-MRTGNAD heptapeptide part of the McC precursor. However, unlike other microcins, which are fully processed within the producing cells before export, further McC maturation is necessary within the target bacteria to attain its cytotoxic form. McC undergoes a double-step processing. First of which is the deformylation of the formylated heptapeptide precursor, essentially nullifying the detoxification process of its immunity protein <italic>mccE</italic>. This deformylation allows the second maturation step, which is ensured by broadly specific endoproteases PepA, PepB, and PepN, which remove the peptide moiety of the microcin. This last processing step releases the toxic entity, which is a non-hydrolyzable analog of aspartyl-adenylate (Asp-RS) that blocks aspartyl-tRNA synthetase and thus transcription (<xref ref-type="bibr" rid="B100">Kazakov et al., 2008</xref>). This subtle cheating mechanism nicely exemplifies the Trojan horse strategy used by microcins. Moreover, <xref ref-type="bibr" rid="B159">Ran et al. (2017)</xref> observed that when increasing the concentration until the mM level, McC was able to inhibit the activity of &#x03B2;-galactosidase, respiration chain dehydrogenases, and 6-phosphogluconate dehydrogenase without damaging the inner membrane, showing that McC develops a second mechanism of action that operates at higher concentrations.</p>
</sec>
<sec id="S3.SS2.SSS3">
<title>Inhibition of Nucleic Acid Biosynthesis</title>
<p>Quinolone antibiotics (nalidixic acid, ciprofloxacin, &#x2026;) inhibit DNA synthesis by targeting two essential type II topoisomerases, DNA gyrase and topoisomerase IV, and converting them into toxic enzymes that fragment the bacterial chromosome (<xref ref-type="table" rid="T2">Table 2</xref> and <xref ref-type="fig" rid="F2">Figure 2A</xref>). These interactions result in erroneous unwinding of DNA, introduction of double strand breaks and cell death (<xref ref-type="bibr" rid="B67">Fabrega et al., 2009</xref>). Besides, rifampicin inhibits DNA-dependent RNA polymerase (RNAP) activity by forming a stable complex with the enzyme. It binds in a pocket of the RNAP &#x03B2; subunit, deep within the DNA/RNA channel, while away from the active site. The inhibitor directly blocks the path of the elongating RNA when the transcript becomes two to three nucleotides in length. It thus suppresses the initiation of RNA synthesis (<xref ref-type="bibr" rid="B28">Campbell et al., 2001</xref>).</p>
<p>The target of MccB17 is also a topoisomerase (<xref ref-type="table" rid="T2">Table 2</xref> and <xref ref-type="fig" rid="F2">Figure 2B</xref>). MccB17 enters sensitive bacteria using the OmpF porin, diffuses through the periplasmic space and binds to the inner membrane transporter SbmA to be delivered into the cytoplasm (<xref ref-type="bibr" rid="B113">Lavi&#x00F1;a et al., 1986</xref>). It induces gyrase-dependent formation of a stable cleavage complex instead of the transient break that normally happens during the catalytic cycle. It causes covalent links between DNA gyrase and double stranded DNA, hence blocking DNA replication and maintenance. Similar to fluoroquinolones, MccB17 targets the cleavage of both DNA strands, which is a critical step in the DNA gyrase supercoiling cycle, but the MccB17-induced cleavage pattern is different from that of quinolones (for a review on MccB17 activity see <xref ref-type="bibr" rid="B41">Collin and Maxwell, 2019</xref>). The stringent role of the heterocycles in MccB17 activity has been evidenced (<xref ref-type="bibr" rid="B165">Roy et al., 1999</xref>). Introduction of an extra oxazole ring at position Ser<sup>52</sup> in MccB17 results in 40% higher antibacterial activity than that of wild-type MccB17 (<xref ref-type="bibr" rid="B165">Roy et al., 1999</xref>). Bis-heterocycles play a particularly essential role, with the central MccB17 region that contains two thiazoles and a thiazole/oxazole forming the critical core for DNA cleavage (<xref ref-type="bibr" rid="B41">Collin and Maxwell, 2019</xref>). Moreover, the C-terminal part of MccB17 is crucial for both uptake by sensitive cells and DNA gyrase inhibition, while the N-terminal region is only moderately important for uptake (<xref ref-type="bibr" rid="B179">Shkundina et al., 2014</xref>). Interestingly, MccB17 congeners that belong to the LAP family of RiPPs do not share all similar mechanisms, targeting either DNA gyrase or the 70S ribosome. Indeed, MccB17-like compounds from <italic>P. syringae</italic> are active against <italic>E. coli</italic> and essentially <italic>Pseudomonas</italic> species including <italic>P. aeruginosa</italic>, through DNA gyrase inhibition (<xref ref-type="bibr" rid="B134">Metelev et al., 2013</xref>), while the other analogs do not (see section above &#x201C;Inhibition of Protein Biosynthesis&#x201D;).</p>
<p>Such as rifampicin, the lasso peptide MccJ25 targets the RNAP (<xref ref-type="table" rid="T2">Table 2</xref> and <xref ref-type="fig" rid="F2">Figure 2B</xref>). To reach its intracellular target, MccJ25 hijacks the ferrichrome receptor FhuA to cross the outer membrane (<xref ref-type="bibr" rid="B127">Mathavan et al., 2014</xref>) and is internalized into the cytoplam by the inner membrane protein SbmA. Finally, MccJ25 binds to the RNAP secondary channel, which connects the enzyme surface with the RNAP catalytic center, and through which nucleotide triphosphate substrates (NTP) migrate to the catalytic center (<xref ref-type="bibr" rid="B1">Adelman et al., 2004</xref>; <xref ref-type="bibr" rid="B140">Mukhopadhyay et al., 2004</xref>), whereby inactivating transcription in a partial competitive manner. The loop is involved in recognition and uptake of MccJ25 by the iron-siderophore transporter FhuA, while the macrolactam ring and C-terminal tail are responsible for binding to the RNA polymerase target (<xref ref-type="bibr" rid="B52">Destoumieux-Garz&#x00F3;n et al., 2005</xref>; <xref ref-type="bibr" rid="B176">Semenova et al., 2005</xref>). The crystal structure of MccJ25 bound to <italic>E. coli</italic> RNAP was determined and the residues critical for the interaction were identified (<xref ref-type="bibr" rid="B22">Braffman et al., 2019</xref>). MccJ25 binds deep within the secondary channel, such as to clash with NTP binding and explaining the partial competitive mechanism of inhibition with respect to NTPs previously proposed (<xref ref-type="bibr" rid="B140">Mukhopadhyay et al., 2004</xref>). Besides, it was shown that at higher concentrations, MccJ25 induces perturbations of the cytoplasmic membrane permeability and disruption of the cytoplasmic membrane gradient of <italic>S. enterica</italic> Newport (<xref ref-type="bibr" rid="B162">Rintoul et al., 2001</xref>). At much higher concentrations, it can also stimulate the production of reactive oxygen species (<xref ref-type="bibr" rid="B15">Bellomio et al., 2007</xref>). This shows once again the multiple mechanisms brought into play by a given microcin, which both explains their high efficiency and suggests lower risks of resistance acquisition. Several antibacterial lasso peptides, have been shown to also target RNAP through binding to the secondary channel, although their different antibacterial activity spectrum. This is the case for capistruin produced by <italic>Burkholderia thailandensis</italic> and active against <italic>Burkholderia</italic> and <italic>Pseudomonas</italic> species (<xref ref-type="bibr" rid="B104">Knappe et al., 2008</xref>; <xref ref-type="bibr" rid="B108">Kuznedelov et al., 2011</xref>; <xref ref-type="bibr" rid="B22">Braffman et al., 2019</xref>), ubonodin from <italic>B. ubonensis</italic> and active against pathogenic members of the <italic>B. cepacia</italic> complex (<xref ref-type="bibr" rid="B37">Cheung-Lee et al., 2020</xref>), citrocin from <italic>Citrobacter</italic> sp., active against <italic>E. coli</italic> and <italic>Citrobacter</italic> sp. (<xref ref-type="bibr" rid="B36">Cheung-Lee et al., 2019</xref>). By contrast, acinetodin and klebsidin from human-associated strains of <italic>Acinetobacter</italic> and <italic>Klebsiella</italic>, display no activity or low activity against <italic>K. pneumoniae</italic>, while they bind RNAP (<xref ref-type="bibr" rid="B133">Metelev et al., 2017b</xref>), showing that the spectrum of activity of lasso peptide microcins appears to be driven by the uptake in target bacteria rather than the intracellular target. This is in agreement with the spectrum of activity of MccJ25 against a collection of <italic>Salmonella</italic> strains, which is associated mainly with differences in the FhuA sequences (<xref ref-type="bibr" rid="B16">Ben Said et al., 2020</xref>).</p>
</sec>
</sec>
<sec id="S3.SS3">
<title>Mechanisms of Action Specific to Microcins</title>
<p>MccH47 is bactericidal and targets the membrane bound F<sub>0</sub> proton channel subunits of ATP synthase (<xref ref-type="bibr" rid="B193">Trujillo et al., 2001</xref>; <xref ref-type="bibr" rid="B163">Rodriguez and Lavi&#x00F1;a, 2003</xref>; <xref ref-type="bibr" rid="B149">Palmer et al., 2020</xref>), causing an unregulated influx of protons. It uses FepA-, Cir-, Fiu-TonB dependent receptors to reach its inner membrane target (<xref ref-type="bibr" rid="B152">Patzer et al., 2003</xref>). The mechanism of action of the class IIa MccPDI is poorly identified. It was told to require close bacterial proximity to be cytotoxic, hence the name PDI (Proximity Dependent Inhibition) (<xref ref-type="bibr" rid="B64">Eberhart et al., 2012</xref>), since co-cultures of producing and sensitive strains separated by a semi-permeable film inhibit its activity. Why proximity is required for activity is unknown, but it could be only a consequence of a concentration-dependence effect (<xref ref-type="bibr" rid="B121">Lu et al., 2019</xref>). MccPDI that uses the porin OmpF to cross the outer membrane (<xref ref-type="bibr" rid="B224">Zhao et al., 2015</xref>; <xref ref-type="bibr" rid="B121">Lu et al., 2019</xref>) was shown (<xref ref-type="bibr" rid="B224">Zhao et al., 2015</xref>) to require a functional ATP synthase for exerting its cytotoxic activity, while (<xref ref-type="bibr" rid="B121">Lu et al., 2019</xref>) proposed it would induce membrane damage.</p>
</sec>
<sec id="S3.SS4">
<title>Mechanisms of Action Specific to Antibiotics</title>
<sec id="S3.SS4.SSS1">
<title>Inhibition of Cell Wall Formation</title>
<p>The cell envelope of Gram-negative bacteria consists of a phospholipid bilayer inner membrane that wraps the cytoplasm, and an asymetric outer membrane essentially composed of phospholipids at the inner leaflet and LPS at the outer leaflet, which protects the cell from the environment. In between is the periplasm that shelters a thin peptidoglycan layer (<xref ref-type="bibr" rid="B40">Collet et al., 2020</xref>). This double-membrane complex system and in particular the peptidoglycan, often called the cell wall, is a main target for antibiotics and antimicrobials. &#x03B2;-lactam antibiotics, which include in particular penicillins, cephalosporins and carbapenems, harbor the &#x03B2;-lactam ring in their structure that mimics the <sc>D</sc>-alanyl <sc>D</sc>-alanine terminal amino acid residues of the precursor subunits of the peptidoglycan layer, and so far interacts with penicillin binding proteins (PBPs). This induces a disruption of the peptidoglycan layer leading to the lysis of the bacterium (<xref ref-type="bibr" rid="B97">Kapoor et al., 2017</xref>). Besides, fosfomycin inhibits bacterial cell wall biosynthesis in an early stage; it integrates the cell and inactivates an essential enzyme in peptidoglycan synthesis (<xref ref-type="bibr" rid="B56">Dijkmans et al., 2017</xref>). &#x03B2;-lactams, mainly carpabenems and second, third and fourth generation of cephalosporins as well as fosfomycin have a broad spectrum antibacterial activity.</p>
</sec>
<sec id="S3.SS4.SSS2">
<title>Inhibition of Folic Acid Metabolism</title>
<p>Trimethoprim and sulfonamides act at distinct steps in folic acid metabolism. Sulfonamides inhibit dihydropteroate synthase, which acts at an early step in folic acid biosynthesis in a competitive manner with higher affinity for the enzyme than the natural substrate, <italic>p</italic>-amino benzoic acid (PABA). For its part, trimethroprim inhibits dihydrofolate reductase, thus operating at a later stage of folic acid synthesis (<xref ref-type="bibr" rid="B215">Yoneyama and Katsumata, 2006</xref>).</p>
</sec>
</sec>
</sec>
<sec id="S4">
<title>Mechanisms of Resistance and Potential Cross- and Co-Resistance Between Antibiotics and Microcins</title>
<p>Various mechanisms of resistance to antibiotics and/or to microcins are reported including essentially modifications of the cellular target by mutations or protein interactions, changes in the structure of the antimicrobial molecule, perturbations of binding or penetration of the antibiotic into sensitive cells and specific cell wall modifications. Several mechanisms are specific, but bacteria may use common mechanisms of resistance against microcins and antibiotics that could induce cross-resistance, which occurs when a single mechanism provides resistance to several antimicrobial molecules differing in their structures, simultaneously. In contrast, co-resistance occurs when two or more different resistance genes encoding several unrelated resistance mechanisms are located on the same genetic element (plasmid, transposon) (<xref ref-type="bibr" rid="B33">Chapman, 2003</xref>). In the following section, we describe different mechanisms of resistance and the possible occurrence of cross- and co-resistance between antibiotics and microcins (<xref ref-type="table" rid="T2">Table 2</xref> and <xref ref-type="fig" rid="F3">Figure 3</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption><p>Mechanisms of cross-resistance and co-resistance of antibiotics and microcins in Gram-negative bacteria. &#x03B2;-LAC, &#x03B2;-lactams; QNL, quinolones; TET, tetracycline; AMG, aminoglycosides; FOS, fosfomycin; CHL, chloramphenicol; CS, colistin; RIF, rifampicin; ALB, albomycin.</p></caption>
<graphic xlink:href="fmicb-11-586433-g003.tif"/>
</fig>
<sec id="S4.SS1">
<title>Prevention of Intracellular Accumulation of the Toxic Entity: Efflux Pumps and Decreased Uptake</title>
<p>On one side, outer membrane porins and inner membrane transporters, which are involved in the uptake of antibiotics and microcins into sensitive cells, and on the other side efflux pumps, which pump the toxic compounds out of the bacteria, both constitute a first line resistance strategy (<xref ref-type="bibr" rid="B74">Ghai and Ghai, 2018</xref>). Porins, which ensure passive uptake of substrates across the outer membrane (see section mechanisms of action above), serve as the first gate for many antibiotics and several class I and II microcins. Furthermore, efflux pumps can be specific for a single substrate or can confer resistance to multiple antimicrobials by facilitating their extrusion before they can reach their intended targets (<xref ref-type="bibr" rid="B6">Anes et al., 2015</xref>). In Gram-negative bacteria, overexpression of efflux pumps is one of the mechanisms of resistance to &#x03B2;-lactams (<xref ref-type="bibr" rid="B5">Amaral et al., 2014</xref>) and to quinolones encoded by <italic>qep</italic>A and <italic>oqx</italic>AB genes (<xref ref-type="bibr" rid="B67">Fabrega et al., 2009</xref>). Likewise, reduced porin levels, which induce decrease of antibiotic concentration inside sensitive cells, is another mechanism of resistance to &#x03B2;-lactams in Gram-negative bacteria (<xref ref-type="bibr" rid="B153">Pfeifer et al., 2010</xref>), including <italic>K. pneumoniae</italic> (<xref ref-type="bibr" rid="B92">Jacoby et al., 2004</xref>) and <italic>P. aeruginosa</italic> (<xref ref-type="bibr" rid="B116">Li et al., 1994</xref>). Besides, mutations and deletions of genes encoding porins induce resistance to antibiotics. Indeed, <italic>ompF</italic> mutant was resistant to several &#x03B2;-lactam antibiotics in some Gram-negative pathogens, including <italic>E. coli</italic> and the deletion of OmpA resulted in increased susceptibility to several antibiotics including &#x03B2;-lactams in <italic>A. baumannii</italic> (<xref ref-type="bibr" rid="B182">Smani et al., 2014</xref>).</p>
<p>For microcins, the <italic>E. coli</italic> ABC exporter of unknown function Yojl, mediates resistance to MccJ25 by pumping the microcin out of the cells with the help of TolC, maintaining its concentration below the toxic concentration (<xref ref-type="bibr" rid="B51">Delgado et al., 2005</xref>). Yojl is located at the inner membrane and is coupled to the TolC protein at the outer membrane which ensures the last export step, similar to the MccJ25 gene cluster-encoded ABC exporter McjD, which warrants both microcin export and self-immunity for the producing cells (<xref ref-type="bibr" rid="B21">Bountra et al., 2017</xref>; <xref ref-type="bibr" rid="B14">Beis and Rebuffat, 2019</xref>). Similarly, McC is expelled from producing cells through a major facilitator superfamily (MFS) efflux pump (<xref ref-type="bibr" rid="B177">Severinov and Nair, 2012</xref>). Thus, the activation of several efflux pumps simultaneously could induce a co-resistance to antibiotics and microcins.</p>
<p>The iron-siderophore receptor FhuA is not only required for iron import, but it is also a target for bacteriocins (colicin M, MccJ25) and antibiotics (albomycin, rifamycin). Indeed, FhuA external loops L3, L4, L7, L8, and L11 are involved in the sensitivity to colicin M and the antibiotics albomycin and rifamycin. So far, a further mutation, insertion or deletion in the sequence encoding these loops may induce a cross-resistance between colicin M and these two antibiotics (<xref ref-type="bibr" rid="B205">Wang et al., 2018</xref>). Concomitantly, MccJ25 was also shown to require a primary interaction with the FhuA external loops L5, L7, L8 and L11 for its recognition and further internalization via this receptor (<xref ref-type="bibr" rid="B52">Destoumieux-Garz&#x00F3;n et al., 2005</xref>). The level of sensitivity to MccJ25 also varies depending on the acquisition of specific FhuA, with a maximal sensitivity obtained with <italic>E. coli</italic> FhuA, while several <italic>Salmonella</italic> serovars are resistant due to a lack of efficiency of their FhuA receptor for MccJ25 uptake (<xref ref-type="bibr" rid="B199">Vincent et al., 2004</xref>; <xref ref-type="bibr" rid="B16">Ben Said et al., 2020</xref>). Similarly, various mutations in FhuA, especially in the cork domain, were reported to reduce the uptake and consequently the sensitivity to albomycin (<xref ref-type="bibr" rid="B66">Endriss et al., 2003</xref>). It could thus be hypothesized too that cross-resistance can occur between MccJ25 and albomycin. Besides, membrane permeabilization induced by a synthetic cationic peptide (KFF)<sub>3</sub>K was shown to induce the sensitivity of MccJ25 resistant clinical isolates, thus making the microcin entry independent of FhuA and SbmA proteins (<xref ref-type="bibr" rid="B155">Pomares et al., 2010</xref>), and thus confirming that microcin uptake is the first source of resistance to MccJ25. Therefore, both uptake decrease of the toxic entity and pumping it out of the sensitive cells are efficient mechanisms to confer resistance to MccJ25.</p>
<p>Resistance to siderophore microcins which carry a catechol siderophore PTM is also primarily induced by uptake impairment (<xref ref-type="bibr" rid="B187">Thomas et al., 2004</xref>; <xref ref-type="bibr" rid="B126">Massip and Oswald, 2020</xref>). As seen before, MccE492, MccM and MccH47 are recognized and internalized in sensitive bacteria via the TonB-dependent FepA, Fiu and Cir iron-catecholate receptors. According to <xref ref-type="bibr" rid="B187">Thomas et al. (2004)</xref>, a <italic>fepA</italic>, <italic>fiu</italic> double mutation, the triple <italic>cir</italic>, <italic>fiu</italic>, <italic>fepA</italic> mutation and the <italic>tonB</italic> mutation induce complete resistance to MccE492, MccM, and MccH47, while deletion of <italic>exbB</italic> and <italic>exbD</italic> does not affect the sensitivity to all three siderophore microcins (<xref ref-type="bibr" rid="B196">Vassiliadis et al., 2010</xref>). Although it does not carry a siderophore PTM, MccL requires the TonB dependent catecholate receptor Cir for uptake. Mutations/deletions in Cir and TonB, or suppression of the proton motive force, which is required for the TonB function, afford MccL resistance in <italic>E. coli</italic> and <italic>Salmonella</italic>, while the proteins involved in serine or sugar transport are not involved (<xref ref-type="bibr" rid="B139">Morin et al., 2011</xref>). On the other hand, a mutation in the energy transducer TonB was shown to reduce uptake and confer resistance to ceftazidime. Moreover, ceftazidime-resistant TonB mutants were shown to be cross-resistant to fluoroquinolones and lactivicin, a siderophore-conjugated non-&#x03B2;-lactam antibiotic (<xref ref-type="bibr" rid="B27">Calvopina et al., 2020</xref>). Thus, a high probability exists for a possible cross-resistance between these antibiotics and microcins.</p>
<p>Resistance to MccN/24 is afforded by mutations in genes encoding the outer membrane porin OmpF (<xref ref-type="bibr" rid="B95">Jeanteur et al., 1994</xref>), or the inner membrane transporter SdaC involved in serine uptake and used for MccV activity (<xref ref-type="bibr" rid="B73">Gerard et al., 2005</xref>). Resistance to MccPDI also involves OmpF and more precisely the K<sup>47</sup>G<sup>48</sup>N<sup>49</sup> amino acid motif found in the predicted outer loop L1 of the porin (<xref ref-type="bibr" rid="B224">Zhao et al., 2015</xref>; <xref ref-type="bibr" rid="B121">Lu et al., 2019</xref>). In addition, mutations in DsbA and DsbB proteins, presumably involved in the formation of disulfide bonds in OmpF, induce resistance to MccPDI (<xref ref-type="bibr" rid="B224">Zhao et al., 2015</xref>). Mutations in <italic>ompF</italic> and <italic>ompR</italic> genes encoding OmpF induce a reduced sensitivity to MccB17. Moreover, a mutation in the <italic>sbm</italic>A gene encoding the inner membrane transporter SbmA, which translocates MccB17 from the inner membrane to the cytoplasm, induces high resistance to MccB17 (<xref ref-type="bibr" rid="B113">Lavi&#x00F1;a et al., 1986</xref>).</p>
<p>As regard the efflux systems involved in resistance to microcins, resistance to MccN/24 is controlled by the multiple antibiotic resistance (<italic>mar</italic>) operon (<xref ref-type="bibr" rid="B30">Carlson et al., 2001</xref>), which modulates efflux pump and porin expression via two encoded transcription factors, MarR and MarA (<xref ref-type="bibr" rid="B178">Sharma et al., 2017</xref>). MarA plays an important role in antibiotic resistance by activating the expression of the <italic>acrAB-tolC</italic> encoded efflux pump (<xref ref-type="bibr" rid="B223">Zhang et al., 2008</xref>) and also regulates biofilm formation (<xref ref-type="bibr" rid="B101">Kettles et al., 2019</xref>). Resistance to MccN/24 in <italic>Salmonella</italic> cells appears concomitantly with a multiple antibiotic resistance phenotype to ciprofloxacin, tetracycline, chloramphenicol and rifampicin (<xref ref-type="bibr" rid="B30">Carlson et al., 2001</xref>). So far, cross-resistance between MccN/24 and antibiotics raised above is quite possible.</p>
<p>Additional mechanisms involve specific cell wall modifications. Those include surexpression of capsule polysaccharides that can increase resistance to various antimicrobials including both antibiotics, in particular polymixins, and antimicrobial peptides (<xref ref-type="bibr" rid="B29">Campos et al., 2004</xref>). Interestingly, capsule polysaccharides are not involved in MccJ25 resistance of the YojI deficient strain (<xref ref-type="bibr" rid="B51">Delgado et al., 2005</xref>). Alterations of the LPS resulting in truncated LPS structures promote, among other pleiotropic effects, resistance to antimicrobial peptides and hydrophobic antibiotics (<xref ref-type="bibr" rid="B148">Pagnout et al., 2019</xref>).</p>
</sec>
<sec id="S4.SS2">
<title>Changes in Target Sites</title>
<p>To allow DNA supercoiling, bacteria use two type II topoisomerases, DNA gyrase and topoisomerase IV, which are both the targets of quinolones. They form a ternary cleavage complex gyrase/DNA/quinolone, thus blocking DNA replication. Mutations in genes encoding DNA gyrase (<italic>gyrA</italic>, <italic>gyrB</italic>) and topoisomerase IV (<italic>parC</italic>, <italic>parE</italic>) lead to quinolone resistance. Besides, a plasmid-mediated protection of DNA gyrase and topoisomerase IV from the action of quinolones is ensured in a non-specific manner by the gyrase interacting protein Qnr. Qnr is a 218 amino acid pentapeptide repeat protein (PRP) encoded by <italic>qnr</italic> genes, which blocks the action of quinolones on the DNA gyrase and topoisomerase IV in a lesser extent (<xref ref-type="bibr" rid="B67">Fabrega et al., 2009</xref>; <xref ref-type="bibr" rid="B91">Jacoby et al., 2015</xref>). Indeed, one of these mutations is the well-known GyrB W<sup>751</sup>R mutation which induces resistance to quinolones and is also linked to resistance to MccB17 (<xref ref-type="bibr" rid="B200">Viz&#x00E1;n et al., 1991</xref>). GyrB Trp<sup>751</sup> is strongly implicated in the interaction of DNA gyrase with MccB17 (<xref ref-type="bibr" rid="B87">Heddle et al., 2001</xref>) and <italic>gyrB</italic> point mutation changing Trp<sup>751</sup> for Arg leads to a protein variant resistant to MccB17 (<xref ref-type="bibr" rid="B49">del Castillo et al., 2001</xref>). Additionally, partial resistance to MccB17 is provided by mutations at position 83 in GyrA or 447 in GyrB (<xref ref-type="bibr" rid="B91">Jacoby et al., 2015</xref>). Consequently, cross-resistance to MccB17 and quinolones could occur. Otherwise, it is well known that immunity genes are responsible for protecting the producing bacteria from their own bacteriocin. Indeed, three genes <italic>mcbE, mcbF</italic>, and <italic>mcbG</italic> are involved in cell protection from endogenous and exogenous MccB17. Interestingly strains harboring these genes are shown to be highly resistant to fluoroquinolones (<xref ref-type="bibr" rid="B189">Tran and Jacoby, 2002</xref>). These mechanisms seem to be responsible for co-resistance to MccB17 and quinolones.</p>
<p>Mutation of the gene <italic>rpo</italic>B encoding the &#x03B2;&#x2032; subunit of RNAP (see section mechanisms of action above) induces resistance to rifampicin (<xref ref-type="bibr" rid="B28">Campbell et al., 2001</xref>; <xref ref-type="bibr" rid="B79">Goldstein, 2014</xref>). Likewise, alterations in the 30S or 50S subunit of the ribosome lead to resistance to antibiotics that act on these proteins, mainly tetracycline, chloramphenicol, streptolydigin and aminoglycosides (<xref ref-type="bibr" rid="B97">Kapoor et al., 2017</xref>). Similarly, first studies performed to understand the mechanism of action of MccJ25 have shown that a point mutation causing a substitution of Thr<sup>931</sup> for Ile in the conserved segment of the <italic>rpo</italic>C gene coding for the largest RNAP subunit &#x03B2;&#x2032; conferred resistance to MccJ25, suggesting a mechanism involving occlusion of the RNAP secondary channel (<xref ref-type="bibr" rid="B50">Delgado et al., 2001</xref>; <xref ref-type="bibr" rid="B222">Yuzenkova et al., 2002</xref>). It was shown further from the crystal structure of the MccJ25-RNAP complex that MccJ25 binds within the RNAP secondary channel and interferes with the traffic of NTPs to the catalytic center (<xref ref-type="bibr" rid="B22">Braffman et al., 2019</xref>). Furthermore, additional <italic>rpoC</italic> mutations affecting amino acids in the conserved segments G, G&#x2032; and F and exposed into the RNAP secondary channel, also led to MccJ25 resistance <italic>in vivo</italic> and <italic>in vitro</italic>. While MccJ25 acts on the &#x03B2;&#x2032; subunit, and rifampicin on the &#x03B2; subunit, streptolydigin acts on both subunits. So far, a cross-resistance between MccJ25 and the above cited antibiotics mainly streptolydigin and rifampicin appears to be highly expected (<xref ref-type="bibr" rid="B214">Yang and Price, 1995</xref>; <xref ref-type="bibr" rid="B186">Temiakov et al., 2005</xref>).</p>
<p>For other antibiotics and microcins, no specific cross-resistance appears to be predictable. Chromosomally mediated colistin resistance occurs mainly via the addition of cationic moieties onto the negatively charged lipid A, while the plasmid mediated colistin resistance (MCR) is acquired via a plasmid-borne copy of an <italic>mcr</italic> gene. MCR-1 is the most prevalent MCR enzyme reported for the first time in 2015 followed by nine homologs described to date (<xref ref-type="bibr" rid="B31">Carroll et al., 2019</xref>). MCR-1-mediated colistin resistance confers protection against this last resort antibiotic via the presence of modified LPS within the cytoplasmic membrane, rather than the outer membrane (<xref ref-type="bibr" rid="B168">Sabnis et al., 2019</xref>). More precisely, the phosphoethanolamine transferase activity of MCR-1 adds a cationic phosphoethanolamine moiety to the anionic lipid domain A of LPS, which results in a net negative charge decrease and thus a lower affinity for the polymyxins.</p>
<p>Fosfomycin inhibits the bacterial cell wall synthesis at the early initiating step of the peptidoglycan synthesis. More specifically, it inhibits UDP-<italic>N</italic>-acetylglucosamine enolpyruvyl transferase (or MurA), the enzyme involved in transfer of the enolpyruvyl part of phosphoenolpyruvate to the 3&#x2032;-hydroxyl group of UDP-<italic>N</italic>-acetylglucosamine, which is the first step in the biosynthesis pathway of peptidoglycan. Mutations in the <italic>murA</italic> gene confer resistance to fosfomycin due to the replacement of cysteine with aspartate in the active site of MurA, which prevents fosfomycin binding (<xref ref-type="bibr" rid="B68">Falagas et al., 2019</xref>). Moreover, resistance to fosfomycin can occur from chromosomal mutations in the structural genes that encode the GlpT and UhpT membrane transporters. GlpT and UhpT transport glycerol-3-phosphate and glycerol-6-phosphate sugars in bacteria, respectively and are used by fosfomycin to facilitate its entry in bacteria. These mutations block fosfomycin cell penetration (<xref ref-type="bibr" rid="B68">Falagas et al., 2019</xref>).</p>
<p>On the microcin side, the F<sub>1</sub>F<sub>0</sub>-ATP synthase has been shown to be the target of MccH47 (<xref ref-type="bibr" rid="B163">Rodriguez and Lavi&#x00F1;a, 2003</xref>) and MccPDI (<xref ref-type="bibr" rid="B224">Zhao et al., 2015</xref>). <italic>E. coli</italic> ATP synthase consists of a membrane-bound F<sub>0</sub> sector, which ensures proton translocation, connected to a cytoplasmic F<sub>1</sub> sector. They form a complex made up of eight different subunits, which are encoded by the <italic>atp</italic> operon, <italic>atpIBEFHAGDC</italic>. Three subunits form the F<sub>0</sub> proton channel and five subunits the catalytic F<sub>1</sub> domain. Mutations on genes <italic>atpB</italic>, <italic>atpE</italic>, <italic>atpF</italic> encoding the three subunits F<sub>0</sub>a, F<sub>0</sub>c, F<sub>0</sub>b respectively, which constitute the F<sub>0</sub> proton channel, result in resistance to MccH47 (<xref ref-type="bibr" rid="B163">Rodriguez and Lavi&#x00F1;a, 2003</xref>). Furthermore, deletion of genes encoding subunits in the F<sub>1</sub> and F<sub>0</sub> domains of ATP synthase (<italic>atpA</italic> and <italic>atpF</italic> encoding F<sub>1</sub>&#x03B1; and F<sub>0</sub>b subunits, or <italic>atpE</italic> and <italic>atpH</italic> encoding F<sub>0</sub>c and F<sub>1</sub>&#x03B4; subunits), result in a loss of susceptibility to MccPDI simultaneously to the loss of ATP synthase function (<xref ref-type="bibr" rid="B224">Zhao et al., 2015</xref>). None of these mechanisms appears to be shared between antibiotics and microcins.</p>
</sec>
<sec id="S4.SS3">
<title>Inactivation of the Toxic Entity</title>
<p>Several Gram-negative bacteria produce different enzymes that are able to modify antibiotics and thus induce resistance, such as the very well-known &#x03B2;-lactamases, which disrupt the specific structure of &#x03B2;-lactams (<xref ref-type="bibr" rid="B174">Sawa et al., 2020</xref>). &#x03B2;-lactamases are classified into four classes including group 1 (class C) cephalosporinases, group 2 (classes A and D) broad-spectrum, inhibitor-resistant, and extended-spectrum &#x03B2;-lactamases as well as serine carbapenemases, and group 3 (class B) metallo-&#x03B2;-lactamases (<xref ref-type="bibr" rid="B26">Bush and Jacoby, 2010</xref>). Other enzymes including aminoglycosides modifying enzymes, such as phosphotransferases (APHs), nucleotidyltranferases (ANTs) and acetyltransferases (AACs), which phosphorylate, adenylate and acetylate these compounds, respectively could also be involved in development of resistance (<xref ref-type="bibr" rid="B158">Ramirez and Tolmasky, 2010</xref>).</p>
<p>Acetylation is a widespread and efficient mechanism of resistance against different antibiotics. Modification of the piperazine ring of the fluoroquinolones is induced by an acetylase AAC(6&#x2032;)-Ib-cr, which provides one of the mechanisms of resistance of bacteria to quinolones (<xref ref-type="bibr" rid="B67">Fabrega et al., 2009</xref>). Chloramphenicol is also inactivated by acetylation which is performed by chloramphenicol acetyltransferases (CATs) (<xref ref-type="bibr" rid="B181">Smale, 2010</xref>). Acetylation is also a major mechanism of resistance to McC, then suggesting a high risk of cross-resistance between chloramphenicol and McC. Before its ultimate processing by non-specific aminopeptidases, which happens in sensitive cells to release the toxic non-hydrolyzable analog of aspartyl-adenylate, McC is exported outside the producer by the MccC pump and uptaken by sensitive cells using the porin OmpF and the inner membrane transporter YejABEF (see section Mechanisms of action). However, although most of produced McC is efficiently exported, intracellular processing also occurs inside the producing cells that ineluctably leads to the accumulation of the toxic entity that cannot be exported by the MccC pump and results in self-poisoning. Therefore, <italic>E. coli mcc</italic> gene clusters include genes (<italic>mccE</italic> and <italic>mccF</italic>) that encode proteins ensuring the self-immunity of the producer. The MccE acetyltransferase acetylates the &#x03B1;-amino group of processed McC, making it unable to bind to AspRS (<xref ref-type="bibr" rid="B2">Agarwal et al., 2011</xref>). So far, MccE makes <italic>E. coli</italic> simultaneously resistant to albomycin and McC (<xref ref-type="bibr" rid="B143">Novikova et al., 2010</xref>). MccE belongs to the general control non-repressible 5-related <italic>N</italic>-acetyltransferases (GNAT) superfamily, and shows high similarity with chromosomally encoded acetyltransferases RimI, RimJ, and RimL, which acetylate the N-termini of ribosomal proteins S18, S5, and L12 (<xref ref-type="bibr" rid="B169">Salah Ud-Din et al., 2016</xref>). Indeed, <italic>E. coli</italic> RimL induces resistance to McC by acetylating the amino group of the processed McC aspartate by the same mechanism as MccE (<xref ref-type="bibr" rid="B99">Kazakov et al., 2014</xref>). Similarly, when overproduced, RimL makes cells resistant to albomycin by acetylating processed albomycin, which contains a pyrimidine nucleotide instead of adenosine. Subsequently, a potential cross-resistance between McC and albomycin is quite possible (<xref ref-type="bibr" rid="B99">Kazakov et al., 2014</xref>). The MccF serine protease hydrolyses the carboxamide bond between the C-terminal aspartamide and AMP of both intact and processed McC, thus inactivating the aspartyl-adenylate (<xref ref-type="bibr" rid="B3">Agarwal et al., 2012</xref>). Moreover, McC inactivation is also ensured by phosphoramidases belonging to the histidine-triad (HIT) superfamily hydrolases that can either be encoded in certain <italic>mcc</italic>-like biosynthetic clusters or by genes located elsewhere in bacterial genomes (<xref ref-type="bibr" rid="B211">Yagmurov et al., 2020</xref>). Resistance to McC-like compounds produced by <italic>S. enterica</italic>, <italic>Nocardiopsis kunsanensis</italic>, <italic>P. fluorescens</italic> or <italic>Hyalangium minutum</italic> is conferred by hydrolysis of the phosphoramide bond in the toxic aspartamide-adenylate (<xref ref-type="bibr" rid="B211">Yagmurov et al., 2020</xref>).Therefore, it appears that resistance to McC and McC-like microcins by toxin inactivation can occur via both enzymes encoded in the microcin biosynthesis clusters and more generalist and non-specific enzymes sharing structural similarities.</p>
<p>Finally, impairment of the final three-dimensional structure of the antibacterial peptide, such as by preventing the formation of disulfide bridges, could be a last mechanism resulting in resistance to microcins. This has been poorly explored until now, but is however illustrated by MccPDI for which mutations in <italic>dsbA</italic>, <italic>dsbB</italic> genes induce resistance to MccPDI (<xref ref-type="bibr" rid="B224">Zhao et al., 2015</xref>). Genes <italic>dsbA</italic>, <italic>dsbB</italic> encode DsbA and DsbB thiol-redox enzymes that usually catalyze disulfide bond formation for proteins that are transported into the periplasm, and which would be possibly involved in formation of the disulfide bond that stabilizes this microcin.</p>
</sec>
</sec>
<sec id="S5">
<title>Inhibitory Effect of Microcins Against Antibiotic Resistant Gram-Negative Bacteria</title>
<p>The spectrum of inhibitory activity of microcins includes a wide number of bacteria which are phylogenetically related to the producing strain including <italic>Salmonella, Shigella</italic> and <italic>E. coli</italic>. The inhibition activity of the different microcins against non-multidrug-resistant strains has been reported in the literature. However, the potency of these microcins specifically against MDR bacteria has not been systematically described and only few studies have addressed this special issue.</p>
<p>MccJ25 was shown to exhibit a high antimicrobial activity against MDR <italic>Salmonella</italic> and <italic>E. coli</italic> (<xref ref-type="bibr" rid="B125">Martin-G&#x00F3;mez et al., 2019</xref>; <xref ref-type="bibr" rid="B219">Yu et al., 2019</xref>). The antimicrobial activity of MccJ25 was also extensively studied against a collection of MDR strains of <italic>S. enterica</italic> spp. <italic>enterica</italic> (<xref ref-type="bibr" rid="B16">Ben Said et al., 2020</xref>). Interestingly, this study has shown that <italic>Salmonella</italic> strains exhibit various sensitivity profiles to MccJ25 and that MIC values vary from 0.06 to 400 &#x03BC;g/mL (0.028&#x2013;189 nM), independently of the resistance profiles to antibiotics or the serovars. Other studies have shown that MccJ25 displays a great inhibitory potential against <italic>Salmonella</italic> and <italic>E. coli</italic> (<xref ref-type="bibr" rid="B167">Sabl&#x00E9; et al., 2000</xref>; <xref ref-type="bibr" rid="B50">Delgado et al., 2001</xref>; <xref ref-type="bibr" rid="B162">Rintoul et al., 2001</xref>; <xref ref-type="bibr" rid="B184">Soudy et al., 2012</xref>). MccPDI is known to inhibit foodborne pathogenic enterohemorrhagic <italic>E. coli</italic> serotypes O157:H7 and O26 (<xref ref-type="bibr" rid="B64">Eberhart et al., 2012</xref>) as well as <italic>Shigella</italic> strains and <italic>E. coli</italic> isolates that are MDR strains (<xref ref-type="bibr" rid="B121">Lu et al., 2019</xref>). Likewise, MccH47 has demonstrated a potent effect against <italic>Enterobacteriaceae</italic> MDR strains including <italic>Salmonella</italic> and <italic>E. coli</italic> carbapenemase, extended spectrum &#x03B2;-lactamase and metallo-&#x03B2;-lactamase producers. MccH47 has MIC values less than 75 &#x03BC;g/mL (13 &#x03BC;M) for all tested strains (<xref ref-type="bibr" rid="B149">Palmer et al., 2020</xref>).</p>
<p>The remaining microcins revealed similar narrow spectra of activity against non-MDR <italic>Enterobacteriaceae</italic>, mainly <italic>Salmonella</italic> and <italic>E. coli.</italic> Indeed, MccE492 was shown to have inhibitory activity <italic>in vitro</italic> against a wide range of <italic>Enterobacteriaceae</italic> including <italic>Klebsiella</italic>, <italic>Enterobacter</italic>, <italic>E. coli</italic> and <italic>Salmonella</italic> while MccM was shown to inhibit <italic>Salmonella</italic> and <italic>E. coli</italic> (<xref ref-type="bibr" rid="B196">Vassiliadis et al., 2010</xref>). MccN/24 is active against <italic>E. coli</italic> and <italic>S. enterica</italic> Typhimurium, but not against <italic>L. monocytogenes</italic> or <italic>Campylobacter jejuni</italic> (<xref ref-type="bibr" rid="B209">Wooley et al., 1999</xref>). It was also reported by <xref ref-type="bibr" rid="B98">Kaur et al. (2016)</xref> that MccN/24 exhibits a potent activity against <italic>Salmonella</italic> strains. Furthermore, MccV is active against some pathogenic <italic>E. coli</italic> with MIC values ranging from 7.7 &#x00D7; 10<sup>&#x2013;3</sup> to 13.25 &#x03BC;g/mL (0.89&#x2013;1517.94 nM) (<xref ref-type="bibr" rid="B20">Boubezari et al., 2018</xref>). MccS is lethal to virulent enterohemorrhagic and enteropathogenic <italic>E. coli</italic> through inhibiting the adherence of EPEC <italic>E. coli</italic> to intestinal epithelial cells in an <italic>in vitro</italic> adherence assay (<xref ref-type="bibr" rid="B226">Zsch&#x00FC;ttig et al., 2012</xref>). MccL exhibits a strong antibacterial activity against <italic>Enterobacteriaceae</italic>, including the <italic>S. enterica</italic> serovars Typhimurium and Enteritidis (<xref ref-type="bibr" rid="B139">Morin et al., 2011</xref>).</p>
<p>Only a few studies have systematically assessed the efficiency of microcins (and, more generally, of bacteriocins), for the inhibition of MDR bacteria, and/or the microcin/bacteriocin and antibiotic cross-resistance (<xref ref-type="bibr" rid="B16">Ben Said et al., 2020</xref>; <xref ref-type="bibr" rid="B109">Kuznetsova et al., 2020</xref>). Although the activities reported so far are encouraging, more systematic studies on the inhibitory potential of microcins against MDR strains remain necessary to confirm the potential of microcins as alternatives to antibiotics against MDR and are thus of high research priority. Future directions of research should relate to both qualitative and quantitative <italic>in vitro</italic> characterization of the inhibitory activity of different microcins against a large panel of clinical isolates of MDR pathogenic bacteria of medical and veterinary interest, coming from well characterized reference collections. The development of resistance of these strains against the various microcins deserves being invertigated as well as studying the possible synergistic effects between microcins and certain antibiotics or biocides, as already started with Gram-positive bacteriocins (<xref ref-type="bibr" rid="B128">Mathur et al., 2017</xref>). Indeed, the identification of compounds with synergistic or additive effects could represent an effective strategy to limit the development of bacteria resistant to both microcins and antibiotics. Such an approach, and more widely combination treatment therapeutic strategies, could be facilitated by the development of optimized methods to quantify synergy effects more rapidly and efficiently (<xref ref-type="bibr" rid="B70">Fatsis-Kavalopoulos et al., 2020</xref>).</p>
</sec>
<sec id="S6">
<title>Microcins and the Immune System</title>
<p>Inflammation is one of the key processes allowing the immune system being alerted of risks for the host, such as pathogen attacks. But its dysregulation results in chronic inflammation and subsequent diseases, pointing that inflammation results in both beneficial and adverse effects. In general, interactions of bacteriocins or microcins with the immune system have not been investigated deeply, which hampers evaluating previsible risks and benefits for all characterized microcins. MccE492 was reported to induce apoptosis against human cell lines without inducing an inflammatory response (<xref ref-type="bibr" rid="B89">Hetz et al., 2002</xref>; <xref ref-type="bibr" rid="B110">Lagos et al., 2009</xref>). But most of all, two microcins, MccB17 and especially MccJ25, have been chiefly studied in this regard.</p>
<p>A pionneer study showed that polyclonal antibodies were raised in rabbits against mature MccB17, indicating that it could induce immune reaction once introduced in host body (<xref ref-type="bibr" rid="B216">Yorgey et al., 1993</xref>). In an in-depth study on the effects of oxazole compounds on intestinal inflammation (<xref ref-type="bibr" rid="B90">Iyer et al., 2018</xref>) have shown that, similar to environmental or synthetic ones, short-size oxazole compounds derived from MccB17 degradation were able to induce inflammation in mouse intestinal epithelial cells, while full-length MccB17 was not (<xref ref-type="bibr" rid="B90">Iyer et al., 2018</xref>; <xref ref-type="bibr" rid="B41">Collin and Maxwell, 2019</xref>). This effect was attributed to a cascade response where oxazole compounds activate IDO1, the rate-limiting enzyme in tryptophan catabolism, and in turn tryptophan-derived metabolites activate the aryl hydrocarbon receptor Ahr, which limits CD1d-restricted production of the anti-inflammatory cytokine IL-10 and results in natural killer T-cell mediated intestinal inflammation (<xref ref-type="bibr" rid="B90">Iyer et al., 2018</xref>). It was pointed that this oxazole-induced intestinal inflammation is independent of the antimicrobial activity of the compounds. Moreover, it was proposed that the CD1d-dependent immunomodulatory effect is limited by the size of the compounds, explaining the absence of effect of native MccB17, although its content in oxazole rings.</p>
<p>An <italic>in vitro</italic> study showed that MccJ25 protects IPEC-J2 cells against enterotoxigenic <italic>E. coli</italic> (ETEC) without raising cytotoxicity and alleviates the inflammatory responses through modulation of the levels of pro-inflammatory cytokines, interleukins 6 (IL-6), IL-8 and tumor necrosis factor-&#x03B1; (TNF-&#x03B1;) (<xref ref-type="bibr" rid="B217">Yu et al., 2018a</xref>). An anti-inflammatory effect of MccJ25 associated with killing of the pathogen was shown in an ETEC-infected mouse model (<xref ref-type="bibr" rid="B57">Ding et al., 2020</xref>; <xref ref-type="bibr" rid="B220">Yu et al., 2020</xref>). Similar to gentamicin treated mice, the levels of pro-inflammatory cytokines were significantly decreased in jejunum, ileum and colon tissues of mice administered MccJ25, compared to the control group, while the anti-inflammatory IL-10 level increased. Inhibition of ETEC-induced expression of inflammatory cytokines in the jejunum was proposed to be due to down-regulation by MccJ25 of the NF-&#x03BA;B and mitogen-activated protein kinase (MAPK) pathways (<xref ref-type="bibr" rid="B57">Ding et al., 2020</xref>). Moreover, absence of immunomodulatory effect and toxicity of MccJ25 was observed at the therapeutic dose (9 mg/kg), much higher doses only (18 mg/kg) being able to cause a low toxicity (<xref ref-type="bibr" rid="B218">Yu et al., 2018b</xref>). Furthermore, MccJ25 also decreases the serum concentration levels of the pro-inflammatory cytokines IL-6, IL-1&#x03B2;, and TNF-&#x03B1;, together with an increase in anti-inflammatory IL-10 in weaned pigs (<xref ref-type="bibr" rid="B203">Wang et al., 2020</xref>) and in broiler chicken (<xref ref-type="bibr" rid="B221">Yu et al., 2017</xref>) fed with MccJ25-supplemented diet. Taken together, these <italic>in vivo</italic> studies conducted in different animal models indicate that MccJ25 diet supplementation can lower inflammation together with affording protection against pathogens, providing interesting perspectives in inflammatory intestinal diseases. Therefore, it appears that none of the studied microcins appears to induce adverse inflammation imbalance and have a detrimental effect on the host.</p>
</sec>
<sec id="S7">
<title>Potential Applications of Microcins and Future Prospect</title>
<p>Microcins exhibit a number of advantages for potential applications, among which their absence of toxicity to eukaryotic cells and their chemical stability. Indeed, the three-dimensional structures or PTMs of most microcins increases their stability to harsh conditions, such as those that are encountered in the gut (<xref ref-type="bibr" rid="B141">Naimi et al., 2020</xref>). This favors their delivery to the gut without the help of specific formulations, if not for avoiding immunity response. However, unfortunately, the spectrum of inhibitory activity of the different microcins has not been deeply investigated, hampering significant development in veterinary or human medical domains. The antimicrobial activity of most microcins (MccB17, McC and a few others) was determined in order to decipher their mechanism of action and the most tested bacterium was <italic>E. coli</italic> (<xref ref-type="bibr" rid="B87">Heddle et al., 2001</xref>; <xref ref-type="bibr" rid="B135">Metlitskaya et al., 2006</xref>; <xref ref-type="bibr" rid="B177">Severinov and Nair, 2012</xref>). Thus, while for a few microcins the spectrum of inhibition is well known, for the remaining this information is still missing. A more systematic study involving a significant number of clinical and veterinary pathogens, including MDR strains, remains necessary to establish the exact spectrum of inhibition of each microcin.</p>
<p>An important characteristic making microcins good candidates as alternatives to antibiotics is that they are prominent actors of competitions in microbiota and particularly in the gut microbiota, which is the most studied. Microcins play a significant role in niche competition (for a review see <xref ref-type="bibr" rid="B118">Li and Rebuffat, 2020</xref>), essentially in interference competition, which involves the secretion of harmful molecules such as the microcins, for direct attack of competitors. But also in a lesser extent, they are involved in the indirect process of exploitative competition, as exemplified by siderophore microcins which are able to capture iron and thus deplete the surroundings of this essential element. Thereby, the siderophore microcins MccH47 and MccM, both produced by the probiotic <italic>E. coli</italic> strain Nissle 1917, have been shown to mediate competition among <italic>Enterobacteriaceae</italic> in mouse model and to impair the growth of the pathogen <italic>S. enterica</italic> serovar Typhimurium in the inflamed gut, where iron is scarce, without perturbing significantly the microbiota equilibrium (<xref ref-type="bibr" rid="B172">Sassone-Corsi et al., 2016</xref>). Thanks to their natural role in their niche, which involves both high potency and narrow spectrum of activity, the molecules from microbiota, such as the microcins in the gut microbiota (<xref ref-type="bibr" rid="B59">Donia and Fischbach, 2015</xref>; <xref ref-type="bibr" rid="B72">Garcia-Gutierrez et al., 2019</xref>), or other bacteriocins in the rumen (<xref ref-type="bibr" rid="B147">Oyama et al., 2017</xref>), are thus of high potential. However, exploration of the capacity of microorganisms belonging to various microbiota still remains underdeveloped so far. Its development in combination with genome mining approaches and innovative computational technologies should allow finding novel microcins, and possibly novel mechanisms of action.</p>
<p>To explore the potential applications of microcins in animal and human health, <italic>in vivo</italic> studies have been conducted, although they are still few and only concern a few microcins, essentially MccJ25. For instance, a significant decrease of <italic>S.</italic> Typhimurium was recorded in chicken, using an <italic>E. coli</italic> transformant strain producing MccN/24, although continuous administration of the transformant was needed to ensure colonization within the <italic>in vivo</italic> model (<xref ref-type="bibr" rid="B209">Wooley et al., 1999</xref>). MccJ25 has been shown to decrease <italic>S. enterica</italic> counts in the liver and spleen in mice (<xref ref-type="bibr" rid="B120">Lopez et al., 2007</xref>) and in the gastrointestinal tract of turkeys (<xref ref-type="bibr" rid="B71">Forkus et al., 2017</xref>), and to relieve diarrhea and systematic inflammation in weaned pigs (<xref ref-type="bibr" rid="B221">Yu et al., 2017</xref>). Furthermore, MccJ25 was shown to improve performance, fecal microbiota composition and systematic inflammation of broilers (<xref ref-type="bibr" rid="B203">Wang et al., 2020</xref>). Further studies are needed however to validate the potential of microcins as therapeutic agents in human or veterinary medicine.</p>
<p>Finally, developing safe probiotics engineered to produce potent microcins is a complementary and efficient approach. It relies on previous studies of commercially available probiotics, <italic>E. coli</italic> Nissle 1917 (Mutaflor<sup>&#x00AE;</sup>) and <italic>E. coli</italic> G3/10 (Symbioflor2<sup>&#x00AE;</sup>), producers of microcins MccH47 and MccM (<xref ref-type="bibr" rid="B172">Sassone-Corsi et al., 2016</xref>; <xref ref-type="bibr" rid="B126">Massip and Oswald, 2020</xref>) and MccS (<xref ref-type="bibr" rid="B226">Zsch&#x00FC;ttig et al., 2012</xref>), respectively, which were shown to act in bacterial competition and kill pathogens in inflamed gut (<xref ref-type="bibr" rid="B172">Sassone-Corsi et al., 2016</xref>), or suppress adherence of enteropathogenic <italic>E. coli</italic> (<xref ref-type="bibr" rid="B226">Zsch&#x00FC;ttig et al., 2012</xref>). Thus, <italic>S. enterica</italic> carriage was significantly reduced in turkey gastrointestinal tract using <italic>E. coli</italic> Nissle engineered to produce MccJ25 (<xref ref-type="bibr" rid="B71">Forkus et al., 2017</xref>). Furthermore, <italic>E. coli</italic> Nissle was engineered to produce MccH47 in response to tetrathionate, which is produced in gut inflammation conditions and is favorable to <italic>Salmonella</italic> growth (<xref ref-type="bibr" rid="B150">Palmer et al., 2018</xref>). In this system, MccH47 was produced in response to the tetrathionate environmental signal serving as an inducing molecule, and inhibited the pathogen <italic>S.</italic> Typhimurium, both in static inhibition assays and in ecological competition experiments.</p>
</sec>
<sec id="S8">
<title>Conclusion</title>
<p>As it can be seen through this review, microcins offer an attractive track for designing novel antimicrobial strategies and envisage alternatives to conventional antibiotics, despite the potential risks of resistance, cross-resistance and co-resistance that have been pointed. The microcin attractivity relies first on their two-step mechanisms of action. The first step ensures uptake of the microcin and involves most often a Trojan horse strategy. It is exemplarily illustrated by MccC, for which the last processing step of the uptaken harmless nucleotide peptide is ensured in the targeted bacteria by common proteases. It is also exemplified by siderophore microcins (MccE492, MccM, MccH47) or the lasso microcin MccJ25 that mimic the natural ligands of siderophore receptors to hijack them. The second step implies either membrane perturbations or inhibition of critical enzymes, and therefore vital functions in bacteria. Indeed, in certain cases such strategies are shared by antibiotics, which can result in cross-resistance, as pointed in this review. These two steps can also constitute a drawback toward resistance development as inhibiting one of them could potentially confer resistance to microcin. However, a few microcins, such as McC and MccJ25, bring into play a second and independent mechanism that intervenes at higher concentrations. Such a secondary mechanism has not been brought to light for other microcins, but it must be said that it has not been thoroughly investigated. Such a succession of different mechanisms limits the emergence of bacterial resistance, as the energetic costs induced by setting up distinct resistance mechanisms simultaneously is hard to assume by the bacteria.</p>
<p>Other characteristics, which have been underlined in the review, support their interesting potential: (i) a potent activity in the GI tract, (ii) a narrow spectrum of activity, which makes them active against pathogens while preserving host microbiota, (iii) an important role in microbial competitions, which makes them actors in maintaining microbiota equilibrium, (iv) an efficient activity <italic>in vivo</italic> in different animal models. Developing strategies based on Nature-derived mechanisms and molecules that are able to minimize both niche perturbations and resistance thus appears as a promising direction in the light of recent analysis of the frequency and mechanisms of resistance of antimicrobial peptides and antibiotics (<xref ref-type="bibr" rid="B102">Kintses et al., 2019</xref>). Finally, as the production costs of antimicrobial peptides and in particular of RiPPs remain high, a possible strategy to use microcins and simultaneously increase their potency could be to associate them to conventional antibiotics. This would take full advantage of the lower costs of production of antibiotics, of an increased potency when synergistic effects are obtained, and of the possibility of combining distinct mechanisms of action. Therefore, relying on the current knowledge on the topology of microcins and their targets, the microcin biosynthesis pathways, and their mechanisms of action and of resistance, directions of research involving a more dynamic exploration of diverse microbiota associated with the development of microcin bioengineering would presumably accelerate the diversification of anti-AMR strategies.</p>
</sec>
<sec id="S9">
<title>Author Contributions</title>
<p>All authors listed have made a substantial, direct and intellectual contribution to the work, approved the final manuscript for publication. ST and LBS drafted the manuscript and contributed equally to its preparation. SR, IF, and SZ revised the manuscript. LBS and SR wrote the final version of the manuscript. ST, LBS, and SZ designed and prepared the figures.</p>
</sec>
<sec id="conf1">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> We acknowledge financial support received for this work from the International Development research Center (IDRC 109048-001), the National Science and Engineering Research Council of Canada (grant number 06593-2018; NSERC-METABIOLAC industrial research chair grant number IRCPJ 499946-15) and the National Museum of Natural History (MNHN).</p>
</fn>
</fn-group>
<sec id="S11" sec-type="supplementary material"><title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fmicb.2020.586433/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fmicb.2020.586433/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Image_1.pdf" id="FS1" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adelman</surname> <given-names>K.</given-names></name> <name><surname>Yuzenkova</surname> <given-names>J.</given-names></name> <name><surname>La Porta</surname> <given-names>A.</given-names></name> <name><surname>Zenkin</surname> <given-names>N.</given-names></name> <name><surname>Lee</surname> <given-names>J.</given-names></name> <name><surname>Lis</surname> <given-names>J. T.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Molecular mechanism of transcription inhibition by peptide antibiotic Microcin J25.</article-title> <source><italic>Mol. Cell.</italic></source> <volume>14</volume> <fpage>753</fpage>&#x2013;<lpage>762</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2004.05.017</pub-id> <pub-id pub-id-type="pmid">15200953</pub-id></citation></ref>
<ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname> <given-names>V.</given-names></name> <name><surname>Metlitskaya</surname> <given-names>A.</given-names></name> <name><surname>Severinov</surname> <given-names>K.</given-names></name> <name><surname>Nair</surname> <given-names>S. K.</given-names></name></person-group> (<year>2011</year>). <article-title>Structural basis for microcin C7 inactivation by the MccE acetyltransferase.</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>286</volume> <fpage>21295</fpage>&#x2013;<lpage>21303</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M111.226282</pub-id> <pub-id pub-id-type="pmid">21507941</pub-id></citation></ref>
<ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname> <given-names>V.</given-names></name> <name><surname>Tikhonov</surname> <given-names>A.</given-names></name> <name><surname>Metlitskaya</surname> <given-names>A.</given-names></name> <name><surname>Severinov</surname> <given-names>K.</given-names></name> <name><surname>Nair</surname> <given-names>S. K.</given-names></name></person-group> (<year>2012</year>). <article-title>Structure and function of a serine carboxypeptidase adapted for degradation of the protein synthesis antibiotic microcin C7.</article-title> <source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source> <volume>109</volume> <fpage>4425</fpage>&#x2013;<lpage>4430</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1114224109</pub-id> <pub-id pub-id-type="pmid">22388748</pub-id></citation></ref>
<ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aguilera</surname> <given-names>P.</given-names></name> <name><surname>Marcoleta</surname> <given-names>A.</given-names></name> <name><surname>Lobos-Ruiz</surname> <given-names>P.</given-names></name> <name><surname>Arranz</surname> <given-names>R.</given-names></name> <name><surname>Valpuesta</surname> <given-names>J. M.</given-names></name> <name><surname>Monasterio</surname> <given-names>O.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Identification of key amino acid residues modulating intracellular and in vitro microcin E492 amyloid formation.</article-title> <source><italic>Front. Microbiol.</italic></source> <volume>7</volume>:<issue>35</issue>. <pub-id pub-id-type="doi">10.3389/fmicb.2016.00035</pub-id> <pub-id pub-id-type="pmid">26858708</pub-id></citation></ref>
<ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amaral</surname> <given-names>L.</given-names></name> <name><surname>Martins</surname> <given-names>A.</given-names></name> <name><surname>Spengler</surname> <given-names>G.</given-names></name> <name><surname>Molnar</surname> <given-names>J.</given-names></name></person-group> (<year>2014</year>). <article-title>Efflux pumps of Gram-negative bacteria, what they do, how they do it, with what and how to deal with them.</article-title> <source><italic>Front. Pharmacol.</italic></source> <volume>4</volume>:<issue>168</issue>. <pub-id pub-id-type="doi">10.3389/fphar.2013.00168</pub-id> <pub-id pub-id-type="pmid">24427138</pub-id></citation></ref>
<ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anes</surname> <given-names>J.</given-names></name> <name><surname>McCusker</surname> <given-names>M. P.</given-names></name> <name><surname>Fanning</surname> <given-names>S.</given-names></name> <name><surname>Martins</surname> <given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>The ins and outs of RND efflux pumps in <italic>Escherichia coli</italic>.</article-title> <source><italic>Front. Microbiol.</italic></source> <volume>6</volume>:<issue>587</issue>. <pub-id pub-id-type="doi">10.3389/fmicb.2015.00587</pub-id> <pub-id pub-id-type="pmid">26113845</pub-id></citation></ref>
<ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arnison</surname> <given-names>P. G.</given-names></name> <name><surname>Bibb</surname> <given-names>M. J.</given-names></name> <name><surname>Bierbaum</surname> <given-names>G.</given-names></name> <name><surname>Bowers</surname> <given-names>A. A.</given-names></name> <name><surname>Bugni</surname> <given-names>T. S.</given-names></name> <name><surname>Bulaj</surname> <given-names>G.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Ribosomally synthesized and post-translationally modified peptide natural products, overview and recommendations for a universal nomenclature.</article-title> <source><italic>Nat. Prod. Rep.</italic></source> <volume>30</volume> <fpage>108</fpage>&#x2013;<lpage>160</lpage>. <pub-id pub-id-type="doi">10.1039/c2np20085f</pub-id> <pub-id pub-id-type="pmid">23165928</pub-id></citation></ref>
<ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arranz</surname> <given-names>R.</given-names></name> <name><surname>Mercado</surname> <given-names>G.</given-names></name> <name><surname>Martin-Benito</surname> <given-names>J.</given-names></name> <name><surname>Giraldo</surname> <given-names>R.</given-names></name> <name><surname>Monasterio</surname> <given-names>O.</given-names></name> <name><surname>Lagos</surname> <given-names>R.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Structural characterization of microcin E492 amyloid formation, Identification of the precursors.</article-title> <source><italic>J. Struct. Biol.</italic></source> <volume>178</volume> <fpage>54</fpage>&#x2013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsb.2012.02.015</pub-id> <pub-id pub-id-type="pmid">22420976</pub-id></citation></ref>
<ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asensio</surname> <given-names>C.</given-names></name> <name><surname>Perez-Diaz</surname> <given-names>J. C.</given-names></name></person-group> (<year>1976</year>). <article-title>A new family of low molecular weight antibiotics from enterobacteria.</article-title> <source><italic>Biochem. Biophys. Res. Commun.</italic></source> <volume>69</volume> <fpage>7</fpage>&#x2013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/s0006-291x(76)80264-1</pub-id></citation></ref>
<ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Azpiroz</surname> <given-names>M. F.</given-names></name> <name><surname>Lavi&#x00F1;a</surname> <given-names>M.</given-names></name></person-group> (<year>2007</year>). <article-title>Modular structure of microcin H47 and colicin V.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>51</volume> <fpage>2412</fpage>&#x2013;<lpage>2419</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.01606-06</pub-id> <pub-id pub-id-type="pmid">17452478</pub-id></citation></ref>
<ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bantysh</surname> <given-names>O.</given-names></name> <name><surname>Serebryakova</surname> <given-names>M.</given-names></name> <name><surname>Makarova</surname> <given-names>K. S.</given-names></name> <name><surname>Dubiley</surname> <given-names>S.</given-names></name> <name><surname>Datsenko</surname> <given-names>K. A.</given-names></name> <name><surname>Severinov</surname> <given-names>K.</given-names></name></person-group> (<year>2014</year>). <article-title>Enzymatic synthesis of bioinformatically predicted microcin C-like compounds encoded by diverse bacteria.</article-title> <source><italic>mBio</italic></source> <volume>5</volume>:<issue>e01059-14</issue>. <pub-id pub-id-type="doi">10.1128/mBio.01059-14</pub-id> <pub-id pub-id-type="pmid">24803518</pub-id></citation></ref>
<ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baquero</surname> <given-names>F.</given-names></name> <name><surname>Lanza</surname> <given-names>V. F.</given-names></name> <name><surname>Baquero</surname> <given-names>M. R.</given-names></name> <name><surname>Del Campo</surname> <given-names>R.</given-names></name> <name><surname>Bravo-Vazquez</surname> <given-names>D. A.</given-names></name></person-group> (<year>2019</year>). <article-title>Microcins in <italic>Enterobacteriaceae</italic>, Peptide antimicrobials in the eco-active intestinal chemosphere.</article-title> <source><italic>Front. Microbiol.</italic></source> <volume>10</volume>:<issue>2261</issue>. <pub-id pub-id-type="doi">10.3389/fmicb.2019.02261</pub-id> <pub-id pub-id-type="pmid">31649628</pub-id></citation></ref>
<ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baquero</surname> <given-names>F.</given-names></name> <name><surname>Moreno</surname> <given-names>F.</given-names></name></person-group> (<year>1984</year>). <article-title>The microcins.</article-title> <source><italic>FEMS Microbiol. Lett.</italic></source> <volume>23</volume> <fpage>117</fpage>&#x2013;<lpage>124</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-642-76974-0_12</pub-id></citation></ref>
<ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beis</surname> <given-names>K.</given-names></name> <name><surname>Rebuffat</surname> <given-names>S.</given-names></name></person-group> (<year>2019</year>). <article-title>Multifaceted ABC transporters associated to microcin and bacteriocin export.</article-title> <source><italic>Res. Microbiol.</italic></source> <volume>170</volume> <fpage>399</fpage>&#x2013;<lpage>406</lpage>. <pub-id pub-id-type="doi">10.1016/j.resmic.2019.07.002</pub-id> <pub-id pub-id-type="pmid">31401108</pub-id></citation></ref>
<ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bellomio</surname> <given-names>A.</given-names></name> <name><surname>Vincent</surname> <given-names>P. A.</given-names></name> <name><surname>de Arcuri</surname> <given-names>B. F.</given-names></name> <name><surname>Farias</surname> <given-names>R. N.</given-names></name> <name><surname>Morero</surname> <given-names>R. D.</given-names></name></person-group> (<year>2007</year>). <article-title>Microcin J25 has dual and independent mechanisms of action in <italic>Escherichia coli</italic>, RNA polymerase inhibition and increased superoxide production.</article-title> <source><italic>J. Bacteriol.</italic></source> <volume>189</volume> <fpage>4180</fpage>&#x2013;<lpage>4186</lpage>. <pub-id pub-id-type="doi">10.1128/jb.00206-07</pub-id> <pub-id pub-id-type="pmid">17400747</pub-id></citation></ref>
<ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ben Said</surname> <given-names>L.</given-names></name> <name><surname>Emond-Rheault</surname> <given-names>J. G.</given-names></name> <name><surname>Soltani</surname> <given-names>S.</given-names></name> <name><surname>Telhig</surname> <given-names>S.</given-names></name> <name><surname>Zirah</surname> <given-names>S.</given-names></name> <name><surname>Rebuffat</surname> <given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Phenomic and genomic approaches to studying the inhibition of multiresistant <italic>Salmonella enterica</italic> by microcin J25.</article-title> <source><italic>Environ. Microbiol</italic>.</source> <volume>22</volume> <fpage>2907</fpage>&#x2013;<lpage>2920</lpage>. <pub-id pub-id-type="doi">10.1111/1462-2920.15045</pub-id> <pub-id pub-id-type="pmid">32363677</pub-id></citation></ref>
<ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bieler</surname> <given-names>S.</given-names></name> <name><surname>Estrada</surname> <given-names>L.</given-names></name> <name><surname>Lagos</surname> <given-names>R.</given-names></name> <name><surname>Baeza</surname> <given-names>M.</given-names></name> <name><surname>Castilla</surname> <given-names>J.</given-names></name> <name><surname>Soto</surname> <given-names>C.</given-names></name></person-group> (<year>2005</year>). <article-title>Amyloid formation modulates the biological activity of a bacterial protein.</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>280</volume> <fpage>26880</fpage>&#x2013;<lpage>26885</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M502031200</pub-id> <pub-id pub-id-type="pmid">15917245</pub-id></citation></ref>
<ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bieler</surname> <given-names>S.</given-names></name> <name><surname>Silva</surname> <given-names>F.</given-names></name> <name><surname>Belin</surname> <given-names>D.</given-names></name></person-group> (<year>2010</year>). <article-title>The polypeptide core of microcin E492 stably associates with the mannose permease and interferes with mannose metabolism.</article-title> <source><italic>Res. Microbiol.</italic></source> <volume>161</volume> <fpage>706</fpage>&#x2013;<lpage>710</lpage>. <pub-id pub-id-type="doi">10.1016/j.resmic.2010.07.003</pub-id> <pub-id pub-id-type="pmid">20674740</pub-id></citation></ref>
<ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bieler</surname> <given-names>S.</given-names></name> <name><surname>Silva</surname> <given-names>F.</given-names></name> <name><surname>Soto</surname> <given-names>C.</given-names></name> <name><surname>Belin</surname> <given-names>D.</given-names></name></person-group> (<year>2006</year>). <article-title>Bactericidal activity of both secreted and nonsecreted microcin E492 requires the mannose permease.</article-title> <source><italic>J. Bacteriol.</italic></source> <volume>188</volume> <fpage>7049</fpage>&#x2013;<lpage>7061</lpage>. <pub-id pub-id-type="doi">10.1128/jb.00688-06</pub-id> <pub-id pub-id-type="pmid">17015644</pub-id></citation></ref>
<ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boubezari</surname> <given-names>M. T.</given-names></name> <name><surname>Idoui</surname> <given-names>T.</given-names></name> <name><surname>Hammami</surname> <given-names>R.</given-names></name> <name><surname>Fernandez</surname> <given-names>B.</given-names></name> <name><surname>Gomaa</surname> <given-names>A.</given-names></name> <name><surname>Fliss</surname> <given-names>I.</given-names></name></person-group> (<year>2018</year>). <article-title>Bacteriocinogenic properties of <italic>Escherichia coli</italic> P2C isolated from pig gastrointestinal tract, purification and characterization of microcin V.</article-title> <source><italic>Arch. Microbiol.</italic></source> <volume>200</volume> <fpage>771</fpage>&#x2013;<lpage>782</lpage>. <pub-id pub-id-type="doi">10.1007/s00203-018-1482-6</pub-id> <pub-id pub-id-type="pmid">29417164</pub-id></citation></ref>
<ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bountra</surname> <given-names>K.</given-names></name> <name><surname>Hagelueken</surname> <given-names>G.</given-names></name> <name><surname>Choudhury</surname> <given-names>H. G.</given-names></name> <name><surname>Corradi</surname> <given-names>V.</given-names></name> <name><surname>El Omari</surname> <given-names>K.</given-names></name> <name><surname>Wagner</surname> <given-names>A.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Structural basis for antibacterial peptide self-immunity by the bacterial ABC transporter McjD.</article-title> <source><italic>Embo. J.</italic></source> <volume>36</volume> <fpage>3062</fpage>&#x2013;<lpage>3079</lpage>. <pub-id pub-id-type="doi">10.15252/embj.201797278</pub-id> <pub-id pub-id-type="pmid">28864543</pub-id></citation></ref>
<ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Braffman</surname> <given-names>N. R.</given-names></name> <name><surname>Piscotta</surname> <given-names>F. J.</given-names></name> <name><surname>Hauver</surname> <given-names>J.</given-names></name> <name><surname>Campbell</surname> <given-names>E. A.</given-names></name> <name><surname>Link</surname> <given-names>A. J.</given-names></name> <name><surname>Darst</surname> <given-names>S. A.</given-names></name></person-group> (<year>2019</year>). <article-title>Structural mechanism of transcription inhibition by lasso peptides microcin J25 and capistruin.</article-title> <source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source> <volume>116</volume> <fpage>1273</fpage>&#x2013;<lpage>1278</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1817352116</pub-id> <pub-id pub-id-type="pmid">30626643</pub-id></citation></ref>
<ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname> <given-names>E. E. F.</given-names></name> <name><surname>Cooper</surname> <given-names>A.</given-names></name> <name><surname>Carrillo</surname> <given-names>C.</given-names></name> <name><surname>Blais</surname> <given-names>B.</given-names></name></person-group> (<year>2019</year>). <article-title>Selection of multidrug-resistant bacteria in medicated animal feeds.</article-title> <source><italic>Front. Microbiol.</italic></source> <volume>10</volume>:<issue>456</issue>. <pub-id pub-id-type="doi">10.3389/fmicb.2019.00456</pub-id> <pub-id pub-id-type="pmid">30894847</pub-id></citation></ref>
<ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Budic</surname> <given-names>M.</given-names></name> <name><surname>Rijavec</surname> <given-names>M.</given-names></name> <name><surname>Petkovsek</surname> <given-names>Z.</given-names></name> <name><surname>Zgur-Bertok</surname> <given-names>D.</given-names></name></person-group> (<year>2011</year>). <article-title><italic>Escherichia coli</italic> bacteriocins, antimicrobial efficacy and prevalence among isolates from patients with bacteraemia.</article-title> <source><italic>PLoS One</italic></source> <volume>6</volume>:<issue>e28769</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0028769</pub-id> <pub-id pub-id-type="pmid">22205967</pub-id></citation></ref>
<ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burkhart</surname> <given-names>B. J.</given-names></name> <name><surname>Hudson</surname> <given-names>G. A.</given-names></name> <name><surname>Dunbar</surname> <given-names>K. L.</given-names></name> <name><surname>Mitchell</surname> <given-names>D. A.</given-names></name></person-group> (<year>2015</year>). <article-title>A prevalent peptide-binding domain guides ribosomal natural product biosynthesis.</article-title> <source><italic>Nat. Chem. Biol.</italic></source> <volume>11</volume> <fpage>564</fpage>&#x2013;<lpage>570</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.1856</pub-id> <pub-id pub-id-type="pmid">26167873</pub-id></citation></ref>
<ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bush</surname> <given-names>K.</given-names></name> <name><surname>Jacoby</surname> <given-names>G. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Updated functional classification of beta-lactamases.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>54</volume> <fpage>969</fpage>&#x2013;<lpage>976</lpage>. <pub-id pub-id-type="doi">10.1128/aac.01009-09</pub-id> <pub-id pub-id-type="pmid">19995920</pub-id></citation></ref>
<ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calvopina</surname> <given-names>K.</given-names></name> <name><surname>Dulyayangkul</surname> <given-names>P.</given-names></name> <name><surname>Heesom</surname> <given-names>K. J.</given-names></name> <name><surname>Avison</surname> <given-names>M. B.</given-names></name></person-group> (<year>2020</year>). <article-title>TonB-dependent uptake of beta-lactam antibiotics in the opportunistic human pathogen <italic>Stenotrophomonas maltophilia</italic>.</article-title> <source><italic>Mol. Microbiol.</italic></source> <volume>113</volume> <fpage>492</fpage>&#x2013;<lpage>503</lpage>. <pub-id pub-id-type="doi">10.1111/mmi.14434</pub-id> <pub-id pub-id-type="pmid">31773806</pub-id></citation></ref>
<ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname> <given-names>E. A.</given-names></name> <name><surname>Korzheva</surname> <given-names>N.</given-names></name> <name><surname>Mustaev</surname> <given-names>A.</given-names></name> <name><surname>Murakami</surname> <given-names>K.</given-names></name> <name><surname>Nair</surname> <given-names>S.</given-names></name> <name><surname>Goldfarb</surname> <given-names>A.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>Structural mechanism for rifampicin inhibition of bacterial RNA polymerase.</article-title> <source><italic>Cell</italic></source> <volume>104</volume> <fpage>901</fpage>&#x2013;<lpage>912</lpage>. <pub-id pub-id-type="doi">10.1016/s0092-8674(01)00286-0</pub-id></citation></ref>
<ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Campos</surname> <given-names>M. A.</given-names></name> <name><surname>Vargas</surname> <given-names>M. A.</given-names></name> <name><surname>Regueiro</surname> <given-names>V.</given-names></name> <name><surname>Llompart</surname> <given-names>C. M.</given-names></name> <name><surname>Albert&#x00ED;</surname> <given-names>S.</given-names></name> <name><surname>Bengoechea</surname> <given-names>J. A.</given-names></name></person-group> (<year>2004</year>). <article-title>Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides.</article-title> <source><italic>Infect. Immun.</italic></source> <volume>72</volume> <fpage>7107</fpage>&#x2013;<lpage>7114</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.72.12.7107-7114.2004</pub-id> <pub-id pub-id-type="pmid">15557634</pub-id></citation></ref>
<ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carlson</surname> <given-names>S. A.</given-names></name> <name><surname>Frana</surname> <given-names>T. S.</given-names></name> <name><surname>Griffith</surname> <given-names>R. W.</given-names></name></person-group> (<year>2001</year>). <article-title>Antibiotic resistance in <italic>Salmonella enterica</italic> serovar Typhimurium exposed to microcin-producing <italic>Escherichia coli</italic>.</article-title> <source><italic>Appl. Environ. Microbiol.</italic></source> <volume>67</volume> <fpage>3763</fpage>&#x2013;<lpage>3766</lpage>. <pub-id pub-id-type="doi">10.1128/aem.67.8.3763-3766.2001</pub-id> <pub-id pub-id-type="pmid">11472964</pub-id></citation></ref>
<ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carroll</surname> <given-names>L. M.</given-names></name> <name><surname>Gaballa</surname> <given-names>A.</given-names></name> <name><surname>Guldimann</surname> <given-names>C.</given-names></name> <name><surname>Sullivan</surname> <given-names>G.</given-names></name> <name><surname>Henderson</surname> <given-names>L. O.</given-names></name> <name><surname>Wiedmann</surname> <given-names>M.</given-names></name></person-group> (<year>2019</year>). <article-title>Identification of novel mobilized colistin resistance gene mcr-9 in a multidrug-resistant, colistin-susceptible <italic>Salmonella enterica</italic> serotype Typhimurium isolate.</article-title> <source><italic>mBio</italic></source> <volume>10</volume>:<issue>e0853-19</issue>. <pub-id pub-id-type="doi">10.1128/mBio.00853-19</pub-id> <pub-id pub-id-type="pmid">31064835</pub-id></citation></ref>
<ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cascales</surname> <given-names>E.</given-names></name> <name><surname>Buchanan</surname> <given-names>S. K.</given-names></name> <name><surname>Duch&#x00E9;</surname> <given-names>D.</given-names></name> <name><surname>Kleanthous</surname> <given-names>C.</given-names></name> <name><surname>Lloub&#x00E8;s</surname> <given-names>R.</given-names></name> <name><surname>Postle</surname> <given-names>K.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Colicin biology.</article-title> <source><italic>Microbiol. Mol. Biol. Rev.</italic></source> <volume>71</volume> <fpage>158</fpage>&#x2013;<lpage>229</lpage>. <pub-id pub-id-type="doi">10.1128/mmbr.00036-06</pub-id> <pub-id pub-id-type="pmid">17347522</pub-id></citation></ref>
<ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chapman</surname> <given-names>J. S.</given-names></name></person-group> (<year>2003</year>). <article-title>Disinfectant resistance mechanisms, cross-resistance, and co-resistance.</article-title> <source><italic>Int. Biodeterior. Biodegrad.</italic></source> <volume>51</volume> <fpage>271</fpage>&#x2013;<lpage>276</lpage>. <pub-id pub-id-type="doi">10.1016/S0964-8305(03)00044-1</pub-id></citation></ref>
<ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chehade</surname> <given-names>H.</given-names></name> <name><surname>Braun</surname> <given-names>V.</given-names></name></person-group> (<year>1988</year>). <article-title>Iron-regulated synthesis and uptake of colicin V.</article-title> <source><italic>FEMS Microbiol. Lett.</italic></source> <volume>52</volume> <fpage>177</fpage>&#x2013;<lpage>181</lpage>. <pub-id pub-id-type="doi">10.111/j.1574-6968.1988.tb02591.x</pub-id></citation></ref>
<ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheung-Lee</surname> <given-names>W. L.</given-names></name> <name><surname>Link</surname> <given-names>A. J.</given-names></name></person-group> (<year>2019</year>). <article-title>Genome mining for lasso peptides, past, present, and future.</article-title> <source><italic>J. Ind. Microbiol. Biot</italic>.</source> <volume>46</volume> <fpage>1371</fpage>&#x2013;<lpage>1379</lpage>. <pub-id pub-id-type="doi">10.1007/s10295-019-02197-z</pub-id> <pub-id pub-id-type="pmid">31165971</pub-id></citation></ref>
<ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheung-Lee</surname> <given-names>W. L.</given-names></name> <name><surname>Parry</surname> <given-names>M. E.</given-names></name> <name><surname>Cartagena</surname> <given-names>A. J.</given-names></name> <name><surname>Darst</surname> <given-names>S. A.</given-names></name> <name><surname>Link</surname> <given-names>A. J.</given-names></name></person-group> (<year>2019</year>). <article-title>Discovery and structure of the antimicrobial lasso peptide citrocin.</article-title> <source><italic>J. Biol. Chem</italic>.</source> <volume>294</volume> <fpage>6822</fpage>&#x2013;<lpage>6830</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.RA118.006494</pub-id> <pub-id pub-id-type="pmid">30846564</pub-id></citation></ref>
<ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheung-Lee</surname> <given-names>W. L.</given-names></name> <name><surname>Parry</surname> <given-names>M. E.</given-names></name> <name><surname>Zong</surname> <given-names>C.</given-names></name> <name><surname>Cartagena</surname> <given-names>A. J.</given-names></name> <name><surname>Darst</surname> <given-names>S. A.</given-names></name> <name><surname>Connell</surname> <given-names>N. D.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Discovery of ubonodin, an antimicrobial lasso peptide active against members of the <italic>Burkholderia cepacia</italic> complex.</article-title> <source><italic>Chembiochem</italic>.</source> <volume>21</volume> <fpage>1335</fpage>&#x2013;<lpage>1340</lpage>. <pub-id pub-id-type="doi">10.1002/cbic.201900707</pub-id> <pub-id pub-id-type="pmid">31765515</pub-id></citation></ref>
<ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname> <given-names>U.</given-names></name> <name><surname>Lee</surname> <given-names>C. R.</given-names></name></person-group> (<year>2019</year>). <article-title>Distinct roles of outer membrane porins in antibiotic resistance and membrane integrity in <italic>Escherichia coli</italic>.</article-title> <source><italic>Front. Microbiol</italic>.</source> <volume>10</volume>:<issue>953</issue>. <pub-id pub-id-type="doi">10.3389/fmicb.2019.00953</pub-id> <pub-id pub-id-type="pmid">31114568</pub-id></citation></ref>
<ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chopra</surname> <given-names>I.</given-names></name> <name><surname>Roberts</surname> <given-names>M.</given-names></name></person-group> (<year>2001</year>). <article-title>Tetracycline antibiotics, mode of action, applications, molecular biology, and epidemiology of bacterial resistance.</article-title> <source><italic>Microbiol. Mol. Biol. Rev.</italic></source> <volume>65</volume> <fpage>232</fpage>&#x2013;<lpage>260</lpage>. <pub-id pub-id-type="doi">10.1128/mmbr.65.2.232-260.2001</pub-id> <pub-id pub-id-type="pmid">11381101</pub-id></citation></ref>
<ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Collet</surname> <given-names>J.-F.</given-names></name> <name><surname>Cho</surname> <given-names>S.-H.</given-names></name> <name><surname>Iorga</surname> <given-names>B. I.</given-names></name> <name><surname>Goemans</surname> <given-names>C. V.</given-names></name></person-group> (<year>2020</year>). <article-title>How the assembly and protection of the bacterial cell envelope depend on cysteine residues.</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>295</volume> <fpage>11984</fpage>&#x2013;<lpage>11994</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.REV120.011201</pub-id></citation></ref>
<ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Collin</surname> <given-names>F.</given-names></name> <name><surname>Maxwell</surname> <given-names>A.</given-names></name></person-group> (<year>2019</year>). <article-title>The microbial toxin Microcin B17, prospects for the development of new antibacterial agents.</article-title> <source><italic>J. Mol. Biol.</italic></source> <volume>431</volume> <fpage>3400</fpage>&#x2013;<lpage>3426</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2019.05.050</pub-id> <pub-id pub-id-type="pmid">31181289</pub-id></citation></ref>
<ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Corsini</surname> <given-names>G.</given-names></name> <name><surname>Karahanian</surname> <given-names>E.</given-names></name> <name><surname>Tello</surname> <given-names>M.</given-names></name> <name><surname>Fernandez</surname> <given-names>K.</given-names></name> <name><surname>Rivero</surname> <given-names>D.</given-names></name> <name><surname>Saavedra</surname> <given-names>J. M.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Purification and characterization of the antimicrobial peptide microcin N.</article-title> <source><italic>FEMS Microbiol. Lett.</italic></source> <volume>312</volume> <fpage>119</fpage>&#x2013;<lpage>125</lpage>. <pub-id pub-id-type="doi">10.1111/j.1574-6968.2010.02106.x</pub-id> <pub-id pub-id-type="pmid">20979348</pub-id></citation></ref>
<ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cotter</surname> <given-names>P. D.</given-names></name> <name><surname>Ross</surname> <given-names>R. P.</given-names></name> <name><surname>Hill</surname> <given-names>C.</given-names></name></person-group> (<year>2013</year>). <article-title>Bacteriocins - a viable alternative to antibiotics?</article-title> <source><italic>Nat. Rev. Microbiol</italic>.</source> <volume>11</volume> <fpage>95</fpage>&#x2013;<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro2937</pub-id> <pub-id pub-id-type="pmid">23268227</pub-id></citation></ref>
<ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crosa</surname> <given-names>J. H.</given-names></name> <name><surname>Walsh</surname> <given-names>C. T.</given-names></name></person-group> (<year>2002</year>). <article-title>Genetics and assembly line enzymology of siderophore biosynthesis in bacteria.</article-title> <source><italic>Microbiol. Mol. Biol. Rev.</italic></source> <volume>66</volume> <fpage>223</fpage>&#x2013;<lpage>249</lpage>. <pub-id pub-id-type="doi">10.1128/mmbr.66.2.223-249.2002</pub-id> <pub-id pub-id-type="pmid">12040125</pub-id></citation></ref>
<ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname> <given-names>E. A.</given-names></name> <name><surname>Bevis</surname> <given-names>H. E.</given-names></name> <name><surname>Delves-Broughton</surname> <given-names>J.</given-names></name></person-group> (<year>1997</year>). <article-title>The use of the bacteriocin, nisin, as a preservative in ricotta-type cheeses to control the food-borne pathogen <italic>Listeria monocytogenes</italic>.</article-title> <source><italic>Lett. Appl. Microbiol</italic>.</source> <volume>24</volume> <fpage>343</fpage>&#x2013;<lpage>346</lpage>. <pub-id pub-id-type="doi">10.1046/j.1472-765x.1997.00145.x</pub-id> <pub-id pub-id-type="pmid">9172439</pub-id></citation></ref>
<ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Kraker</surname> <given-names>M. E.</given-names></name> <name><surname>Stewardson</surname> <given-names>A. J.</given-names></name> <name><surname>Harbarth</surname> <given-names>S.</given-names></name></person-group> (<year>2016</year>). <article-title>Will 10 million people die a year due to antimicrobial resistance by 2050?</article-title> <source><italic>PLoS Med</italic>.</source> <volume>13</volume>:<issue>e1002184</issue>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1002184</pub-id> <pub-id pub-id-type="pmid">27898664</pub-id></citation></ref>
<ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Lorenzo</surname> <given-names>V.</given-names></name></person-group> (<year>1984</year>). <article-title>Isolation and characterization of microcin E 492 from <italic>Klebsiella pneumoniae</italic>.</article-title> <source><italic>Arch. Microbiol.</italic></source> <volume>139</volume> <fpage>72</fpage>&#x2013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1007/BF00692715</pub-id> <pub-id pub-id-type="pmid">6385903</pub-id></citation></ref>
<ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deegan</surname> <given-names>L. H.</given-names></name> <name><surname>Cotter</surname> <given-names>P. D.</given-names></name> <name><surname>Hill</surname> <given-names>C.</given-names></name> <name><surname>Ross</surname> <given-names>P.</given-names></name></person-group> (<year>2006</year>). <article-title>Bacteriocins, biological tools for bio-preservation and shelf-life extension.</article-title> <source><italic>Int. Dairy J.</italic></source> <volume>16</volume> <fpage>1058</fpage>&#x2013;<lpage>1071</lpage>. <pub-id pub-id-type="doi">10.1016/j.idairyj.2005.10.026</pub-id></citation></ref>
<ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>del Castillo</surname> <given-names>F. J.</given-names></name> <name><surname>del Castillo</surname> <given-names>I.</given-names></name> <name><surname>Moreno</surname> <given-names>F.</given-names></name></person-group> (<year>2001</year>). <article-title>Construction and characterization of mutations at codon 751 of the <italic>Escherichia coli</italic> gyrB gene that confer resistance to the antimicrobial peptide microcin B17 and alter the activity of DNA gyrase.</article-title> <source><italic>J. Bacteriol.</italic></source> <volume>183</volume> <fpage>2137</fpage>&#x2013;<lpage>2140</lpage>. <pub-id pub-id-type="doi">10.1128/jb.183.6.2137-2140.2001</pub-id> <pub-id pub-id-type="pmid">11222617</pub-id></citation></ref>
<ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Delgado</surname> <given-names>M. A.</given-names></name> <name><surname>Rintoul</surname> <given-names>M. R.</given-names></name> <name><surname>Farias</surname> <given-names>R. N.</given-names></name> <name><surname>Salom&#x00F3;n</surname> <given-names>R. A.</given-names></name></person-group> (<year>2001</year>). <article-title><italic>Escherichia coli</italic> RNA polymerase is the target of the cyclopeptide antibiotic microcin J25.</article-title> <source><italic>J. Bacteriol.</italic></source> <volume>183</volume> <fpage>4543</fpage>&#x2013;<lpage>4550</lpage>. <pub-id pub-id-type="doi">10.1128/jb.183.15.4543-4550.2001</pub-id> <pub-id pub-id-type="pmid">11443089</pub-id></citation></ref>
<ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Delgado</surname> <given-names>M. A.</given-names></name> <name><surname>Vincent</surname> <given-names>P. A.</given-names></name> <name><surname>Farias</surname> <given-names>R. N.</given-names></name> <name><surname>Salom&#x00F3;n</surname> <given-names>R. A.</given-names></name></person-group> (<year>2005</year>). <article-title>YojI of <italic>Escherichia coli</italic> functions as a microcin J25 efflux pump.</article-title> <source><italic>J. Bacteriol.</italic></source> <volume>187</volume> <fpage>3465</fpage>&#x2013;<lpage>3470</lpage>. <pub-id pub-id-type="doi">10.1128/jb.187.10.3465-3470.2005</pub-id> <pub-id pub-id-type="pmid">15866933</pub-id></citation></ref>
<ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Destoumieux-Garz&#x00F3;n</surname> <given-names>D.</given-names></name> <name><surname>Duquesne</surname> <given-names>S.</given-names></name> <name><surname>Peduzzi</surname> <given-names>J.</given-names></name> <name><surname>Goulard</surname> <given-names>C.</given-names></name> <name><surname>Desmadril</surname> <given-names>M.</given-names></name> <name><surname>Letellier</surname> <given-names>L.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>The iron-siderophore transporter FhuA is the receptor for the antimicrobial peptide microcin J25, role of the microcin Val11-Pro16 beta-hairpin region in the recognition mechanism.</article-title> <source><italic>Biochem. J.</italic></source> <volume>389</volume> <fpage>869</fpage>&#x2013;<lpage>876</lpage>. <pub-id pub-id-type="doi">10.1042/bj20042107</pub-id> <pub-id pub-id-type="pmid">15862112</pub-id></citation></ref>
<ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Destoumieux-Garz&#x00F3;n</surname> <given-names>D.</given-names></name> <name><surname>Peduzzi</surname> <given-names>J.</given-names></name> <name><surname>Thomas</surname> <given-names>X.</given-names></name> <name><surname>Djediat</surname> <given-names>C.</given-names></name> <name><surname>Rebuffat</surname> <given-names>S.</given-names></name></person-group> (<year>2006</year>). <article-title>Parasitism of iron-siderophore receptors of <italic>Escherichia coli</italic> by the siderophore-peptide microcin E492m and its unmodified counterpart.</article-title> <source><italic>Biometals</italic></source> <volume>19</volume> <fpage>181</fpage>&#x2013;<lpage>191</lpage>. <pub-id pub-id-type="doi">10.1007/s10534-005-4452-9</pub-id> <pub-id pub-id-type="pmid">16718603</pub-id></citation></ref>
<ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Destoumieux-Garz&#x00F3;n</surname> <given-names>D.</given-names></name> <name><surname>Thomas</surname> <given-names>X.</given-names></name> <name><surname>Santamaria</surname> <given-names>M.</given-names></name> <name><surname>Goulard</surname> <given-names>C.</given-names></name> <name><surname>Barth&#x00E9;l&#x00E9;my</surname> <given-names>M.</given-names></name> <name><surname>Boscher</surname> <given-names>B.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Microcin E492 antibacterial activity, evidence for a TonB-dependent inner membrane permeabilization on <italic>Escherichia coli</italic>.</article-title> <source><italic>Mol. Microbiol.</italic></source> <volume>49</volume> <fpage>1031</fpage>&#x2013;<lpage>1041</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2958.2003.03610.x</pub-id> <pub-id pub-id-type="pmid">12890026</pub-id></citation></ref>
<ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dickey</surname> <given-names>S. W.</given-names></name> <name><surname>Cheung</surname> <given-names>G. Y. C.</given-names></name> <name><surname>Otto</surname> <given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Different drugs for bad bugs, antivirulence strategies in the age of antibiotic resistance.</article-title> <source><italic>Nat. Rev. Drug Discov.</italic></source> <volume>16</volume> <fpage>457</fpage>&#x2013;<lpage>471</lpage>. <pub-id pub-id-type="doi">10.1038/nrd.2017.23</pub-id> <pub-id pub-id-type="pmid">28337021</pub-id></citation></ref>
<ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dijkmans</surname> <given-names>A. C.</given-names></name> <name><surname>Zacarias</surname> <given-names>N. V. O.</given-names></name> <name><surname>Burggraaf</surname> <given-names>J.</given-names></name> <name><surname>Mouton</surname> <given-names>J. W.</given-names></name> <name><surname>Wilms</surname> <given-names>E. B.</given-names></name> <name><surname>van Nieuwkoop</surname> <given-names>C.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Fosfomycin, pharmacological, clinical and future perspectives.</article-title> <source><italic>Antibiotics</italic></source> <volume>6</volume>:<issue>24</issue>. <pub-id pub-id-type="doi">10.3390/antibiotics6040024</pub-id> <pub-id pub-id-type="pmid">29088073</pub-id></citation></ref>
<ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname> <given-names>X.</given-names></name> <name><surname>Yu</surname> <given-names>H.</given-names></name> <name><surname>Qiao</surname> <given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Lasso peptide microcin J25 effectively enhances gut barrier function and modulates inflammatory response in an enterotoxigenic <italic>Escherichia coli</italic>-challenged mouse model.</article-title> <source><italic>Int. J. Mol. Sci.</italic></source> <volume>21</volume>:<issue>E6500</issue>. <pub-id pub-id-type="doi">10.3390/ijms21186500</pub-id> <pub-id pub-id-type="pmid">32899529</pub-id></citation></ref>
<ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Doi</surname> <given-names>Y.</given-names></name> <name><surname>Bonomo</surname> <given-names>R. A.</given-names></name> <name><surname>Hooper</surname> <given-names>D. C.</given-names></name> <name><surname>Kaye</surname> <given-names>K. S.</given-names></name> <name><surname>Johnson</surname> <given-names>J. R.</given-names></name> <name><surname>Clancy</surname> <given-names>C. J.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Gram-negative bacterial infections, research priorities, accomplishments, and future directions of the antibacterial resistance leadership group.</article-title> <source><italic>Clin. Infect. Dis.</italic></source> <volume>64</volume> <fpage>S30</fpage>&#x2013;<lpage>S35</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciw829</pub-id> <pub-id pub-id-type="pmid">28350901</pub-id></citation></ref>
<ref id="B59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Donia</surname> <given-names>M. S.</given-names></name> <name><surname>Fischbach</surname> <given-names>M. A.</given-names></name></person-group> (<year>2015</year>). <article-title>Human Microbiota. Small molecules from the human microbiota.</article-title> <source><italic>Science</italic></source> <volume>349</volume>:<issue>1254766</issue>. <pub-id pub-id-type="doi">10.1126/science.1254766</pub-id> <pub-id pub-id-type="pmid">26206939</pub-id></citation></ref>
<ref id="B60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drider</surname> <given-names>D.</given-names></name> <name><surname>Rebuffat</surname> <given-names>S.</given-names></name></person-group> (<year>2011</year>). <source><italic>Antimicrobial Peptides, From Genes to Applications.</italic></source> <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Springer-Verlag New York</publisher-name>.</citation></ref>
<ref id="B61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drissi</surname> <given-names>F.</given-names></name> <name><surname>Buffet</surname> <given-names>S.</given-names></name> <name><surname>Raoult</surname> <given-names>D.</given-names></name> <name><surname>Merhej</surname> <given-names>V.</given-names></name></person-group> (<year>2015</year>). <article-title>Common occurrence of antibacterial agents in human intestinal microbiota.</article-title> <source><italic>Front. Microbiol.</italic></source> <volume>6</volume>:<issue>441</issue>. <pub-id pub-id-type="doi">10.3389/fmicb.2015.00441</pub-id> <pub-id pub-id-type="pmid">25999943</pub-id></citation></ref>
<ref id="B62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duquesne</surname> <given-names>S.</given-names></name> <name><surname>Destoumieux-Garz&#x00F3;n</surname> <given-names>D.</given-names></name> <name><surname>Peduzzi</surname> <given-names>J.</given-names></name> <name><surname>Rebuffat</surname> <given-names>S.</given-names></name></person-group> (<year>2007a</year>). <article-title>Microcins, gene-encoded antibacterial peptides from enterobacteria.</article-title> <source><italic>Nat. Prod. Rep.</italic></source> <volume>24</volume> <fpage>708</fpage>&#x2013;<lpage>734</lpage>. <pub-id pub-id-type="doi">10.1039/b516237h</pub-id> <pub-id pub-id-type="pmid">17653356</pub-id></citation></ref>
<ref id="B63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duquesne</surname> <given-names>S.</given-names></name> <name><surname>Destoumieux-Garz&#x00F3;n</surname> <given-names>D.</given-names></name> <name><surname>Zirah</surname> <given-names>S.</given-names></name> <name><surname>Goulard</surname> <given-names>C.</given-names></name> <name><surname>Peduzzi</surname> <given-names>J.</given-names></name> <name><surname>Rebuffat</surname> <given-names>S.</given-names></name></person-group> (<year>2007b</year>). <article-title>Two enzymes catalyze the maturation of a lasso peptide in <italic>Escherichia coli</italic>.</article-title> <source><italic>Chem. Biol.</italic></source> <volume>14</volume> <fpage>793</fpage>&#x2013;<lpage>803</lpage>. <pub-id pub-id-type="doi">10.1016/j.chembiol.2007.06.004</pub-id> <pub-id pub-id-type="pmid">17656316</pub-id></citation></ref>
<ref id="B64"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eberhart</surname> <given-names>L. J.</given-names></name> <name><surname>Deringer</surname> <given-names>J. R.</given-names></name> <name><surname>Brayton</surname> <given-names>K. A.</given-names></name> <name><surname>Sawant</surname> <given-names>A. A.</given-names></name> <name><surname>Besser</surname> <given-names>T. E.</given-names></name> <name><surname>Call</surname> <given-names>D. R.</given-names></name></person-group> (<year>2012</year>). <article-title>Characterization of a novel microcin that kills enterohemorrhagic <italic>Escherichia coli</italic> O157, H7 and O26.</article-title> <source><italic>Appl. Environ. Microbiol.</italic></source> <volume>78</volume> <fpage>6592</fpage>&#x2013;<lpage>6599</lpage>. <pub-id pub-id-type="doi">10.1128/AEM.01067-12</pub-id> <pub-id pub-id-type="pmid">22773653</pub-id></citation></ref>
<ref id="B65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Egan</surname> <given-names>K.</given-names></name> <name><surname>Ross</surname> <given-names>R. P.</given-names></name> <name><surname>Hill</surname> <given-names>C.</given-names></name></person-group> (<year>2017</year>). <article-title>Bacteriocins, antibiotics in the age of the microbiome.</article-title> <source><italic>Emerging Top Life Sci.</italic></source> <volume>1</volume> <fpage>55</fpage>&#x2013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1042/ETLS20160015</pub-id></citation></ref>
<ref id="B66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Endriss</surname> <given-names>F.</given-names></name> <name><surname>Braun</surname> <given-names>M.</given-names></name> <name><surname>Killmann</surname> <given-names>H.</given-names></name> <name><surname>Braun</surname> <given-names>V.</given-names></name></person-group> (<year>2003</year>). <article-title>Mutant analysis of the <italic>Escherichia coli</italic> FhuA protein reveals sites of FhuA activity.</article-title> <source><italic>J. Bacteriol.</italic></source> <volume>185</volume> <fpage>4683</fpage>&#x2013;<lpage>4692</lpage>. <pub-id pub-id-type="doi">10.1128/jb.185.16.4683-4692.2003</pub-id> <pub-id pub-id-type="pmid">12896986</pub-id></citation></ref>
<ref id="B67"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fabrega</surname> <given-names>A.</given-names></name> <name><surname>Madurga</surname> <given-names>S.</given-names></name> <name><surname>Giralt</surname> <given-names>E.</given-names></name> <name><surname>Vila</surname> <given-names>J.</given-names></name></person-group> (<year>2009</year>). <article-title>Mechanism of action of and resistance to quinolones.</article-title> <source><italic>Microb. Biotechnol.</italic></source> <volume>2</volume> <fpage>40</fpage>&#x2013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1111/j.1751-7915.2008.00063.x</pub-id> <pub-id pub-id-type="pmid">21261881</pub-id></citation></ref>
<ref id="B68"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Falagas</surname> <given-names>M. E.</given-names></name> <name><surname>Athanasaki</surname> <given-names>F.</given-names></name> <name><surname>Voulgaris</surname> <given-names>G. L.</given-names></name> <name><surname>Triarides</surname> <given-names>N. A.</given-names></name> <name><surname>Vardakas</surname> <given-names>K. Z.</given-names></name></person-group> (<year>2019</year>). <article-title>resistance to fosfomycin, mechanisms, frequency and clinical consequences.</article-title> <source><italic>Int. J. Antimicrob. Agents</italic></source> <volume>53</volume> <fpage>22</fpage>&#x2013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2018.09.013</pub-id> <pub-id pub-id-type="pmid">30268576</pub-id></citation></ref>
<ref id="B69"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fath</surname> <given-names>M. J.</given-names></name> <name><surname>Zhang</surname> <given-names>L. H.</given-names></name> <name><surname>Rush</surname> <given-names>J.</given-names></name> <name><surname>Kolter</surname> <given-names>R.</given-names></name></person-group> (<year>1994</year>). <article-title>Purification and characterization of colicin V from <italic>Escherichia coli</italic> culture supernatants.</article-title> <source><italic>Biochemistry</italic></source> <volume>33</volume>, <fpage>6911</fpage>&#x2013;<lpage>6917</lpage>. <pub-id pub-id-type="doi">10.1021/bi00188a021</pub-id> <pub-id pub-id-type="pmid">8204625</pub-id></citation></ref>
<ref id="B70"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fatsis-Kavalopoulos</surname> <given-names>N.</given-names></name> <name><surname>Roemhild</surname> <given-names>R.</given-names></name> <name><surname>Tang</surname> <given-names>P.-C.</given-names></name> <name><surname>Kreuger</surname> <given-names>J.</given-names></name> <name><surname>Andersson</surname> <given-names>D. I.</given-names></name></person-group> (<year>2020</year>). <article-title>CombiANT, antibiotic interaction testing made easy.</article-title> <source><italic>PLoS Biol.</italic></source> <volume>18</volume>:<issue>e3000856</issue>. <pub-id pub-id-type="doi">10.1371/journal.pbio.3000856</pub-id> <pub-id pub-id-type="pmid">32941420</pub-id></citation></ref>
<ref id="B71"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Forkus</surname> <given-names>B.</given-names></name> <name><surname>Ritter</surname> <given-names>S.</given-names></name> <name><surname>Vlysidis</surname> <given-names>M.</given-names></name> <name><surname>Geldart</surname> <given-names>K.</given-names></name> <name><surname>Kaznessis</surname> <given-names>Y. N.</given-names></name></person-group> (<year>2017</year>). <article-title>Antimicrobial probiotics reduce <italic>Salmonella enterica</italic> in turkey gastrointestinal tracts.</article-title> <source><italic>Sci. Rep.</italic></source> <volume>7</volume>:<issue>40695</issue>. <pub-id pub-id-type="doi">10.1038/srep40695</pub-id> <pub-id pub-id-type="pmid">28094807</pub-id></citation></ref>
<ref id="B72"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Gutierrez</surname> <given-names>E.</given-names></name> <name><surname>Mayer</surname> <given-names>M. J.</given-names></name> <name><surname>Cotter</surname> <given-names>P. D.</given-names></name> <name><surname>Narbad</surname> <given-names>A.</given-names></name></person-group> (<year>2019</year>). <article-title>Gut microbiota as a source of novel antimicrobials.</article-title> <source><italic>Gut Microb.</italic></source> <volume>10</volume> <fpage>1</fpage>&#x2013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1080/19490976.2018.1455790</pub-id> <pub-id pub-id-type="pmid">29584555</pub-id></citation></ref>
<ref id="B73"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gerard</surname> <given-names>F.</given-names></name> <name><surname>Pradel</surname> <given-names>N.</given-names></name> <name><surname>Wu</surname> <given-names>L. F.</given-names></name></person-group> (<year>2005</year>). <article-title>Bactericidal activity of colicin V is mediated by an inner membrane protein, SdaC, of <italic>Escherichia coli</italic>.</article-title> <source><italic>J. Bacteriol.</italic></source> <volume>187</volume> <fpage>1945</fpage>&#x2013;<lpage>1950</lpage>. <pub-id pub-id-type="doi">10.1128/jb.187.6.1945-1950.2005</pub-id> <pub-id pub-id-type="pmid">15743941</pub-id></citation></ref>
<ref id="B74"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghai</surname> <given-names>I.</given-names></name> <name><surname>Ghai</surname> <given-names>S.</given-names></name></person-group> (<year>2018</year>). <article-title>Understanding antibiotic resistance via outer membrane permeability.</article-title> <source><italic>Infect. Drug Resist.</italic></source> <volume>11</volume> <fpage>523</fpage>&#x2013;<lpage>530</lpage>. <pub-id pub-id-type="doi">10.2147/IDR.S156995</pub-id> <pub-id pub-id-type="pmid">29695921</pub-id></citation></ref>
<ref id="B75"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghilarov</surname> <given-names>D.</given-names></name> <name><surname>Serebryakova</surname> <given-names>M.</given-names></name> <name><surname>Stevenson</surname> <given-names>C. E. M.</given-names></name> <name><surname>Hearnshaw</surname> <given-names>S. J.</given-names></name> <name><surname>Volkov</surname> <given-names>D. S.</given-names></name> <name><surname>Maxwell</surname> <given-names>A.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>The origins of specificity in the microcin-processing protease TldD/E.</article-title> <source><italic>Structure</italic></source> <volume>25</volume> <fpage>1549</fpage>&#x2013;<lpage>1561.e5</lpage>. <pub-id pub-id-type="doi">10.1016/j.str.2017.08.006</pub-id> <pub-id pub-id-type="pmid">28943336</pub-id></citation></ref>
<ref id="B76"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghilarov</surname> <given-names>D.</given-names></name> <name><surname>Stevenson</surname> <given-names>C. E. M.</given-names></name> <name><surname>Travin</surname> <given-names>D. Y.</given-names></name> <name><surname>Piskunova</surname> <given-names>J.</given-names></name> <name><surname>Serebryakova</surname> <given-names>M.</given-names></name> <name><surname>Maxwell</surname> <given-names>A.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Architecture of microcin B17 synthetase. An octameric protein complex converting a ribosomally synthesized peptide into a DNA gyrase poison.</article-title> <source><italic>Mol. Cell.</italic></source> <volume>73</volume> <fpage>749</fpage>&#x2013;<lpage>762.e5</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2018.11.032</pub-id> <pub-id pub-id-type="pmid">30661981</pub-id></citation></ref>
<ref id="B77"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname> <given-names>C.</given-names></name> <name><surname>Sarkar</surname> <given-names>P.</given-names></name> <name><surname>Issa</surname> <given-names>R.</given-names></name> <name><surname>Haldar</surname> <given-names>J.</given-names></name></person-group> (<year>2019</year>). <article-title>Alternatives to conventional antibiotics in the era of antimicrobial resistance.</article-title> <source><italic>Trends Microbiol.</italic></source> <volume>27</volume> <fpage>323</fpage>&#x2013;<lpage>338</lpage>. <pub-id pub-id-type="doi">10.1016/j.tim.2018.12.010</pub-id> <pub-id pub-id-type="pmid">30683453</pub-id></citation></ref>
<ref id="B78"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname> <given-names>M. K.</given-names></name> <name><surname>Wang</surname> <given-names>B.</given-names></name> <name><surname>Ahmadi</surname> <given-names>S.</given-names></name> <name><surname>Burnham</surname> <given-names>C. A.</given-names></name> <name><surname>Tarr</surname> <given-names>P. I.</given-names></name> <name><surname>Warner</surname> <given-names>B. B.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Developmental dynamics of the preterm infant gut microbiota and antibiotic resistome.</article-title> <source><italic>Nat. Microbiol.</italic></source> <volume>1</volume>:<issue>16024</issue>. <pub-id pub-id-type="doi">10.1038/nmicrobiol.2016.24</pub-id> <pub-id pub-id-type="pmid">27572443</pub-id></citation></ref>
<ref id="B79"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname> <given-names>B. P.</given-names></name></person-group> (<year>2014</year>). <article-title>Resistance to rifampicin, a review.</article-title> <source><italic>J. Antibiot.</italic></source> <volume>67</volume> <fpage>625</fpage>&#x2013;<lpage>630</lpage>. <pub-id pub-id-type="doi">10.1038/ja.2014.107</pub-id> <pub-id pub-id-type="pmid">25118103</pub-id></citation></ref>
<ref id="B80"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname> <given-names>D. M.</given-names></name> <name><surname>O&#x2019;Brien</surname> <given-names>C. L.</given-names></name></person-group> (<year>2006</year>). <article-title>Bacteriocin diversity and the frequency of multiple bacteriocin production in <italic>Escherichia coli</italic>.</article-title> <source><italic>Microbiology</italic></source> <volume>152</volume> <fpage>3239</fpage>&#x2013;<lpage>3244</lpage>. <pub-id pub-id-type="doi">10.1099/mic.0.28690-0</pub-id> <pub-id pub-id-type="pmid">17074895</pub-id></citation></ref>
<ref id="B81"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname> <given-names>D. M.</given-names></name> <name><surname>Oliver</surname> <given-names>E.</given-names></name> <name><surname>Littlefield-Wyer</surname> <given-names>J.</given-names></name></person-group> (<year>2007</year>). &#x201C;<article-title>The diversity of bacteriocins in Gram-negative bacteria</article-title>,&#x201D; in <source><italic>Bacteriocins, Ecology and Evolution</italic></source>, <role>eds</role> <person-group person-group-type="editor"><name><surname>Riley</surname> <given-names>M. A.</given-names></name> <name><surname>Chavan</surname> <given-names>M. A.</given-names></name></person-group> (<publisher-loc>Berlin</publisher-loc>: <publisher-name>Springer</publisher-name>).</citation></ref>
<ref id="B82"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gratia</surname> <given-names>A.</given-names></name></person-group> (<year>1925</year>). <article-title>Sur un remarquable exemple d&#x2019;antagonisme entre deux souches de colibacille.</article-title> <source><italic>C. R. Soc. Biol.</italic></source> <volume>93</volume> <fpage>1041</fpage>&#x2013;<lpage>1042</lpage>.</citation></ref>
<ref id="B83"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guijarro</surname> <given-names>J. I.</given-names></name> <name><surname>Gonz&#x00E1;lez-Pastor</surname> <given-names>J. E.</given-names></name> <name><surname>Baleux</surname> <given-names>F.</given-names></name> <name><surname>San Mill&#x00E1;n</surname> <given-names>J. L.</given-names></name> <name><surname>Castilla</surname> <given-names>M. A.</given-names></name> <name><surname>Rico</surname> <given-names>M.</given-names></name><etal/></person-group> (<year>1995</year>). <article-title>Chemical structure and translation inhibition studies of the antibiotic microcin C7.</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>270</volume> <fpage>23520</fpage>&#x2013;<lpage>23532</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.270.40.23520</pub-id> <pub-id pub-id-type="pmid">7559516</pub-id></citation></ref>
<ref id="B84"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hantke</surname> <given-names>K.</given-names></name></person-group> (<year>2003</year>). <article-title>Is the bacterial ferrous iron transporter FeoB a living fossil?</article-title> <source><italic>Trends Microbiol.</italic></source> <volume>11</volume> <fpage>192</fpage>&#x2013;<lpage>195</lpage>. <pub-id pub-id-type="doi">10.1016/s0966-842x(03)00100-8</pub-id></citation></ref>
<ref id="B85"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>H&#x00E5;varstein</surname> <given-names>L. S.</given-names></name> <name><surname>Diep</surname> <given-names>D. B.</given-names></name> <name><surname>Nes</surname> <given-names>I. F.</given-names></name></person-group> (<year>1995</year>). <article-title>A family of bacteriocin ABC transporters carry out proteolytic processing of their substrates concomitant with export.</article-title> <source><italic>Mol. Microbiol.</italic></source> <volume>16</volume> <fpage>229</fpage>&#x2013;<lpage>240</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2958.1995.tb02295.x</pub-id> <pub-id pub-id-type="pmid">7565085</pub-id></citation></ref>
<ref id="B86"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hawkey</surname> <given-names>P. M.</given-names></name></person-group> (<year>2015</year>). <article-title>Multidrug-resistant Gram-negative bacteria, a product of globalization.</article-title> <source><italic>J. Hosp. Infect.</italic></source> <volume>89</volume> <fpage>241</fpage>&#x2013;<lpage>247</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhin.2015.01.008</pub-id> <pub-id pub-id-type="pmid">25737092</pub-id></citation></ref>
<ref id="B87"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heddle</surname> <given-names>J. G.</given-names></name> <name><surname>Blance</surname> <given-names>S. J.</given-names></name> <name><surname>Zamble</surname> <given-names>D. B.</given-names></name> <name><surname>Hollfelder</surname> <given-names>F.</given-names></name> <name><surname>Miller</surname> <given-names>D. A.</given-names></name> <name><surname>Wentzell</surname> <given-names>L. M.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>The antibiotic microcin B17 is a DNA gyrase poison, characterisation of the mode of inhibition.</article-title> <source><italic>J. Mol. Biol.</italic></source> <volume>307</volume> <fpage>1223</fpage>&#x2013;<lpage>1234</lpage>. <pub-id pub-id-type="doi">10.1006/jmbi.2001.4562</pub-id> <pub-id pub-id-type="pmid">11292337</pub-id></citation></ref>
<ref id="B88"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hegemann</surname> <given-names>J. D.</given-names></name> <name><surname>Zimmermann</surname> <given-names>M.</given-names></name> <name><surname>Zhu</surname> <given-names>S.</given-names></name> <name><surname>Klug</surname> <given-names>D.</given-names></name> <name><surname>Marahiel</surname> <given-names>M. A.</given-names></name></person-group> (<year>2013</year>). <article-title>Lasso peptides from <italic>proteobacteria</italic>. Genome mining employing heterologous expression and mass spectrometry.</article-title> <source><italic>Biopolymers</italic></source> <volume>100</volume> <fpage>527</fpage>&#x2013;<lpage>542</lpage>. <pub-id pub-id-type="doi">10.1002/bip.22326</pub-id> <pub-id pub-id-type="pmid">23897438</pub-id></citation></ref>
<ref id="B89"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hetz</surname> <given-names>C.</given-names></name> <name><surname>Bono</surname> <given-names>M. R.</given-names></name> <name><surname>Barros</surname> <given-names>L. F.</given-names></name> <name><surname>Lagos</surname> <given-names>R.</given-names></name></person-group> (<year>2002</year>). <article-title>Microcin E492, a channel-forming bacteriocin from <italic>Klebsiella pneumoniae</italic>, induces apoptosis in some human cell lines.</article-title> <source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source> <volume>99</volume> <fpage>2696</fpage>&#x2013;<lpage>2701</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.052709699</pub-id> <pub-id pub-id-type="pmid">11880624</pub-id></citation></ref>
<ref id="B90"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iyer</surname> <given-names>S. S.</given-names></name> <name><surname>Gensollen</surname> <given-names>T.</given-names></name> <name><surname>Gandhi</surname> <given-names>A.</given-names></name> <name><surname>Oh</surname> <given-names>S. F.</given-names></name> <name><surname>Neves</surname> <given-names>J. F.</given-names></name> <name><surname>Collin</surname> <given-names>F.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Dietary and microbial oxazoles induce intestinal inflammation by modulating aryl hydrocarbon receptor responses.</article-title> <source><italic>Cell</italic></source> <volume>173</volume> <fpage>1123</fpage>&#x2013;<lpage>1134.e11</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2018.04.037</pub-id> <pub-id pub-id-type="pmid">29775592</pub-id></citation></ref>
<ref id="B91"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacoby</surname> <given-names>G. A.</given-names></name> <name><surname>Corcoran</surname> <given-names>M. A.</given-names></name> <name><surname>Hooper</surname> <given-names>D. C.</given-names></name></person-group> (<year>2015</year>). <article-title>Protective effect of Qnr on agents other than quinolones that target DNA gyrase.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>59</volume> <fpage>6689</fpage>&#x2013;<lpage>6695</lpage>. <pub-id pub-id-type="doi">10.1128/aac.01292-15</pub-id> <pub-id pub-id-type="pmid">26239981</pub-id></citation></ref>
<ref id="B92"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacoby</surname> <given-names>G. A.</given-names></name> <name><surname>Mills</surname> <given-names>D. M.</given-names></name> <name><surname>Chow</surname> <given-names>N.</given-names></name></person-group> (<year>2004</year>). <article-title>Role of beta-lactamases and porins in resistance to ertapenem and other beta-lactams in <italic>Klebsiella pneumoniae</italic>.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>48</volume> <fpage>3203</fpage>&#x2013;<lpage>3206</lpage>. <pub-id pub-id-type="doi">10.1128/aac.48.8.3203-3206.2004</pub-id> <pub-id pub-id-type="pmid">15273152</pub-id></citation></ref>
<ref id="B93"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>James</surname> <given-names>R.</given-names></name> <name><surname>Lazdunski</surname> <given-names>C.</given-names></name> <name><surname>Pattus</surname> <given-names>F.</given-names></name></person-group> (<year>2013</year>). <source><italic>Bacteriocins, Microcins and Lantibiotics.</italic></source> <publisher-loc>Berlin</publisher-loc>: <publisher-name>Springer</publisher-name>.</citation></ref>
<ref id="B94"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname> <given-names>K. B.</given-names></name> <name><surname>Inns</surname> <given-names>P. G.</given-names></name> <name><surname>Housden</surname> <given-names>N. G.</given-names></name> <name><surname>Hopper</surname> <given-names>J. T. S.</given-names></name> <name><surname>Kaminska</surname> <given-names>R.</given-names></name> <name><surname>Lee</surname> <given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Bifurcated binding of the OmpF receptor underpins import of the bacteriocin colicin N into <italic>Escherichia coli</italic>.</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>295</volume> <fpage>9147</fpage>&#x2013;<lpage>9156</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.RA120.013508</pub-id></citation></ref>
<ref id="B95"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jeanteur</surname> <given-names>D.</given-names></name> <name><surname>Schirmer</surname> <given-names>T.</given-names></name> <name><surname>Fourel</surname> <given-names>D.</given-names></name> <name><surname>Simonet</surname> <given-names>V.</given-names></name> <name><surname>Rummel</surname> <given-names>G.</given-names></name> <name><surname>Widmer</surname> <given-names>C.</given-names></name><etal/></person-group> (<year>1994</year>). <article-title>Structural and functional alterations of a colicin-resistant mutant of OmpF porin from <italic>Escherichia coli</italic>.</article-title> <source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source> <volume>91</volume> <fpage>10675</fpage>&#x2013;<lpage>10679</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.91.22.10675</pub-id> <pub-id pub-id-type="pmid">7524100</pub-id></citation></ref>
<ref id="B96"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaeriyama</surname> <given-names>M.</given-names></name> <name><surname>Machida</surname> <given-names>K.</given-names></name> <name><surname>Kitakaze</surname> <given-names>A.</given-names></name> <name><surname>Wang</surname> <given-names>H.</given-names></name> <name><surname>Lao</surname> <given-names>Q.</given-names></name> <name><surname>Fukamachi</surname> <given-names>T.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>OmpC and OmpF are required for growth under hyperosmotic stress above pH 8 in <italic>Escherichia coli</italic>.</article-title> <source><italic>Lett. Appl. Microbiol.</italic></source> <volume>42</volume> <fpage>195</fpage>&#x2013;<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1111/j.1472-765X.2006.01845.x</pub-id> <pub-id pub-id-type="pmid">16478504</pub-id></citation></ref>
<ref id="B97"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kapoor</surname> <given-names>G.</given-names></name> <name><surname>Saigal</surname> <given-names>S.</given-names></name> <name><surname>Elongavan</surname> <given-names>A.</given-names></name></person-group> (<year>2017</year>). <article-title>Action and resistance mechanisms of antibiotics, A guide for clinicians.</article-title> <source><italic>J. Anaesthesiol. Clin. Pharmacol.</italic></source> <volume>33</volume> <fpage>300</fpage>&#x2013;<lpage>305</lpage>. <pub-id pub-id-type="doi">10.4103/joacp.JOACP_349_15</pub-id></citation></ref>
<ref id="B98"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaur</surname> <given-names>K.</given-names></name> <name><surname>Tarassova</surname> <given-names>O.</given-names></name> <name><surname>Dangeti</surname> <given-names>R. V.</given-names></name> <name><surname>Azmi</surname> <given-names>S.</given-names></name> <name><surname>Wishart</surname> <given-names>D.</given-names></name> <name><surname>McMullen</surname> <given-names>L.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Characterization of a highly potent antimicrobial peptide microcin N from uropathogenic <italic>Escherichia coli</italic>.</article-title> <source><italic>FEMS Microbiol. Lett.</italic></source> <volume>363</volume>:<issue>fnw095</issue>. <pub-id pub-id-type="doi">10.1093/femsle/fnw095</pub-id> <pub-id pub-id-type="pmid">27190283</pub-id></citation></ref>
<ref id="B99"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kazakov</surname> <given-names>T.</given-names></name> <name><surname>Kuznedelov</surname> <given-names>K.</given-names></name> <name><surname>Semenova</surname> <given-names>E.</given-names></name> <name><surname>Mukhamedyarov</surname> <given-names>D.</given-names></name> <name><surname>Datsenko</surname> <given-names>K. A.</given-names></name> <name><surname>Metlitskaya</surname> <given-names>A.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>The RimL transacetylase provides resistance to translation inhibitor microcin C.</article-title> <source><italic>J. Bacteriol</italic></source> <volume>196</volume> <fpage>3377</fpage>&#x2013;<lpage>3385</lpage>. <pub-id pub-id-type="doi">10.1128/jb.01584-14</pub-id> <pub-id pub-id-type="pmid">25002546</pub-id></citation></ref>
<ref id="B100"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kazakov</surname> <given-names>T.</given-names></name> <name><surname>Vondenhoff</surname> <given-names>G. H.</given-names></name> <name><surname>Datsenko</surname> <given-names>K. A.</given-names></name> <name><surname>Novikova</surname> <given-names>M.</given-names></name> <name><surname>Metlitskaya</surname> <given-names>A.</given-names></name> <name><surname>Wanner</surname> <given-names>B. L.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title><italic>Escherichia coli</italic> peptidase A, B, or N can process translation inhibitor microcin C.</article-title> <source><italic>J. Bacteriol.</italic></source> <volume>190</volume> <fpage>2607</fpage>&#x2013;<lpage>2610</lpage>. <pub-id pub-id-type="doi">10.1128/jb.01956-07</pub-id> <pub-id pub-id-type="pmid">18223070</pub-id></citation></ref>
<ref id="B101"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kettles</surname> <given-names>R. A.</given-names></name> <name><surname>Tschowri</surname> <given-names>N.</given-names></name> <name><surname>Lyons</surname> <given-names>K. J.</given-names></name> <name><surname>Sharma</surname> <given-names>P.</given-names></name> <name><surname>Hengge</surname> <given-names>R.</given-names></name> <name><surname>Webber</surname> <given-names>M. A.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>The <italic>Escherichia coli</italic> MarA protein regulates the ycgZ-ymgABC operon to inhibit biofilm formation.</article-title> <source><italic>Mol. Microbiol.</italic></source> <volume>112</volume> <fpage>1609</fpage>&#x2013;<lpage>1625</lpage>. <pub-id pub-id-type="doi">10.1111/mmi.14386</pub-id> <pub-id pub-id-type="pmid">31518447</pub-id></citation></ref>
<ref id="B102"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kintses</surname> <given-names>B.</given-names></name> <name><surname>M&#x00E9;hi</surname> <given-names>O.</given-names></name> <name><surname>Ari</surname> <given-names>E.</given-names></name> <name><surname>Sz&#x00E1;mel</surname> <given-names>M.</given-names></name> <name><surname>Gy&#x00F6;rkei</surname> <given-names>A.</given-names></name> <name><surname>Jangir</surname> <given-names>P. K.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Phylogenetic barriers to horizontal transfer of antimicrobial peptide resistance genes in the human gut microbiota.</article-title> <source><italic>Nat. Microbiol.</italic></source> <volume>4</volume> <fpage>447</fpage>&#x2013;<lpage>458</lpage>. <pub-id pub-id-type="doi">10.1038/s41564-018-0313-5</pub-id> <pub-id pub-id-type="pmid">30559406</pub-id></citation></ref>
<ref id="B103"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klaenhammer</surname> <given-names>T. R.</given-names></name></person-group> (<year>1988</year>). <article-title>Bacteriocins of lactic acid bacteria.</article-title> <source><italic>Biochimie</italic></source> <volume>70</volume> <fpage>337</fpage>&#x2013;<lpage>349</lpage>. <pub-id pub-id-type="doi">10.1016/0300-9084(88)90206-4</pub-id></citation></ref>
<ref id="B104"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knappe</surname> <given-names>T. A.</given-names></name> <name><surname>Linne</surname> <given-names>U.</given-names></name> <name><surname>Zirah</surname> <given-names>S.</given-names></name> <name><surname>Rebuffat</surname> <given-names>S.</given-names></name> <name><surname>Xie</surname> <given-names>X.</given-names></name> <name><surname>Marahiel</surname> <given-names>M. A.</given-names></name></person-group> (<year>2008</year>). <article-title>Isolation and structural characterization of capistruin, a lasso peptide predicted from the genome sequence of <italic>Burkholderia thailandensis</italic> E264.</article-title> <source><italic>J. Am. Chem. Soc.</italic></source> <volume>130</volume> <fpage>11446</fpage>&#x2013;<lpage>11454</lpage>. <pub-id pub-id-type="doi">10.1021/ja802966g</pub-id> <pub-id pub-id-type="pmid">18671394</pub-id></citation></ref>
<ref id="B105"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname> <given-names>J.</given-names></name> <name><surname>&#x00D6;zkaya</surname> <given-names>&#x00D6;</given-names></name> <name><surname>K&#x00FC;mmerli</surname> <given-names>R.</given-names></name></person-group> (<year>2019</year>). <article-title>Bacterial siderophores in community and host interactions.</article-title> <source><italic>Nat. Rev. Microbiol.</italic></source> <volume>18</volume> <fpage>152</fpage>&#x2013;<lpage>163</lpage>. <pub-id pub-id-type="doi">10.1038/s41579-019-0284-4</pub-id> <pub-id pub-id-type="pmid">31748738</pub-id></citation></ref>
<ref id="B106"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krause</surname> <given-names>K. M.</given-names></name> <name><surname>Serio</surname> <given-names>A. W.</given-names></name> <name><surname>Kane</surname> <given-names>T. R.</given-names></name> <name><surname>Connolly</surname> <given-names>L. E.</given-names></name></person-group> (<year>2016</year>). <article-title>Aminoglycosides. An overview.</article-title> <source><italic>Cold Spring Harb. Perspect. Med.</italic></source> <volume>6</volume>:<issue>a027029</issue>. <pub-id pub-id-type="doi">10.1101/cshperspect.a027029</pub-id> <pub-id pub-id-type="pmid">27252397</pub-id></citation></ref>
<ref id="B107"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krewulak</surname> <given-names>K. D.</given-names></name> <name><surname>Vogel</surname> <given-names>H. J.</given-names></name></person-group> (<year>2008</year>). <article-title>Structural biology of bacterial iron uptake.</article-title> <source><italic>Biochim. Biophys. Acta</italic></source> <volume>1778</volume> <fpage>1781</fpage>&#x2013;<lpage>1804</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamem.2007.07.026</pub-id> <pub-id pub-id-type="pmid">17916327</pub-id></citation></ref>
<ref id="B108"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuznedelov</surname> <given-names>K.</given-names></name> <name><surname>Semenova</surname> <given-names>E.</given-names></name> <name><surname>Knappe</surname> <given-names>T. A.</given-names></name> <name><surname>Mukhamedyarov</surname> <given-names>D.</given-names></name> <name><surname>Srivastava</surname> <given-names>A.</given-names></name> <name><surname>Chatterjee</surname> <given-names>S.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>The antibacterial threaded-lasso peptide capistruin inhibits bacterial RNA polymerase.</article-title> <source><italic>J. Mol. Biol.</italic></source> <volume>412</volume> <fpage>842</fpage>&#x2013;<lpage>848</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2011.02.060</pub-id> <pub-id pub-id-type="pmid">21396375</pub-id></citation></ref>
<ref id="B109"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuznetsova</surname> <given-names>M. V.</given-names></name> <name><surname>Gizatullina</surname> <given-names>J. S.</given-names></name> <name><surname>Nesterova</surname> <given-names>L. Y.</given-names></name> <name><surname>Star&#x010D;i&#x010D; Erjavec</surname> <given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title><italic>Escherichia coli</italic> isolated from cases of colibacillosis in Russian poultry farms (Perm Krai), Sensitivity to antibiotics and bacteriocins.</article-title> <source><italic>Microorganisms</italic></source> <volume>8</volume>:<issue>741</issue>. <pub-id pub-id-type="doi">10.3390/microorganisms8050741</pub-id> <pub-id pub-id-type="pmid">32429211</pub-id></citation></ref>
<ref id="B110"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lagos</surname> <given-names>R.</given-names></name> <name><surname>Tello</surname> <given-names>M.</given-names></name> <name><surname>Mercado</surname> <given-names>G.</given-names></name> <name><surname>Garcia</surname> <given-names>V.</given-names></name> <name><surname>Monasterio</surname> <given-names>O.</given-names></name></person-group> (<year>2009</year>). <article-title>Antibacterial and antitumorigenic properties of microcin E492, a pore-forming bacteriocin.</article-title> <source><italic>Curr. Pharm. Biotechnol.</italic></source> <volume>10</volume> <fpage>74</fpage>&#x2013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.2174/138920109787048643</pub-id> <pub-id pub-id-type="pmid">19149591</pub-id></citation></ref>
<ref id="B111"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lagos</surname> <given-names>R.</given-names></name> <name><surname>Wilkens</surname> <given-names>M.</given-names></name> <name><surname>Vergara</surname> <given-names>C.</given-names></name> <name><surname>Cecchi</surname> <given-names>X.</given-names></name> <name><surname>Monasterio</surname> <given-names>O.</given-names></name></person-group> (<year>1993</year>). <article-title>Microcin E492 forms ion channels in phospholipid bilayer membrane.</article-title> <source><italic>FEBS Lett.</italic></source> <volume>321</volume> <fpage>145</fpage>&#x2013;<lpage>148</lpage>. <pub-id pub-id-type="doi">10.1016/0014-5793(93)80096-d</pub-id></citation></ref>
<ref id="B112"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lavi&#x00F1;a</surname> <given-names>M.</given-names></name> <name><surname>Gaggero</surname> <given-names>C.</given-names></name> <name><surname>Moreno</surname> <given-names>F.</given-names></name></person-group> (<year>1990</year>). <article-title>Microcin H47, a chromosome-encoded microcin antibiotic of <italic>Escherichia coli</italic>.</article-title> <source><italic>J. Bacteriol.</italic></source> <volume>172</volume> <fpage>6585</fpage>&#x2013;<lpage>6588</lpage>. <pub-id pub-id-type="doi">10.1128/jb.172.11.6585-6588.1990</pub-id> <pub-id pub-id-type="pmid">2228975</pub-id></citation></ref>
<ref id="B113"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lavi&#x00F1;a</surname> <given-names>M.</given-names></name> <name><surname>Pugsley</surname> <given-names>A. P.</given-names></name> <name><surname>Moreno</surname> <given-names>F.</given-names></name></person-group> (<year>1986</year>). <article-title>Identification, mapping, cloning and characterization of a gene (sbmA) required for microcin B17 action on <italic>Escherichia coli</italic> K12.</article-title> <source><italic>J. Gen. Microbiol.</italic></source> <volume>132</volume> <fpage>1685</fpage>&#x2013;<lpage>1693</lpage>. <pub-id pub-id-type="doi">10.1099/00221287-132-6-1685</pub-id> <pub-id pub-id-type="pmid">3543211</pub-id></citation></ref>
<ref id="B114"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lazdunski</surname> <given-names>C. J.</given-names></name> <name><surname>Bouveret</surname> <given-names>E.</given-names></name> <name><surname>Rigal</surname> <given-names>A.</given-names></name> <name><surname>Journet</surname> <given-names>L.</given-names></name> <name><surname>Lloub&#x00E8;s</surname> <given-names>R.</given-names></name> <name><surname>B&#x00E9;n&#x00E9;detti</surname> <given-names>H.</given-names></name></person-group> (<year>1998</year>). <article-title>Colicin import into <italic>Escherichia coli</italic> cells.</article-title> <source><italic>J. Bacteriol.</italic></source> <volume>180</volume> <fpage>4993</fpage>&#x2013;<lpage>5002</lpage>. <pub-id pub-id-type="doi">10.1128/JB.180.19.4993-5002.1998</pub-id> <pub-id pub-id-type="pmid">9748429</pub-id></citation></ref>
<ref id="B115"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname> <given-names>K.</given-names></name> <name><surname>Epstein</surname> <given-names>S.</given-names></name> <name><surname>D&#x2019;Onofrio</surname> <given-names>A.</given-names></name> <name><surname>Ling</surname> <given-names>L. L.</given-names></name></person-group> (<year>2010</year>). <article-title>Uncultured microorganisms as a source of secondary metabolites.</article-title> <source><italic>J. Antibiot.</italic></source> <volume>63</volume> <fpage>468</fpage>&#x2013;<lpage>476</lpage>. <pub-id pub-id-type="doi">10.1038/ja.2010.87</pub-id> <pub-id pub-id-type="pmid">20648021</pub-id></citation></ref>
<ref id="B116"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>X. Z.</given-names></name> <name><surname>Ma</surname> <given-names>D.</given-names></name> <name><surname>Livermore</surname> <given-names>D. M.</given-names></name> <name><surname>Nikaido</surname> <given-names>H.</given-names></name></person-group> (<year>1994</year>). <article-title>Role of efflux pump(s) in intrinsic resistance of <italic>Pseudomonas aeruginosa</italic>, active efflux as a contributing factor to beta-lactam resistance.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>38</volume> <fpage>1742</fpage>&#x2013;<lpage>1752</lpage>. <pub-id pub-id-type="doi">10.1128/aac.38.8.1742</pub-id> <pub-id pub-id-type="pmid">7986004</pub-id></citation></ref>
<ref id="B117"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>X. Z.</given-names></name> <name><surname>Plesiat</surname> <given-names>P.</given-names></name> <name><surname>Nikaido</surname> <given-names>H.</given-names></name></person-group> (<year>2015</year>). <article-title>The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.</article-title> <source><italic>Clin. Microbiol. Rev.</italic></source> <volume>28</volume> <fpage>337</fpage>&#x2013;<lpage>418</lpage>. <pub-id pub-id-type="doi">10.1128/cmr.00117-14</pub-id> <pub-id pub-id-type="pmid">25788514</pub-id></citation></ref>
<ref id="B118"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>Y.</given-names></name> <name><surname>Rebuffat</surname> <given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>The manifold roles of microbial ribosomal peptide-based natural products in physiology and ecology.</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>295</volume> <fpage>34</fpage>&#x2013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.REV119.006545</pub-id> <pub-id pub-id-type="pmid">31784450</pub-id></citation></ref>
<ref id="B119"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>Y.-M.</given-names></name> <name><surname>Milne</surname> <given-names>J. C.</given-names></name> <name><surname>Madison</surname> <given-names>L. L.</given-names></name> <name><surname>Kolter</surname> <given-names>R.</given-names></name> <name><surname>Walsh</surname> <given-names>C. T.</given-names></name></person-group> (<year>1996</year>). <article-title>From peptide precursors to oxazole and thiazole-containing peptide antibiotics, microcin B17 synthase.</article-title> <source><italic>Science</italic></source> <volume>274</volume> <fpage>1188</fpage>&#x2013;<lpage>1193</lpage>. <pub-id pub-id-type="doi">10.1126/science.274.5290.1188</pub-id> <pub-id pub-id-type="pmid">8895467</pub-id></citation></ref>
<ref id="B120"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lopez</surname> <given-names>F. E.</given-names></name> <name><surname>Vincent</surname> <given-names>P. A.</given-names></name> <name><surname>Zenoff</surname> <given-names>A. M.</given-names></name> <name><surname>Salom&#x00F3;n</surname> <given-names>R. A.</given-names></name> <name><surname>Farias</surname> <given-names>R. N.</given-names></name></person-group> (<year>2007</year>). <article-title>Efficacy of microcin J25 in biomatrices and in a mouse model of <italic>Salmonella</italic> infection.</article-title> <source><italic>J. Antimic. Chem.</italic></source> <volume>59</volume> <fpage>676</fpage>&#x2013;<lpage>680</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkm009</pub-id> <pub-id pub-id-type="pmid">17353221</pub-id></citation></ref>
<ref id="B121"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname> <given-names>S. Y.</given-names></name> <name><surname>Gra&#x00E7;a</surname> <given-names>T.</given-names></name> <name><surname>Avillan</surname> <given-names>J. J.</given-names></name> <name><surname>Zhao</surname> <given-names>Z.</given-names></name> <name><surname>Call</surname> <given-names>D. R.</given-names></name></person-group> (<year>2019</year>). <article-title>Microcin PDI inhibits antibiotic-resistant strains of <italic>Escherichia coli</italic> and <italic>Shigella</italic> through a mechanism of membrane disruption and protection by homotrimer self-immunity.</article-title> <source><italic>Appl. Environ. Microbiol.</italic></source> <volume>85</volume>:<issue>e0371-19</issue>. <pub-id pub-id-type="doi">10.1128/aem.00371-19</pub-id> <pub-id pub-id-type="pmid">30902857</pub-id></citation></ref>
<ref id="B122"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>MacVane</surname> <given-names>S. H.</given-names></name></person-group> (<year>2017</year>). <article-title>Antimicrobial resistance in the intensive care unit, A focus on Gram-negative bacterial infections.</article-title> <source><italic>J. Intensive Care Med.</italic></source> <volume>32</volume> <fpage>25</fpage>&#x2013;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1177/0885066615619895</pub-id> <pub-id pub-id-type="pmid">26772199</pub-id></citation></ref>
<ref id="B123"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maksimov</surname> <given-names>M. O.</given-names></name> <name><surname>Pelczer</surname> <given-names>I.</given-names></name> <name><surname>Link</surname> <given-names>A. J.</given-names></name></person-group> (<year>2012</year>). <article-title>Precursor-centric genome-mining approach for lasso peptide discovery.</article-title> <source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source> <volume>109</volume> <fpage>15223</fpage>&#x2013;<lpage>15228</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1208978109</pub-id> <pub-id pub-id-type="pmid">22949633</pub-id></citation></ref>
<ref id="B124"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marcoleta</surname> <given-names>A.</given-names></name> <name><surname>Marin</surname> <given-names>M.</given-names></name> <name><surname>Mercado</surname> <given-names>G.</given-names></name> <name><surname>Valpuesta</surname> <given-names>J. M.</given-names></name> <name><surname>Monasterio</surname> <given-names>O.</given-names></name> <name><surname>Lagos</surname> <given-names>R.</given-names></name></person-group> (<year>2013</year>). <article-title>Microcin E492 amyloid formation is retarded by posttranslational modification.</article-title> <source><italic>J. Bacteriol.</italic></source> <volume>195</volume> <fpage>3995</fpage>&#x2013;<lpage>4004</lpage>. <pub-id pub-id-type="doi">10.1128/jb.00564-13</pub-id> <pub-id pub-id-type="pmid">23836864</pub-id></citation></ref>
<ref id="B125"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martin-G&#x00F3;mez</surname> <given-names>H.</given-names></name> <name><surname>Jorba</surname> <given-names>M.</given-names></name> <name><surname>Albericio</surname> <given-names>F.</given-names></name> <name><surname>Vi&#x00F1;as</surname> <given-names>M.</given-names></name> <name><surname>Tulla-Puche</surname> <given-names>J.</given-names></name></person-group> (<year>2019</year>). <article-title>Chemical Modification of microcin J25 reveals new insights on the stereospecific requirements for antimicrobial activity.</article-title> <source><italic>Int. J. Mol. Sci.</italic></source> <volume>20</volume>:<issue>5152</issue>. <pub-id pub-id-type="doi">10.3390/ijms20205152</pub-id> <pub-id pub-id-type="pmid">31627419</pub-id></citation></ref>
<ref id="B126"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Massip</surname> <given-names>C.</given-names></name> <name><surname>Oswald</surname> <given-names>E.</given-names></name></person-group> (<year>2020</year>). <article-title>Siderophore-microcins in <italic>Escherichia coli</italic>, determinants of digestive colonization, the first step toward virulence.</article-title> <source><italic>Front. Cell Infect. Microbiol.</italic></source> <volume>10</volume>:<issue>381</issue>. <pub-id pub-id-type="doi">10.3389/fcimb.2020.00381</pub-id></citation></ref>
<ref id="B127"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mathavan</surname> <given-names>I.</given-names></name> <name><surname>Zirah</surname> <given-names>S.</given-names></name> <name><surname>Mehmood</surname> <given-names>S.</given-names></name> <name><surname>Choudhury</surname> <given-names>H. G.</given-names></name> <name><surname>Goulard</surname> <given-names>C.</given-names></name> <name><surname>Li</surname> <given-names>Y.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Structural basis for hijacking siderophore receptors by antimicrobial lasso peptides.</article-title> <source><italic>Nat. Chem. Biol.</italic></source> <volume>10</volume> <fpage>340</fpage>&#x2013;<lpage>342</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.1499</pub-id> <pub-id pub-id-type="pmid">24705590</pub-id></citation></ref>
<ref id="B128"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mathur</surname> <given-names>H.</given-names></name> <name><surname>Field</surname> <given-names>D.</given-names></name> <name><surname>Rea</surname> <given-names>M. C.</given-names></name> <name><surname>Cotter</surname> <given-names>P. D.</given-names></name> <name><surname>Hill</surname> <given-names>C.</given-names></name> <name><surname>Ross</surname> <given-names>R. P.</given-names></name></person-group> (<year>2017</year>). <article-title>Bacteriocin-antimicrobial synergy, a medical and food perspective.</article-title> <source><italic>Front. Microbiol.</italic></source> <volume>8</volume>:<issue>1205</issue>. <pub-id pub-id-type="doi">10.3389/fmicb.2017.01205</pub-id> <pub-id pub-id-type="pmid">28706513</pub-id></citation></ref>
<ref id="B129"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McIntosh</surname> <given-names>J. A.</given-names></name> <name><surname>Donia</surname> <given-names>M. S.</given-names></name> <name><surname>Schmidt</surname> <given-names>E. W.</given-names></name></person-group> (<year>2009</year>). <article-title>Ribosomal peptide natural products, bridging the ribosomal and nonribosomal worlds.</article-title> <source><italic>Nat. Prod. Rep.</italic></source> <volume>26</volume> <fpage>537</fpage>&#x2013;<lpage>559</lpage>. <pub-id pub-id-type="doi">10.1039/b714132g</pub-id> <pub-id pub-id-type="pmid">19642421</pub-id></citation></ref>
<ref id="B130"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McIntosh</surname> <given-names>J. A.</given-names></name> <name><surname>Schmidt</surname> <given-names>E. W.</given-names></name></person-group> (<year>2010</year>). <article-title>Marine molecular machines, heterocyclization in cyanobactin biosynthesis.</article-title> <source><italic>Chembiochem</italic></source> <volume>11</volume> <fpage>1413</fpage>&#x2013;<lpage>1421</lpage>. <pub-id pub-id-type="doi">10.1002/cbic.201000196</pub-id> <pub-id pub-id-type="pmid">20540059</pub-id></citation></ref>
<ref id="B131"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Melby</surname> <given-names>J. O.</given-names></name> <name><surname>Nard</surname> <given-names>N. J.</given-names></name> <name><surname>Mitchell</surname> <given-names>D. A.</given-names></name></person-group> (<year>2011</year>). <article-title>Thiazole/oxazole-modified microcins, complex natural products from ribosomal templates.</article-title> <source><italic>Curr. Opin. Chem. Biol.</italic></source> <volume>15</volume> <fpage>369</fpage>&#x2013;<lpage>378</lpage>. <pub-id pub-id-type="doi">10.1016/j.cbpa.2011.02.027</pub-id> <pub-id pub-id-type="pmid">21429787</pub-id></citation></ref>
<ref id="B132"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Metelev</surname> <given-names>M.</given-names></name> <name><surname>Arseniev</surname> <given-names>A.</given-names></name> <name><surname>Bushin</surname> <given-names>L. B.</given-names></name> <name><surname>Kuznedelov</surname> <given-names>K.</given-names></name> <name><surname>Artamonova</surname> <given-names>T. O.</given-names></name> <name><surname>Kondratenko</surname> <given-names>R.</given-names></name><etal/></person-group> (<year>2017a</year>). <article-title>Acinetodin and klebsidin, RNA polymerase targeting lasso peptides produced by human isolates of <italic>Acinetobacter gyllenbergii</italic> and <italic>Klebsiella pneumoniae</italic>.</article-title> <source><italic>ACS Chem. Biol.</italic></source> <volume>12</volume> <fpage>814</fpage>&#x2013;<lpage>824</lpage>. <pub-id pub-id-type="doi">10.1021/acschembio.6b01154</pub-id> <pub-id pub-id-type="pmid">28106375</pub-id></citation></ref>
<ref id="B133"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Metelev</surname> <given-names>M.</given-names></name> <name><surname>Osterman</surname> <given-names>I. A.</given-names></name> <name><surname>Ghilarov</surname> <given-names>D.</given-names></name> <name><surname>Khabibullina</surname> <given-names>N. F.</given-names></name> <name><surname>Yakimov</surname> <given-names>A.</given-names></name> <name><surname>Shabalin</surname> <given-names>K.</given-names></name><etal/></person-group> (<year>2017b</year>). <article-title>Klebsazolicin inhibits 70S ribosome by obstructing the peptide exit tunnel.</article-title> <source><italic>Nat. Chem. Biol.</italic></source> <volume>13</volume> <fpage>1129</fpage>&#x2013;<lpage>1136</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.2462</pub-id> <pub-id pub-id-type="pmid">28846667</pub-id></citation></ref>
<ref id="B134"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Metelev</surname> <given-names>M.</given-names></name> <name><surname>Serebryakova</surname> <given-names>M.</given-names></name> <name><surname>Ghilarov</surname> <given-names>D.</given-names></name> <name><surname>Zhao</surname> <given-names>Y.</given-names></name> <name><surname>Severinov</surname> <given-names>K.</given-names></name></person-group> (<year>2013</year>). <article-title>Structure of microcin B-like compounds produced by <italic>Pseudomonas syringae</italic> and species specificity of their antibacterial action.</article-title> <source><italic>J. Bacteriol.</italic></source> <volume>195</volume> <fpage>4129</fpage>&#x2013;<lpage>4137</lpage>. <pub-id pub-id-type="doi">10.1128/jb.00665-13</pub-id> <pub-id pub-id-type="pmid">23852863</pub-id></citation></ref>
<ref id="B135"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Metlitskaya</surname> <given-names>A.</given-names></name> <name><surname>Kazakov</surname> <given-names>T.</given-names></name> <name><surname>Kommer</surname> <given-names>A.</given-names></name> <name><surname>Pavlova</surname> <given-names>O.</given-names></name> <name><surname>Praetorius-Ibba</surname> <given-names>M.</given-names></name> <name><surname>Ibba</surname> <given-names>M.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Aspartyl-tRNA synthetase is the target of peptide nucleotide antibiotic microcin C.</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>281</volume> <fpage>18033</fpage>&#x2013;<lpage>18042</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M513174200</pub-id> <pub-id pub-id-type="pmid">16574659</pub-id></citation></ref>
<ref id="B136"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname> <given-names>S.</given-names></name> <name><surname>Ross</surname> <given-names>R. P.</given-names></name> <name><surname>Hill</surname> <given-names>C.</given-names></name></person-group> (<year>2017</year>). <article-title>Bacteriocins and bacteriophage; a narrow-minded approach to food and gut microbiology.</article-title> <source><italic>FEMS Microbiol. Rev.</italic></source> <volume>41</volume> <fpage>S129</fpage>&#x2013;<lpage>S153</lpage>. <pub-id pub-id-type="doi">10.1093/femsre/fux022</pub-id> <pub-id pub-id-type="pmid">28830091</pub-id></citation></ref>
<ref id="B137"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname> <given-names>D. A.</given-names></name> <name><surname>Lee</surname> <given-names>S. W.</given-names></name> <name><surname>Pence</surname> <given-names>M. A.</given-names></name> <name><surname>Markley</surname> <given-names>A. L.</given-names></name> <name><surname>Limm</surname> <given-names>J. D.</given-names></name> <name><surname>Nizet</surname> <given-names>V.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Structural and functional dissection of the heterocyclic peptide cytotoxin streptolysin S.</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>284</volume> <fpage>13004</fpage>&#x2013;<lpage>13012</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M900802200</pub-id> <pub-id pub-id-type="pmid">19286651</pub-id></citation></ref>
<ref id="B138"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Montalb&#x00E1;n-L&#x00F3;pez</surname> <given-names>M.</given-names></name> <name><surname>Scott</surname> <given-names>T. A.</given-names></name> <name><surname>Ramesh</surname> <given-names>S. I.</given-names></name> <name><surname>Rahman</surname> <given-names>R.</given-names></name> <name><surname>van Heel</surname> <given-names>A. J.</given-names></name> <name><surname>Viel</surname> <given-names>J. H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>New developments in RiPP discovery, enzymology and engineering.</article-title> <source><italic>Nat. Prod. Rep.</italic></source> <pub-id pub-id-type="doi">10.1039/d0np00027b</pub-id> <comment>[Epub ahead of print]</comment>. <pub-id pub-id-type="pmid">32935693</pub-id></citation></ref>
<ref id="B139"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morin</surname> <given-names>N.</given-names></name> <name><surname>Lanneluc</surname> <given-names>I.</given-names></name> <name><surname>Connil</surname> <given-names>N.</given-names></name> <name><surname>Cottenceau</surname> <given-names>M.</given-names></name> <name><surname>Pons</surname> <given-names>A. M.</given-names></name> <name><surname>Sabl&#x00E9;</surname> <given-names>S.</given-names></name></person-group> (<year>2011</year>). <article-title>Mechanism of bactericidal activity of microcin L in <italic>Escherichia coli</italic> and <italic>Salmonella enterica</italic>.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>55</volume> <fpage>997</fpage>&#x2013;<lpage>1007</lpage>. <pub-id pub-id-type="doi">10.1128/aac.01217-10</pub-id> <pub-id pub-id-type="pmid">21189348</pub-id></citation></ref>
<ref id="B140"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mukhopadhyay</surname> <given-names>J.</given-names></name> <name><surname>Sineva</surname> <given-names>E.</given-names></name> <name><surname>Knight</surname> <given-names>J.</given-names></name> <name><surname>Levy</surname> <given-names>R. M.</given-names></name> <name><surname>Ebright</surname> <given-names>R. H.</given-names></name></person-group> (<year>2004</year>). <article-title>Antibacterial peptide microcin J25 inhibits transcription by binding within and obstructing the RNA polymerase secondary channel.</article-title> <source><italic>Mol. Cell.</italic></source> <volume>14</volume> <fpage>739</fpage>&#x2013;<lpage>751</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2004.06.010</pub-id> <pub-id pub-id-type="pmid">15200952</pub-id></citation></ref>
<ref id="B141"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naimi</surname> <given-names>S.</given-names></name> <name><surname>Zirah</surname> <given-names>S.</given-names></name> <name><surname>Taher</surname> <given-names>M. B.</given-names></name> <name><surname>Theolier</surname> <given-names>J. E.</given-names></name> <name><surname>Fernandez</surname> <given-names>B.</given-names></name> <name><surname>Rebuffat</surname> <given-names>S. F.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Microcin J25 exhibits inhibitory activity against <italic>Salmonella</italic> Newport in continuous fermentation model mimicking swine colonic conditions.</article-title> <source><italic>Front. Microbiol.</italic></source> <volume>11</volume>:<issue>988</issue>. <pub-id pub-id-type="doi">10.3389/fmicb.2020.00988</pub-id> <pub-id pub-id-type="pmid">32528437</pub-id></citation></ref>
<ref id="B142"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nolan</surname> <given-names>E. M.</given-names></name> <name><surname>Walsh</surname> <given-names>C. T.</given-names></name></person-group> (<year>2008</year>). <article-title>Investigations of the MceIJ-catalyzed posttranslational modification of the microcin E492 C-terminus, linkage of ribosomal and nonribosomal peptides to form &#x201C;trojan horse&#x201D; antibiotics.</article-title> <source><italic>Biochemistry</italic></source> <volume>47</volume> <fpage>9289</fpage>&#x2013;<lpage>9299</lpage>. <pub-id pub-id-type="doi">10.1021/bi800826j</pub-id> <pub-id pub-id-type="pmid">18690711</pub-id></citation></ref>
<ref id="B143"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Novikova</surname> <given-names>M.</given-names></name> <name><surname>Kazakov</surname> <given-names>T.</given-names></name> <name><surname>Vondenhoff</surname> <given-names>G. H.</given-names></name> <name><surname>Semenova</surname> <given-names>E.</given-names></name> <name><surname>Rozenski</surname> <given-names>J.</given-names></name> <name><surname>Metlytskaya</surname> <given-names>A.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>MccE provides resistance to protein synthesis inhibitor microcin C by acetylating the processed form of the antibiotic.</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>285</volume> <fpage>12662</fpage>&#x2013;<lpage>12669</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M109.080192</pub-id> <pub-id pub-id-type="pmid">20159968</pub-id></citation></ref>
<ref id="B144"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Novikova</surname> <given-names>M.</given-names></name> <name><surname>Metlitskaya</surname> <given-names>A.</given-names></name> <name><surname>Datsenko</surname> <given-names>K.</given-names></name> <name><surname>Kazakov</surname> <given-names>T.</given-names></name> <name><surname>Kazakov</surname> <given-names>A.</given-names></name> <name><surname>Wanner</surname> <given-names>B.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>The <italic>Escherichia coli</italic> Yej transporter is required for the uptake of translation inhibitor microcin C.</article-title> <source><italic>J. Bacteriol.</italic></source> <volume>189</volume> <fpage>8361</fpage>&#x2013;<lpage>8365</lpage>. <pub-id pub-id-type="doi">10.1128/jb.01028-07</pub-id> <pub-id pub-id-type="pmid">17873039</pub-id></citation></ref>
<ref id="B145"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O&#x2019;Brien</surname> <given-names>G. J.</given-names></name></person-group> (<year>1996</year>). <source><italic>Molecular Analysis of Microcin 24, Genetics, Secretion and Mode of Action of a Novel Microcin.</italic></source> Ph. D thesis, <publisher-name>University of Canterbury</publisher-name>, <publisher-loc>Christchurch</publisher-loc>.</citation></ref>
<ref id="B146"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O&#x2019;Brien</surname> <given-names>G. J.</given-names></name> <name><surname>Mahanty</surname> <given-names>H. K.</given-names></name></person-group> (<year>1994</year>). <article-title>Colicin 24, a new plasmid-borne colicin from a uropathogenic strain of <italic>Escherichia coli</italic>.</article-title> <source><italic>Plasmid</italic></source> <volume>31</volume> <fpage>288</fpage>&#x2013;<lpage>296</lpage>. <pub-id pub-id-type="doi">10.1006/plas.1994.1030</pub-id> <pub-id pub-id-type="pmid">8058821</pub-id></citation></ref>
<ref id="B147"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oyama</surname> <given-names>L. B.</given-names></name> <name><surname>Girdwood</surname> <given-names>S. E.</given-names></name> <name><surname>Cookson</surname> <given-names>A. R.</given-names></name> <name><surname>Fernandez-Fuentes</surname> <given-names>N.</given-names></name> <name><surname>Priv&#x00E9;</surname> <given-names>F.</given-names></name> <name><surname>Vallin</surname> <given-names>H. E.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>The rumen microbiome, an underexplored resource for novel antimicrobial discovery.</article-title> <source><italic>NPJ Biofilms Microb.</italic></source> <volume>3</volume>:<issue>33</issue>. <pub-id pub-id-type="doi">10.1038/s41522-017-0042-1</pub-id> <pub-id pub-id-type="pmid">29214045</pub-id></citation></ref>
<ref id="B148"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pagnout</surname> <given-names>C.</given-names></name> <name><surname>Sohm</surname> <given-names>B.</given-names></name> <name><surname>Razafitianamaharavo</surname> <given-names>A.</given-names></name> <name><surname>Caillet</surname> <given-names>C.</given-names></name> <name><surname>Offroy</surname> <given-names>M.</given-names></name> <name><surname>Leduc</surname> <given-names>M.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Pleiotropic effects of <italic>rfa</italic>-gene mutations on <italic>Escherichia coli</italic> envelope properties.</article-title> <source><italic>Sci. Rep.</italic></source> <volume>9</volume>:<issue>9696</issue>. <pub-id pub-id-type="doi">10.1038/s41598-019-46100-3</pub-id> <pub-id pub-id-type="pmid">31273247</pub-id></citation></ref>
<ref id="B149"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname> <given-names>J. D.</given-names></name> <name><surname>Mortzfeld</surname> <given-names>B. M.</given-names></name> <name><surname>Piattelli</surname> <given-names>E.</given-names></name> <name><surname>Silby</surname> <given-names>M. W.</given-names></name> <name><surname>McCormick</surname> <given-names>B. A.</given-names></name> <name><surname>Bucci</surname> <given-names>V.</given-names></name></person-group> (<year>2020</year>). <article-title>Microcin H47, A Class IIb microcin with potent activity against multidrug resistant <italic>Enterobacteriaceae</italic>.</article-title> <source><italic>ACS Infect. Dis.</italic></source> <volume>6</volume> <fpage>672</fpage>&#x2013;<lpage>679</lpage>. <pub-id pub-id-type="doi">10.1021/acsinfecdis.9b00302</pub-id> <pub-id pub-id-type="pmid">32096972</pub-id></citation></ref>
<ref id="B150"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname> <given-names>J. D.</given-names></name> <name><surname>Piattelli</surname> <given-names>E.</given-names></name> <name><surname>McCormick</surname> <given-names>B. A.</given-names></name> <name><surname>Silby</surname> <given-names>M. W.</given-names></name> <name><surname>Brigham</surname> <given-names>C. J.</given-names></name> <name><surname>Bucci</surname> <given-names>V.</given-names></name></person-group> (<year>2018</year>). <article-title>Engineered probiotic for the inhibition of <italic>Salmonella</italic> via tetrathionate-induced production of microcin H47.</article-title> <source><italic>ACS Infect. Dis.</italic></source> <volume>4</volume> <fpage>39</fpage>&#x2013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1021/acsinfecdis.7b00114</pub-id> <pub-id pub-id-type="pmid">28918634</pub-id></citation></ref>
<ref id="B151"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>P&#x00E4;rn&#x00E4;nen</surname> <given-names>K.</given-names></name> <name><surname>Karkman</surname> <given-names>A.</given-names></name> <name><surname>Hultman</surname> <given-names>J.</given-names></name> <name><surname>Lyra</surname> <given-names>C.</given-names></name> <name><surname>Bengtsson-Palme</surname> <given-names>J.</given-names></name> <name><surname>Larsson</surname> <given-names>D. G. J.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Maternal gut and breast milk microbiota affect infant gut antibiotic resistome and mobile genetic elements.</article-title> <source><italic>Nat. Commun.</italic></source> <volume>9</volume>:<issue>3891</issue>. <pub-id pub-id-type="doi">10.1038/s41467-018-06393-w</pub-id> <pub-id pub-id-type="pmid">30250208</pub-id></citation></ref>
<ref id="B152"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patzer</surname> <given-names>S. I.</given-names></name> <name><surname>Baquero</surname> <given-names>M. R.</given-names></name> <name><surname>Bravo</surname> <given-names>D.</given-names></name> <name><surname>Moreno</surname> <given-names>F.</given-names></name> <name><surname>Hantke</surname> <given-names>K.</given-names></name></person-group> (<year>2003</year>). <article-title>The colicin G, H and X determinants encode microcins M and H47, which might utilize the catecholate siderophore receptors FepA, Cir, Fiu and IroN.</article-title> <source><italic>Microbiology</italic></source> <volume>149</volume> <fpage>2557</fpage>&#x2013;<lpage>2570</lpage>. <pub-id pub-id-type="doi">10.1099/mic.0.26396-0</pub-id> <pub-id pub-id-type="pmid">12949180</pub-id></citation></ref>
<ref id="B153"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pfeifer</surname> <given-names>Y.</given-names></name> <name><surname>Cullik</surname> <given-names>A.</given-names></name> <name><surname>Witte</surname> <given-names>W.</given-names></name></person-group> (<year>2010</year>). <article-title>Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens.</article-title> <source><italic>Int. J. Med. Microbiol.</italic></source> <volume>300</volume> <fpage>371</fpage>&#x2013;<lpage>379</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijmm.2010.04.005</pub-id> <pub-id pub-id-type="pmid">20537585</pub-id></citation></ref>
<ref id="B154"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Poey</surname> <given-names>M. E.</given-names></name> <name><surname>Azpiroz</surname> <given-names>M. F.</given-names></name> <name><surname>Lavi&#x00F1;a</surname> <given-names>M.</given-names></name></person-group> (<year>2006</year>). <article-title>Comparative analysis of chromosome-encoded microcins.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>50</volume> <fpage>1411</fpage>&#x2013;<lpage>1418</lpage>. <pub-id pub-id-type="doi">10.1128/aac.50.4.1411-1418.2006</pub-id> <pub-id pub-id-type="pmid">16569859</pub-id></citation></ref>
<ref id="B155"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pomares</surname> <given-names>M. F.</given-names></name> <name><surname>Delgado</surname> <given-names>M. A.</given-names></name> <name><surname>Corbalan</surname> <given-names>N. S.</given-names></name> <name><surname>Farias</surname> <given-names>R. N.</given-names></name> <name><surname>Vincent</surname> <given-names>P. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Sensitization of microcin J25-resistant strains by a membrane-permeabilizing peptide.</article-title> <source><italic>Appl. Environ. Microbiol.</italic></source> <volume>76</volume> <fpage>6837</fpage>&#x2013;<lpage>6842</lpage>. <pub-id pub-id-type="doi">10.1128/aem.00307-10</pub-id> <pub-id pub-id-type="pmid">20802073</pub-id></citation></ref>
<ref id="B156"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pons</surname> <given-names>A. M.</given-names></name> <name><surname>Delalande</surname> <given-names>F.</given-names></name> <name><surname>Duarte</surname> <given-names>M.</given-names></name> <name><surname>Benoit</surname> <given-names>S.</given-names></name> <name><surname>Lanneluc</surname> <given-names>I.</given-names></name> <name><surname>Sabl&#x00E9;</surname> <given-names>S.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Genetic analysis and complete primary structure of microcin L.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>48</volume> <fpage>505</fpage>&#x2013;<lpage>513</lpage>. <pub-id pub-id-type="doi">10.1128/aac.48.2.505-513.2004</pub-id> <pub-id pub-id-type="pmid">14742202</pub-id></citation></ref>
<ref id="B157"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pugsley</surname> <given-names>A. P.</given-names></name> <name><surname>Moreno</surname> <given-names>F.</given-names></name> <name><surname>De Lorenzo</surname> <given-names>V.</given-names></name></person-group> (<year>1986</year>). <article-title>Microcin-E492-insensitive mutants of <italic>Escherichia coli</italic> K12.</article-title> <source><italic>J. Gen. Microbiol.</italic></source> <volume>132</volume> <fpage>3253</fpage>&#x2013;<lpage>3259</lpage>. <pub-id pub-id-type="doi">10.1099/00221287-132-12-3253</pub-id> <pub-id pub-id-type="pmid">3309133</pub-id></citation></ref>
<ref id="B158"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramirez</surname> <given-names>M. S.</given-names></name> <name><surname>Tolmasky</surname> <given-names>M. E.</given-names></name></person-group> (<year>2010</year>). <article-title>Aminoglycoside modifying enzymes.</article-title> <source><italic>Drug Resist. Updat.</italic></source> <volume>13</volume> <fpage>151</fpage>&#x2013;<lpage>171</lpage>. <pub-id pub-id-type="doi">10.1016/j.drup.2010.08.003</pub-id> <pub-id pub-id-type="pmid">20833577</pub-id></citation></ref>
<ref id="B159"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ran</surname> <given-names>R.</given-names></name> <name><surname>Zeng</surname> <given-names>H.</given-names></name> <name><surname>Zhao</surname> <given-names>D.</given-names></name> <name><surname>Liu</surname> <given-names>R.</given-names></name> <name><surname>Xu</surname> <given-names>X.</given-names></name></person-group> (<year>2017</year>). <article-title>The novel property of heptapeptide of microcin C7 in affecting the cell growth of <italic>Escherichia coli</italic>.</article-title> <source><italic>Molecules</italic></source> <volume>22</volume>:<issue>432</issue>. <pub-id pub-id-type="doi">10.3390/molecules22030432</pub-id> <pub-id pub-id-type="pmid">28282893</pub-id></citation></ref>
<ref id="B160"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rebuffat</surname> <given-names>S.</given-names></name></person-group> (<year>2012</year>). <article-title>Microcins in action, amazing defence strategies of <italic>Enterobacteria</italic>.</article-title> <source><italic>Biochem. Soc. Trans.</italic></source> <volume>40</volume> <fpage>1456</fpage>&#x2013;<lpage>1462</lpage>. <pub-id pub-id-type="doi">10.1042/bst20120183</pub-id> <pub-id pub-id-type="pmid">23176498</pub-id></citation></ref>
<ref id="B161"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rebuffat</surname> <given-names>S.</given-names></name> <name><surname>Blond</surname> <given-names>A.</given-names></name> <name><surname>Destoumieux-Garz&#x00F3;n</surname> <given-names>D.</given-names></name> <name><surname>Goulard</surname> <given-names>C.</given-names></name> <name><surname>Peduzzi</surname> <given-names>J.</given-names></name></person-group> (<year>2004</year>). <article-title>Microcin J25, from the macrocyclic to the lasso structure, implications for biosynthetic, evolutionary and biotechnological perspectives.</article-title> <source><italic>Curr. Protein Pept. Sci.</italic></source> <volume>5</volume> <fpage>383</fpage>&#x2013;<lpage>391</lpage>. <pub-id pub-id-type="doi">10.2174/1389203043379611</pub-id> <pub-id pub-id-type="pmid">15544533</pub-id></citation></ref>
<ref id="B162"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rintoul</surname> <given-names>M. R.</given-names></name> <name><surname>de Arcuri</surname> <given-names>B. F.</given-names></name> <name><surname>Salom&#x00F3;n</surname> <given-names>R. A.</given-names></name> <name><surname>Farias</surname> <given-names>R. N.</given-names></name> <name><surname>Morero</surname> <given-names>R. D.</given-names></name></person-group> (<year>2001</year>). <article-title>The antibacterial action of microcin J25, evidence for disruption of cytoplasmic membrane energization in <italic>Salmonella</italic> Newport.</article-title> <source><italic>FEMS Microbiol. Lett.</italic></source> <volume>204</volume> <fpage>265</fpage>&#x2013;<lpage>270</lpage>. <pub-id pub-id-type="doi">10.1111/j.1574-6968.2001.tb10895.x</pub-id> <pub-id pub-id-type="pmid">11731133</pub-id></citation></ref>
<ref id="B163"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname> <given-names>E.</given-names></name> <name><surname>Lavi&#x00F1;a</surname> <given-names>M.</given-names></name></person-group> (<year>2003</year>). <article-title>The proton channel is the minimal structure of ATP synthase necessary and sufficient for microcin H47 antibiotic action.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>47</volume> <fpage>181</fpage>&#x2013;<lpage>187</lpage>. <pub-id pub-id-type="doi">10.1128/aac.47.1.181-187.2003</pub-id> <pub-id pub-id-type="pmid">12499189</pub-id></citation></ref>
<ref id="B164"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosengren</surname> <given-names>K. J.</given-names></name> <name><surname>Clark</surname> <given-names>R. J.</given-names></name> <name><surname>Daly</surname> <given-names>N. L.</given-names></name> <name><surname>G&#x00F6;ransson</surname> <given-names>U.</given-names></name> <name><surname>Jones</surname> <given-names>A.</given-names></name> <name><surname>Craik</surname> <given-names>D. J.</given-names></name></person-group> (<year>2003</year>). <article-title>Microcin J25 has a threaded sidechain-to-backbone ring structure and not a head-to-tail cyclized backbone.</article-title> <source><italic>J. Am. Chem. Soc.</italic></source> <volume>125</volume> <fpage>12464</fpage>&#x2013;<lpage>12474</lpage>. <pub-id pub-id-type="doi">10.1021/ja0367703</pub-id> <pub-id pub-id-type="pmid">14531690</pub-id></citation></ref>
<ref id="B165"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname> <given-names>R. S.</given-names></name> <name><surname>Kelleher</surname> <given-names>N. L.</given-names></name> <name><surname>Milne</surname> <given-names>J. C.</given-names></name> <name><surname>Walsh</surname> <given-names>C. T.</given-names></name></person-group> (<year>1999</year>). <article-title>In vivo processing and antibiotic activity of microcin B17 analogs with varying ring content and altered bisheterocyclic sites.</article-title> <source><italic>Chem. Biol.</italic></source> <volume>6</volume> <fpage>305</fpage>&#x2013;<lpage>318</lpage>. <pub-id pub-id-type="doi">10.1016/s1074-5521(99)80076-3</pub-id></citation></ref>
<ref id="B166"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sabl&#x00E9;</surname> <given-names>S.</given-names></name> <name><surname>Duarte</surname> <given-names>M.</given-names></name> <name><surname>Bravo</surname> <given-names>D.</given-names></name> <name><surname>Lanneluc</surname> <given-names>I.</given-names></name> <name><surname>Pons</surname> <given-names>A. M.</given-names></name> <name><surname>Cottenceau</surname> <given-names>G.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Wild-type <italic>Escherichia coli</italic> producing microcins B17, D93, J25, and L; cloning of genes for microcin L production and immunity.</article-title> <source><italic>Can. J. Microbiol.</italic></source> <volume>49</volume> <fpage>357</fpage>&#x2013;<lpage>361</lpage>. <pub-id pub-id-type="doi">10.1139/w03-047</pub-id> <pub-id pub-id-type="pmid">12897830</pub-id></citation></ref>
<ref id="B167"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sabl&#x00E9;</surname> <given-names>S.</given-names></name> <name><surname>Pons</surname> <given-names>A. M.</given-names></name> <name><surname>Gendron-Gaillard</surname> <given-names>S.</given-names></name> <name><surname>Cottenceau</surname> <given-names>G.</given-names></name></person-group> (<year>2000</year>). <article-title>Antibacterial activity evaluation of microcin J25 against diarrheagenic <italic>Escherichia coli</italic>.</article-title> <source><italic>Appl. Environ. Microbiol.</italic></source> <volume>66</volume> <fpage>4595</fpage>&#x2013;<lpage>4597</lpage>. <pub-id pub-id-type="doi">10.1128/aem.66.10.4595-4597.2000</pub-id> <pub-id pub-id-type="pmid">11010926</pub-id></citation></ref>
<ref id="B168"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sabnis</surname> <given-names>A.</given-names></name> <name><surname>Kl&#x00F6;ckner</surname> <given-names>A.</given-names></name> <name><surname>Becce</surname> <given-names>M.</given-names></name> <name><surname>Evans</surname> <given-names>L. E.</given-names></name> <name><surname>Furniss</surname> <given-names>R. C. D.</given-names></name> <name><surname>Mavridou</surname> <given-names>D. A. I.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane.</article-title> <source><italic>bioRxiv</italic></source> [Preprint], <pub-id pub-id-type="doi">10.1101/479618</pub-id></citation></ref>
<ref id="B169"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salah Ud-Din</surname> <given-names>A. I.</given-names></name> <name><surname>Tikhomirova</surname> <given-names>A.</given-names></name> <name><surname>Roujeinikova</surname> <given-names>A.</given-names></name></person-group> (<year>2016</year>). <article-title>Structure and functional diversity of GCN5-related N-acetyltransferases (GNAT).</article-title> <source><italic>Int. J. Mol. Sci.</italic></source> <volume>17</volume>:<issue>1018</issue>. <pub-id pub-id-type="doi">10.3390/ijms17071018</pub-id> <pub-id pub-id-type="pmid">27367672</pub-id></citation></ref>
<ref id="B170"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salom&#x00F3;n</surname> <given-names>R. A.</given-names></name> <name><surname>Farias</surname> <given-names>R. N.</given-names></name></person-group> (<year>1992</year>). <article-title>Microcin 25, a novel antimicrobial peptide produced by <italic>Escherichia coli</italic>.</article-title> <source><italic>J. Bacteriol.</italic></source> <volume>174</volume> <fpage>7428</fpage>&#x2013;<lpage>7435</lpage>. <pub-id pub-id-type="doi">10.1128/jb.174.22.7428-7435.1992</pub-id> <pub-id pub-id-type="pmid">1429464</pub-id></citation></ref>
<ref id="B171"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salom&#x00F3;n</surname> <given-names>R. A.</given-names></name> <name><surname>Far&#x00ED;as</surname> <given-names>R. N.</given-names></name></person-group> (<year>1993</year>). <article-title>The FhuA protein is involved in microcin 25 uptake.</article-title> <source><italic>J. Bacteriol.</italic></source> <volume>175</volume> <fpage>7741</fpage>&#x2013;<lpage>7742</lpage>. <pub-id pub-id-type="doi">10.1128/jb.175.23.7741-7742.1993</pub-id> <pub-id pub-id-type="pmid">8244949</pub-id></citation></ref>
<ref id="B172"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sassone-Corsi</surname> <given-names>M.</given-names></name> <name><surname>Nuccio</surname> <given-names>S. P.</given-names></name> <name><surname>Liu</surname> <given-names>H.</given-names></name> <name><surname>Hernandez</surname> <given-names>D.</given-names></name> <name><surname>Vu</surname> <given-names>C. T.</given-names></name> <name><surname>Takahashi</surname> <given-names>A. A.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Microcins mediate competition among <italic>Enterobacteriaceae</italic> in the inflamed gut.</article-title> <source><italic>Nature</italic></source> <volume>540</volume> <fpage>280</fpage>&#x2013;<lpage>283</lpage>. <pub-id pub-id-type="doi">10.1038/nature20557</pub-id> <pub-id pub-id-type="pmid">27798599</pub-id></citation></ref>
<ref id="B173"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname> <given-names>M.</given-names></name> <name><surname>Machida</surname> <given-names>K.</given-names></name> <name><surname>Arikado</surname> <given-names>E.</given-names></name> <name><surname>Saito</surname> <given-names>H.</given-names></name> <name><surname>Kakegawa</surname> <given-names>T.</given-names></name> <name><surname>Kobayashi</surname> <given-names>H.</given-names></name></person-group> (<year>2000</year>). <article-title>Expression of outer membrane proteins in <italic>Escherichia coli</italic> growing at acid pH.</article-title> <source><italic>Appl. Environ. Microbiol.</italic></source> <volume>66</volume> <fpage>943</fpage>&#x2013;<lpage>947</lpage>. <pub-id pub-id-type="doi">10.1128/aem.66.3.943-947.2000</pub-id> <pub-id pub-id-type="pmid">10698756</pub-id></citation></ref>
<ref id="B174"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sawa</surname> <given-names>T.</given-names></name> <name><surname>Kooguchi</surname> <given-names>K.</given-names></name> <name><surname>Moriyama</surname> <given-names>K.</given-names></name></person-group> (<year>2020</year>). <article-title>Molecular diversity of extended-spectrum beta-lactamases and carbapenemases, and antimicrobial resistance.</article-title> <source><italic>J. Intens. Care</italic></source> <volume>8</volume>:<issue>13</issue>. <pub-id pub-id-type="doi">10.1186/s40560-020-0429-6</pub-id> <pub-id pub-id-type="pmid">32015881</pub-id></citation></ref>
<ref id="B175"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schindler</surname> <given-names>P. R.</given-names></name> <name><surname>Teuber</surname> <given-names>M.</given-names></name></person-group> (<year>1975</year>). <article-title>Action of polymyxin B on bacterial membranes, morphological changes in the cytoplasm and in the outer membrane of <italic>Salmonella typhimurium</italic> and <italic>Escherichia coli</italic> B.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>8</volume> <fpage>95</fpage>&#x2013;<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1128/aac.8.1.95</pub-id> <pub-id pub-id-type="pmid">169730</pub-id></citation></ref>
<ref id="B176"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Semenova</surname> <given-names>E.</given-names></name> <name><surname>Yuzenkova</surname> <given-names>Y.</given-names></name> <name><surname>Peduzzi</surname> <given-names>J.</given-names></name> <name><surname>Rebuffat</surname> <given-names>S.</given-names></name> <name><surname>Severinov</surname> <given-names>K.</given-names></name></person-group> (<year>2005</year>). <article-title>Structure-activity analysis of microcinJ25, distinct parts of the threaded lasso molecule are responsible for interaction with bacterial RNA polymerase.</article-title> <source><italic>J. Bacteriol.</italic></source> <volume>187</volume> <fpage>3859</fpage>&#x2013;<lpage>3863</lpage>. <pub-id pub-id-type="doi">10.1128/jb.187.11.3859-3863.2005</pub-id> <pub-id pub-id-type="pmid">15901712</pub-id></citation></ref>
<ref id="B177"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Severinov</surname> <given-names>K.</given-names></name> <name><surname>Nair</surname> <given-names>S. K.</given-names></name></person-group> (<year>2012</year>). <article-title>Microcin C, biosynthesis and mechanisms of bacterial resistance.</article-title> <source><italic>Future Microbiol.</italic></source> <volume>7</volume> <fpage>281</fpage>&#x2013;<lpage>289</lpage>. <pub-id pub-id-type="doi">10.2217/fmb.11.148</pub-id> <pub-id pub-id-type="pmid">22324995</pub-id></citation></ref>
<ref id="B178"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname> <given-names>P.</given-names></name> <name><surname>Haycocks</surname> <given-names>J. R. J.</given-names></name> <name><surname>Middlemiss</surname> <given-names>A. D.</given-names></name> <name><surname>Kettles</surname> <given-names>R. A.</given-names></name> <name><surname>Sellars</surname> <given-names>L. E.</given-names></name> <name><surname>Ricci</surname> <given-names>V.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>The multiple antibiotic resistance operon of enteric bacteria controls DNA repair and outer membrane integrity.</article-title> <source><italic>Nat. Commun.</italic></source> <volume>8</volume>:<issue>1444</issue>. <pub-id pub-id-type="doi">10.1038/s41467-017-01405-7</pub-id> <pub-id pub-id-type="pmid">29133912</pub-id></citation></ref>
<ref id="B179"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shkundina</surname> <given-names>I.</given-names></name> <name><surname>Serebryakova</surname> <given-names>M.</given-names></name> <name><surname>Severinov</surname> <given-names>K.</given-names></name></person-group> (<year>2014</year>). <article-title>The C-terminal part of microcin B is crucial for DNA gyrase inhibition and antibiotic uptake by sensitive cells.</article-title> <source><italic>J. Bacteriol.</italic></source> <volume>196</volume> <fpage>1759</fpage>&#x2013;<lpage>1767</lpage>. <pub-id pub-id-type="doi">10.1128/jb.00015-14</pub-id> <pub-id pub-id-type="pmid">24563033</pub-id></citation></ref>
<ref id="B180"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sikandar</surname> <given-names>A.</given-names></name> <name><surname>Koehnke</surname> <given-names>J.</given-names></name></person-group> (<year>2019</year>). <article-title>The role of protein-protein interactions in the biosynthesis of ribosomally synthesized and post-translationally modified peptides.</article-title> <source><italic>Nat. Prod. Rep.</italic></source> <volume>36</volume> <fpage>1576</fpage>&#x2013;<lpage>1588</lpage>. <pub-id pub-id-type="doi">10.1039/c8np00064f</pub-id> <pub-id pub-id-type="pmid">30920567</pub-id></citation></ref>
<ref id="B181"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smale</surname> <given-names>S. T.</given-names></name></person-group> (<year>2010</year>). <article-title>Chloramphenicol acetyltransferase assay.</article-title> <source><italic>Cold Spring Harb. Protoc.</italic></source> <volume>2010</volume>:<issue>pdb.prot5422</issue>. <pub-id pub-id-type="doi">10.1101/pdb.prot5422</pub-id> <pub-id pub-id-type="pmid">20439409</pub-id></citation></ref>
<ref id="B182"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smani</surname> <given-names>Y.</given-names></name> <name><surname>F&#x00E0;brega</surname> <given-names>A.</given-names></name> <name><surname>Roca</surname> <given-names>I.</given-names></name> <name><surname>&#x00E1;nchez-Encinales</surname> <given-names>V. S.</given-names></name> <name><surname>Vila</surname> <given-names>J.</given-names></name> <name><surname>Pach&#x00F3;n</surname> <given-names>J.</given-names></name></person-group> (<year>2014</year>). <article-title>Role of OmpA in the multidrug resistance phenotype of <italic>Acinetobacter baumannii</italic>.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>58</volume> <fpage>1806</fpage>&#x2013;<lpage>1808</lpage>. <pub-id pub-id-type="doi">10.1128/aac.02101-13</pub-id> <pub-id pub-id-type="pmid">24379205</pub-id></citation></ref>
<ref id="B183"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Snyder</surname> <given-names>A. B.</given-names></name> <name><surname>Worobo</surname> <given-names>R. W.</given-names></name></person-group> (<year>2014</year>). <article-title>Chemical and genetic characterization of bacteriocins, antimicrobial peptides for food safety.</article-title> <source><italic>J. Sci. Food Agric.</italic></source> <volume>94</volume> <fpage>28</fpage>&#x2013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1002/jsfa.6293</pub-id> <pub-id pub-id-type="pmid">23818338</pub-id></citation></ref>
<ref id="B184"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Soudy</surname> <given-names>R.</given-names></name> <name><surname>Wang</surname> <given-names>L.</given-names></name> <name><surname>Kaur</surname> <given-names>K.</given-names></name></person-group> (<year>2012</year>). <article-title>Synthetic peptides derived from the sequence of a lasso peptide microcin J25 show antibacterial activity.</article-title> <source><italic>Bioorg. Med. Chem.</italic></source> <volume>20</volume> <fpage>1794</fpage>&#x2013;<lpage>1800</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2011.12.061</pub-id> <pub-id pub-id-type="pmid">22304849</pub-id></citation></ref>
<ref id="B185"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname> <given-names>J.</given-names></name> <name><surname>Liao</surname> <given-names>X. P.</given-names></name> <name><surname>D&#x2019;Souza</surname> <given-names>A. W.</given-names></name> <name><surname>Boolchandani</surname> <given-names>M.</given-names></name> <name><surname>Li</surname> <given-names>S. H.</given-names></name> <name><surname>Cheng</surname> <given-names>K.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Environmental remodeling of human gut microbiota and antibiotic resistome in livestock farms.</article-title> <source><italic>Nat. Commun.</italic></source> <volume>11</volume>:<issue>1427</issue>. <pub-id pub-id-type="doi">10.1038/s41467-020-15222-y</pub-id> <pub-id pub-id-type="pmid">32188862</pub-id></citation></ref>
<ref id="B186"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Temiakov</surname> <given-names>D.</given-names></name> <name><surname>Zenkin</surname> <given-names>N.</given-names></name> <name><surname>Vassylyeva</surname> <given-names>M. N.</given-names></name> <name><surname>Perederina</surname> <given-names>A.</given-names></name> <name><surname>Tahirov</surname> <given-names>T. H.</given-names></name> <name><surname>Kashkina</surname> <given-names>E.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Structural basis of transcription inhibition by antibiotic streptolydigin.</article-title> <source><italic>Mol. Cell.</italic></source> <volume>19</volume> <fpage>655</fpage>&#x2013;<lpage>666</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2005.07.020</pub-id> <pub-id pub-id-type="pmid">16167380</pub-id></citation></ref>
<ref id="B187"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname> <given-names>X.</given-names></name> <name><surname>Destoumieux-Garz&#x00F3;n</surname> <given-names>D.</given-names></name> <name><surname>Peduzzi</surname> <given-names>J.</given-names></name> <name><surname>Afonso</surname> <given-names>C.</given-names></name> <name><surname>Blond</surname> <given-names>A.</given-names></name> <name><surname>Birlirakis</surname> <given-names>N.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Siderophore peptide, a new type of post-translationally modified antibacterial peptide with potent activity.</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>279</volume> <fpage>28233</fpage>&#x2013;<lpage>28242</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M400228200</pub-id> <pub-id pub-id-type="pmid">15102848</pub-id></citation></ref>
<ref id="B188"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tietz</surname> <given-names>J. I.</given-names></name> <name><surname>Schwalen</surname> <given-names>C. J.</given-names></name> <name><surname>Patel</surname> <given-names>P. S.</given-names></name> <name><surname>Maxson</surname> <given-names>T.</given-names></name> <name><surname>Blair</surname> <given-names>P. M.</given-names></name> <name><surname>Tai</surname> <given-names>H.-C.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>A new genome-mining tool redefines the lasso peptide biosynthetic landscape.</article-title> <source><italic>Nat. Chem. Biol.</italic></source> <volume>13</volume> <fpage>470</fpage>&#x2013;<lpage>478</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.2319</pub-id> <pub-id pub-id-type="pmid">28244986</pub-id></citation></ref>
<ref id="B189"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname> <given-names>J. H.</given-names></name> <name><surname>Jacoby</surname> <given-names>G. A.</given-names></name></person-group> (<year>2002</year>). <article-title>Mechanism of plasmid-mediated quinolone resistance.</article-title> <source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source> <volume>99</volume> <fpage>5638</fpage>&#x2013;<lpage>5642</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.082092899</pub-id> <pub-id pub-id-type="pmid">11943863</pub-id></citation></ref>
<ref id="B190"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Travin</surname> <given-names>D. Y.</given-names></name> <name><surname>Bikmetov</surname> <given-names>D.</given-names></name> <name><surname>Severinov</surname> <given-names>K.</given-names></name></person-group> (<year>2020</year>). <article-title>Translation-targeting RiPPs and where to find them.</article-title> <source><italic>Front. Genet.</italic></source> <volume>11</volume>:<issue>226</issue>. <pub-id pub-id-type="doi">10.3389/fgene.2020.00226</pub-id> <pub-id pub-id-type="pmid">32296456</pub-id></citation></ref>
<ref id="B191"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Travin</surname> <given-names>D. Y.</given-names></name> <name><surname>Watson</surname> <given-names>Z. L.</given-names></name> <name><surname>Metelev</surname> <given-names>M.</given-names></name> <name><surname>Ward</surname> <given-names>F. R.</given-names> <suffix>I</suffix></name> <name><surname>Osterman</surname> <given-names>A.</given-names> <suffix>I</suffix></name> <name><surname>Khven</surname> <given-names>M.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Structure of ribosome-bound azole-modified peptide phazolicin rationalizes its species-specific mode of bacterial translation inhibition.</article-title> <source><italic>Nat. Commun.</italic></source> <volume>10</volume>:<issue>4563</issue>. <pub-id pub-id-type="doi">10.1038/s41467-019-12589-5</pub-id> <pub-id pub-id-type="pmid">31594941</pub-id></citation></ref>
<ref id="B192"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trimble</surname> <given-names>M. J.</given-names></name> <name><surname>Mlynarcik</surname> <given-names>P.</given-names></name> <name><surname>Kolar</surname> <given-names>M.</given-names></name> <name><surname>Hancock</surname> <given-names>R. E.</given-names></name></person-group> (<year>2016</year>). <article-title>Polymyxin, Alternative mechanisms of action and resistance.</article-title> <source><italic>Cold Spring Harb. Perspect. Med.</italic></source> <volume>6</volume>:<issue>a025288</issue>. <pub-id pub-id-type="doi">10.1101/cshperspect.a025288</pub-id> <pub-id pub-id-type="pmid">27503996</pub-id></citation></ref>
<ref id="B193"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trujillo</surname> <given-names>M.</given-names></name> <name><surname>Rodriguez</surname> <given-names>E.</given-names></name> <name><surname>Lavi&#x00F1;a</surname> <given-names>M.</given-names></name></person-group> (<year>2001</year>). <article-title>ATP synthase is necessary for microcin H47 antibiotic action.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>45</volume> <fpage>3128</fpage>&#x2013;<lpage>3131</lpage>. <pub-id pub-id-type="doi">10.1128/aac.45.11.3128-3131.2001</pub-id> <pub-id pub-id-type="pmid">11600367</pub-id></citation></ref>
<ref id="B194"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Boeckel</surname> <given-names>T. P.</given-names></name> <name><surname>Brower</surname> <given-names>C.</given-names></name> <name><surname>Gilbert</surname> <given-names>M.</given-names></name> <name><surname>Grenfell</surname> <given-names>B. T.</given-names></name> <name><surname>Levin</surname> <given-names>S. A.</given-names></name> <name><surname>Robinson</surname> <given-names>T. P.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Global trends in antimicrobial use in food animals.</article-title> <source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source> <volume>112</volume> <fpage>5649</fpage>&#x2013;<lpage>5654</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1503141112</pub-id> <pub-id pub-id-type="pmid">25792457</pub-id></citation></ref>
<ref id="B195"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Boeckel</surname> <given-names>T. P.</given-names></name> <name><surname>Glennon</surname> <given-names>E. E.</given-names></name> <name><surname>Chen</surname> <given-names>D.</given-names></name> <name><surname>Gilbert</surname> <given-names>M.</given-names></name> <name><surname>Robinson</surname> <given-names>T. P.</given-names></name> <name><surname>Grenfell</surname> <given-names>B. T.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Reducing antimicrobial use in food animals.</article-title> <source><italic>Science</italic></source> <volume>357</volume> <fpage>1350</fpage>&#x2013;<lpage>1352</lpage>. <pub-id pub-id-type="doi">10.1126/science.aao1495</pub-id> <pub-id pub-id-type="pmid">28963240</pub-id></citation></ref>
<ref id="B196"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vassiliadis</surname> <given-names>G.</given-names></name> <name><surname>Destoumieux-Garz&#x00F3;n</surname> <given-names>D.</given-names></name> <name><surname>Lombard</surname> <given-names>C.</given-names></name> <name><surname>Rebuffat</surname> <given-names>S.</given-names></name> <name><surname>Peduzzi</surname> <given-names>J.</given-names></name></person-group> (<year>2010</year>). <article-title>Isolation and characterization of two members of the siderophore-microcin family, microcins M and H47.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>54</volume> <fpage>288</fpage>&#x2013;<lpage>297</lpage>. <pub-id pub-id-type="doi">10.1128/aac.00744-09</pub-id> <pub-id pub-id-type="pmid">19884380</pub-id></citation></ref>
<ref id="B197"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vassiliadis</surname> <given-names>G.</given-names></name> <name><surname>Peduzzi</surname> <given-names>J.</given-names></name> <name><surname>Zirah</surname> <given-names>S.</given-names></name> <name><surname>Thomas</surname> <given-names>X.</given-names></name> <name><surname>Rebuffat</surname> <given-names>S.</given-names></name> <name><surname>Destoumieux-Garz&#x00F3;n</surname> <given-names>D.</given-names></name></person-group> (<year>2007</year>). <article-title>Insight into siderophore-carrying peptide biosynthesis, enterobactin is a precursor for microcin E492 posttranslational modification.</article-title> <source><italic>Antimicrob. Agents Chemother.</italic></source> <volume>51</volume> <fpage>3546</fpage>&#x2013;<lpage>3553</lpage>. <pub-id pub-id-type="doi">10.1128/aac.00261-07</pub-id> <pub-id pub-id-type="pmid">17646411</pub-id></citation></ref>
<ref id="B198"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ventola</surname> <given-names>C. L.</given-names></name></person-group> (<year>2015</year>). <article-title>The antibiotic resistance crisis, part 1, causes and threats.</article-title> <source><italic>P&#x0026;T</italic></source> <volume>40</volume> <fpage>277</fpage>&#x2013;<lpage>283</lpage>.</citation></ref>
<ref id="B199"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname> <given-names>P. A.</given-names></name> <name><surname>Delgado</surname> <given-names>M. A.</given-names></name> <name><surname>Farias</surname> <given-names>R. N.</given-names></name> <name><surname>Salom&#x00F3;n</surname> <given-names>R. A.</given-names></name></person-group> (<year>2004</year>). <article-title>Inhibition of <italic>Salmonella enterica</italic> serovars by microcin J25.</article-title> <source><italic>FEMS Microbiol. Lett.</italic></source> <volume>236</volume> <fpage>103</fpage>&#x2013;<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1016/j.femsle.2004.05.027</pub-id> <pub-id pub-id-type="pmid">15212798</pub-id></citation></ref>
<ref id="B200"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Viz&#x00E1;n</surname> <given-names>J. L.</given-names></name> <name><surname>Hern&#x00E1;ndez-Chico</surname> <given-names>C.</given-names></name> <name><surname>del Castillo</surname> <given-names>I.</given-names></name> <name><surname>Moreno</surname> <given-names>F.</given-names></name></person-group> (<year>1991</year>). <article-title>The peptide antibiotic microcin B17 induces double-strand cleavage of DNA mediated by <italic>E. coli</italic> DNA gyrase.</article-title> <source><italic>EMBO J.</italic></source> <volume>10</volume> <fpage>467</fpage>&#x2013;<lpage>476</lpage>. <pub-id pub-id-type="doi">10.1002/j.1460-2075.1991.tb07969.x</pub-id></citation></ref>
<ref id="B201"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vondenhoff</surname> <given-names>G. H.</given-names></name> <name><surname>Dubiley</surname> <given-names>S.</given-names></name> <name><surname>Severinov</surname> <given-names>K.</given-names></name> <name><surname>Lescrinier</surname> <given-names>E.</given-names></name> <name><surname>Rozenski</surname> <given-names>J.</given-names></name> <name><surname>Van Aerschot</surname> <given-names>A.</given-names></name></person-group> (<year>2011</year>). <article-title>Extended targeting potential and improved synthesis of microcin C analogs as antibacterials.</article-title> <source><italic>Bioorg. Med. Chem.</italic></source> <volume>19</volume> <fpage>5462</fpage>&#x2013;<lpage>5467</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2011.07.052</pub-id> <pub-id pub-id-type="pmid">21855353</pub-id></citation></ref>
<ref id="B202"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>G.</given-names></name> <name><surname>Li</surname> <given-names>X.</given-names></name> <name><surname>Wang</surname> <given-names>Z.</given-names></name></person-group> (<year>2016</year>). <article-title>APD3, the antimicrobial peptide database as a tool for research and education.</article-title> <source><italic>Nucleic Acids Res.</italic></source> <volume>44</volume> <fpage>D1087</fpage>&#x2013;<lpage>D1093</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkv1278</pub-id> <pub-id pub-id-type="pmid">26602694</pub-id></citation></ref>
<ref id="B203"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>G.</given-names></name> <name><surname>Song</surname> <given-names>Q.</given-names></name> <name><surname>Huang</surname> <given-names>S.</given-names></name> <name><surname>Wang</surname> <given-names>Y.</given-names></name> <name><surname>Cai</surname> <given-names>S.</given-names></name> <name><surname>Yu</surname> <given-names>H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Effect of antimicrobial peptide microcin J25 on growth performance, immune regulation, and intestinal microbiota in broiler chickens challenged with <italic>Escherichia coli</italic> and <italic>Salmonella</italic>.</article-title> <source><italic>Animals</italic></source> <volume>10</volume>:<issue>345</issue>. <pub-id pub-id-type="doi">10.3390/ani10020345</pub-id> <pub-id pub-id-type="pmid">32098236</pub-id></citation></ref>
<ref id="B204"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>X. W.</given-names></name> <name><surname>Zhang</surname> <given-names>W. B.</given-names></name></person-group> (<year>2018</year>). <article-title>Chemical topology and complexity of protein architectures.</article-title> <source><italic>Trends Biochem. Sci.</italic></source> <volume>43</volume> <fpage>806</fpage>&#x2013;<lpage>817</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2018.07.001</pub-id> <pub-id pub-id-type="pmid">30041839</pub-id></citation></ref>
<ref id="B205"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y.</given-names></name> <name><surname>Chen</surname> <given-names>X.</given-names></name> <name><surname>Hu</surname> <given-names>Y.</given-names></name> <name><surname>Zhu</surname> <given-names>G.</given-names></name> <name><surname>White</surname> <given-names>A. P.</given-names></name> <name><surname>Koster</surname> <given-names>W.</given-names></name></person-group> (<year>2018</year>). <article-title>Evolution and sequence diversity of FhuA in <italic>Salmonella</italic> and <italic>Escherichia</italic>.</article-title> <source><italic>Infect. Immun.</italic></source> <volume>86</volume>:<issue>e00573-18</issue>. <pub-id pub-id-type="doi">10.1128/iai.00573-18</pub-id> <pub-id pub-id-type="pmid">30150258</pub-id></citation></ref>
<ref id="B206"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wester</surname> <given-names>C. W.</given-names></name> <name><surname>Durairaj</surname> <given-names>L.</given-names></name> <name><surname>Evans</surname> <given-names>A. T.</given-names></name> <name><surname>Schwartz</surname> <given-names>D. N.</given-names></name> <name><surname>Husain</surname> <given-names>S.</given-names></name> <name><surname>Martinez</surname> <given-names>E.</given-names></name></person-group> (<year>2002</year>). <article-title>Antibiotic resistance, a survey of physician perceptions.</article-title> <source><italic>Arch. Intern. Med.</italic></source> <volume>162</volume> <fpage>2210</fpage>&#x2013;<lpage>2216</lpage>. <pub-id pub-id-type="doi">10.1001/archinte.162.19.2210</pub-id> <pub-id pub-id-type="pmid">12390064</pub-id></citation></ref>
<ref id="B207"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilkens</surname> <given-names>M.</given-names></name> <name><surname>Villanueva</surname> <given-names>J. E.</given-names></name> <name><surname>Cofr&#x00E9;</surname> <given-names>J.</given-names></name> <name><surname>Chnaiderman</surname> <given-names>J.</given-names></name> <name><surname>Lagos</surname> <given-names>R.</given-names></name></person-group> (<year>1997</year>). <article-title>Cloning and expression in <italic>Escherichia coli</italic> of genetic determinants for production of and immunity to microcin E492 from <italic>Klebsiella pneumoniae</italic>.</article-title> <source><italic>J. Bacteriol.</italic></source> <volume>179</volume> <fpage>4789</fpage>&#x2013;<lpage>4794</lpage>. <pub-id pub-id-type="doi">10.1128/jb.179.15.4789-4794.1997</pub-id> <pub-id pub-id-type="pmid">9244266</pub-id></citation></ref>
<ref id="B208"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname> <given-names>B. R.</given-names></name> <name><surname>Bogdan</surname> <given-names>A. R.</given-names></name> <name><surname>Miyazawa</surname> <given-names>M.</given-names></name> <name><surname>Hashimoto</surname> <given-names>K.</given-names></name> <name><surname>Tsuji</surname> <given-names>Y.</given-names></name></person-group> (<year>2016</year>). <article-title>Siderophores in iron metabolism, from mechanism to therapy potential.</article-title> <source><italic>Trends Mol. Med.</italic></source> <volume>22</volume> <fpage>1077</fpage>&#x2013;<lpage>1090</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmed.2016.10.005</pub-id> <pub-id pub-id-type="pmid">27825668</pub-id></citation></ref>
<ref id="B209"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wooley</surname> <given-names>R. E.</given-names></name> <name><surname>Gibbs</surname> <given-names>P. S.</given-names></name> <name><surname>Shotts</surname> <given-names>E. B.</given-names> <suffix>Jr.</suffix></name></person-group> (<year>1999</year>). <article-title>Inhibition of <italic>Salmonella</italic> Typhimurium in the chicken intestinal tract by a transformed avirulent avian <italic>Escherichia coli</italic>.</article-title> <source><italic>Avian Dis.</italic></source> <volume>43</volume> <fpage>245</fpage>&#x2013;<lpage>250</lpage>. <pub-id pub-id-type="doi">10.2307/1592614</pub-id></citation></ref>
<ref id="B210"><citation citation-type="journal"><collab>World Health Organization [WHO]</collab> (<year>2017</year>). <source><italic>Antibiotic Resistance Fact Sheet.</italic></source> <publisher-loc>Geneva</publisher-loc>: <publisher-name>WHO</publisher-name>.</citation></ref>
<ref id="B211"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yagmurov</surname> <given-names>E.</given-names></name> <name><surname>Tsibulskaya</surname> <given-names>D.</given-names></name> <name><surname>Livenskyi</surname> <given-names>A.</given-names></name> <name><surname>Serebryakova</surname> <given-names>M.</given-names></name> <name><surname>Wolf</surname> <given-names>Y. I.</given-names></name> <name><surname>Borukhov</surname> <given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Histidine-triad hydrolases provide resistance to peptide-nucleotide antibiotics.</article-title> <source><italic>mBio</italic></source> <volume>11</volume>:<issue>e0497-20</issue>. <pub-id pub-id-type="doi">10.1128/mBio.00497-20</pub-id> <pub-id pub-id-type="pmid">32265328</pub-id></citation></ref>
<ref id="B212"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname> <given-names>K. P.</given-names></name> <name><surname>Li</surname> <given-names>Y.</given-names></name> <name><surname>Zirah</surname> <given-names>S.</given-names></name> <name><surname>Goulard</surname> <given-names>C.</given-names></name> <name><surname>Knappe</surname> <given-names>T. A.</given-names></name> <name><surname>Marahiel</surname> <given-names>M. A.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Dissecting the maturation steps of the lasso peptide microcin J25 in vitro.</article-title> <source><italic>Chembiochem</italic></source> <volume>13</volume> <fpage>1046</fpage>&#x2013;<lpage>1052</lpage>. <pub-id pub-id-type="doi">10.1002/cbic.201200016</pub-id> <pub-id pub-id-type="pmid">22488892</pub-id></citation></ref>
<ref id="B213"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>C. C.</given-names></name> <name><surname>Konisky</surname> <given-names>J.</given-names></name></person-group> (<year>1984</year>). <article-title>Colicin V-treated <italic>Escherichia coli</italic> does not generate membrane potential.</article-title> <source><italic>J. Bacteriol.</italic></source> <volume>158</volume> <fpage>757</fpage>&#x2013;<lpage>759</lpage>. <pub-id pub-id-type="doi">10.1128/JB.158.2.757-759.1984</pub-id> <pub-id pub-id-type="pmid">6373733</pub-id></citation></ref>
<ref id="B214"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>X.</given-names></name> <name><surname>Price</surname> <given-names>C. W.</given-names></name></person-group> (<year>1995</year>). <article-title>Streptolydigin resistance can be conferred by alterations to either the beta or beta&#x2019; subunits of <italic>Bacillus subtilis</italic> RNA polymerase.</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>270</volume> <fpage>23930</fpage>&#x2013;<lpage>23933</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.270.41.23930</pub-id> <pub-id pub-id-type="pmid">7592585</pub-id></citation></ref>
<ref id="B215"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoneyama</surname> <given-names>H.</given-names></name> <name><surname>Katsumata</surname> <given-names>R.</given-names></name></person-group> (<year>2006</year>). <article-title>Antibiotic resistance in bacteria and its future for novel antibiotic development.</article-title> <source><italic>Biosci. Biotechnol. Biochem.</italic></source> <volume>70</volume> <fpage>1060</fpage>&#x2013;<lpage>1075</lpage>. <pub-id pub-id-type="doi">10.1271/bbb.70.1060</pub-id> <pub-id pub-id-type="pmid">16717405</pub-id></citation></ref>
<ref id="B216"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yorgey</surname> <given-names>P.</given-names></name> <name><surname>Davagnino</surname> <given-names>J.</given-names></name> <name><surname>Kolter</surname> <given-names>R.</given-names></name></person-group> (<year>1993</year>). <article-title>The maturation pathway of microcin B17, a peptide inhibitor of DNA gyrase.</article-title> <source><italic>Mol. Microbiol.</italic></source> <volume>9</volume> <fpage>897</fpage>&#x2013;<lpage>905</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2958.1993.tb01747.x</pub-id> <pub-id pub-id-type="pmid">8231817</pub-id></citation></ref>
<ref id="B217"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>H.</given-names></name> <name><surname>Ding</surname> <given-names>X.</given-names></name> <name><surname>Shang</surname> <given-names>L.</given-names></name> <name><surname>Zeng</surname> <given-names>X.</given-names></name> <name><surname>Liu</surname> <given-names>H.</given-names></name> <name><surname>Li</surname> <given-names>N.</given-names></name><etal/></person-group> (<year>2018a</year>). <article-title>Protective ability of biogenic antimicrobial peptide microcin J25 against enterotoxigenic <italic>Escherichia coli</italic>-induced intestinal epithelial dysfunction and inflammatory responses IPEC-J2 cells.</article-title> <source><italic>Front. Cell Infect. Microbiol.</italic></source> <volume>8</volume>:<issue>242</issue>. <pub-id pub-id-type="doi">10.3389/fcimb.2018.00242</pub-id> <pub-id pub-id-type="pmid">30057893</pub-id></citation></ref>
<ref id="B218"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>H.</given-names></name> <name><surname>Shang</surname> <given-names>L.</given-names></name> <name><surname>Zeng</surname> <given-names>X.</given-names></name> <name><surname>Li</surname> <given-names>N.</given-names></name> <name><surname>Liu</surname> <given-names>H.</given-names></name> <name><surname>Cai</surname> <given-names>S.</given-names></name><etal/></person-group> (<year>2018b</year>). <article-title>Risks related to high-dosage recombinant antimicrobial peptide microcin J25 in mice model, intestinal microbiota, intestinal barrier function, and immune regulation.</article-title> <source><italic>J. Agric. Food Chem.</italic></source> <volume>66</volume> <fpage>11301</fpage>&#x2013;<lpage>11310</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jafc.8b03405</pub-id> <pub-id pub-id-type="pmid">30298738</pub-id></citation></ref>
<ref id="B219"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>H.</given-names></name> <name><surname>Li</surname> <given-names>N.</given-names></name> <name><surname>Zeng</surname> <given-names>X.</given-names></name> <name><surname>Liu</surname> <given-names>L.</given-names></name> <name><surname>Wang</surname> <given-names>Y.</given-names></name> <name><surname>Wang</surname> <given-names>G.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>A comprehensive antimicrobial activity evaluation of the recombinant microcin J25 against the foodborne pathogens <italic>Salmonella</italic> and <italic>E. coli</italic> O157:H7 by using a matrix of conditions.</article-title> <source><italic>Front. Microbiol.</italic></source> <volume>10</volume>:<issue>1954</issue>. <pub-id pub-id-type="doi">10.3389/fmicb.2019.01954</pub-id> <pub-id pub-id-type="pmid">31507565</pub-id></citation></ref>
<ref id="B220"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>H.</given-names></name> <name><surname>Wang</surname> <given-names>Y.</given-names></name> <name><surname>Zeng</surname> <given-names>X.</given-names></name> <name><surname>Cai</surname> <given-names>S.</given-names></name> <name><surname>Wang</surname> <given-names>G.</given-names></name> <name><surname>Liu</surname> <given-names>L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Therapeutic administration of the recombinant antimicrobial peptide microcin J25 effectively enhances host defenses against gut inflammation and epithelial barrier injury induced by enterotoxigenic <italic>Escherichia coli</italic> infection.</article-title> <source><italic>FASEB J.</italic></source> <volume>34</volume> <fpage>1018</fpage>&#x2013;<lpage>1037</lpage>. <pub-id pub-id-type="doi">10.1096/fj.201901717R</pub-id> <pub-id pub-id-type="pmid">31914603</pub-id></citation></ref>
<ref id="B221"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>H. T.</given-names></name> <name><surname>Ding</surname> <given-names>X. L.</given-names></name> <name><surname>Li</surname> <given-names>N.</given-names></name> <name><surname>Zhang</surname> <given-names>X. Y.</given-names></name> <name><surname>Zeng</surname> <given-names>X. F.</given-names></name> <name><surname>Wang</surname> <given-names>S.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Dietary supplemented antimicrobial peptide microcin J25 improves the growth performance, apparent total tract digestibility, fecal microbiota, and intestinal barrier function of weaned pigs.</article-title> <source><italic>J. Anim. Sci.</italic></source> <volume>95</volume> <fpage>5064</fpage>&#x2013;<lpage>5076</lpage>. <pub-id pub-id-type="doi">10.2527/jas2017.1494</pub-id> <pub-id pub-id-type="pmid">29293710</pub-id></citation></ref>
<ref id="B222"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yuzenkova</surname> <given-names>J.</given-names></name> <name><surname>Delgado</surname> <given-names>M.</given-names></name> <name><surname>Nechaev</surname> <given-names>S.</given-names></name> <name><surname>Savalia</surname> <given-names>D.</given-names></name> <name><surname>Epshtein</surname> <given-names>V.</given-names></name> <name><surname>Artsimovitch</surname> <given-names>I.</given-names></name><etal/></person-group> (<year>2002</year>). <article-title>Mutations of bacterial RNA polymerase leading to resistance to microcin J25.</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>277</volume> <fpage>50867</fpage>&#x2013;<lpage>50875</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M209425200</pub-id> <pub-id pub-id-type="pmid">12401787</pub-id></citation></ref>
<ref id="B223"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>A.</given-names></name> <name><surname>Rosner</surname> <given-names>J. L.</given-names></name> <name><surname>Martin</surname> <given-names>R. G.</given-names></name></person-group> (<year>2008</year>). <article-title>Transcriptional activation by MarA, SoxS and Rob of two tolC promoters using one binding site, a complex promoter configuration for tolC in <italic>Escherichia coli</italic>.</article-title> <source><italic>Mol. Microbiol.</italic></source> <volume>69</volume> <fpage>1450</fpage>&#x2013;<lpage>1455</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2958.2008.06371.x</pub-id> <pub-id pub-id-type="pmid">18673442</pub-id></citation></ref>
<ref id="B224"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>Z.</given-names></name> <name><surname>Eberhart</surname> <given-names>L. J.</given-names></name> <name><surname>Orfe</surname> <given-names>L. H.</given-names></name> <name><surname>Lu</surname> <given-names>S. Y.</given-names></name> <name><surname>Besser</surname> <given-names>T. E.</given-names></name> <name><surname>Call</surname> <given-names>D. R.</given-names></name></person-group> (<year>2015</year>). <article-title>Genome-wide screening identifies six genes that are associated with susceptibility to <italic>Escherichia coli</italic> microcin PDI.</article-title> <source><italic>Appl. Environ. Microbiol.</italic></source> <volume>81</volume> <fpage>6953</fpage>&#x2013;<lpage>6963</lpage>. <pub-id pub-id-type="doi">10.1128/aem.01704-15</pub-id> <pub-id pub-id-type="pmid">26209678</pub-id></citation></ref>
<ref id="B225"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zowawi</surname> <given-names>H. M.</given-names></name> <name><surname>Harris</surname> <given-names>P. N.</given-names></name> <name><surname>Roberts</surname> <given-names>M. J.</given-names></name> <name><surname>Tambyah</surname> <given-names>P. A.</given-names></name> <name><surname>Schembri</surname> <given-names>M. A.</given-names></name> <name><surname>Pezzani</surname> <given-names>M. D.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>The emerging threat of multidrug-resistant Gram-negative bacteria in urology.</article-title> <source><italic>Nat. Rev. Urol.</italic></source> <volume>12</volume> <fpage>570</fpage>&#x2013;<lpage>584</lpage>. <pub-id pub-id-type="doi">10.1038/nrurol.2015.199</pub-id> <pub-id pub-id-type="pmid">26334085</pub-id></citation></ref>
<ref id="B226"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zsch&#x00FC;ttig</surname> <given-names>A.</given-names></name> <name><surname>Zimmermann</surname> <given-names>K.</given-names></name> <name><surname>Blom</surname> <given-names>J.</given-names></name> <name><surname>Goesmann</surname> <given-names>A.</given-names></name> <name><surname>P&#x00F6;hlmann</surname> <given-names>C.</given-names></name> <name><surname>Gunzer</surname> <given-names>F.</given-names></name></person-group> (<year>2012</year>). <article-title>Identification and characterization of microcin S, a new antibacterial peptide produced by probiotic <italic>Escherichia coli</italic> G3/10.</article-title> <source><italic>PLoS One</italic></source> <volume>7</volume>:<issue>e033351</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0033351</pub-id> <pub-id pub-id-type="pmid">22479389</pub-id></citation></ref>
</ref-list>
</back>
</article>
